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Abstract 
The overall aim of this thesis is to investigate the development of new imaging 
biomarkers for clinical application in multiple sclerosis (MS).  
To date, there have been significant advances in the use of magnetic resonance 
imaging (MRI) in the initial diagnostic work-up of patients suspected of having MS 
and also in the monitoring of disease activity during active treatment. However, 
there is often a discrepancy between the clinical and conventional MRI findings 
which arises due to the complex heterogeneous features of MS pathology. The 
development of imaging biomarkers, which are directly linked to the pathological 
processes underlying progressive and relapsing forms of MS, are vital to 
developing a better understanding of the pathological mechanisms driving the 
disease.  
In order to address this, I performed clinical studies in both progressive and 
relapsing forms of MS with both innovative imaging techniques and with other 
more established imaging measures. After the introduction (where I review the 
main characteristics of MS (Chapter I) and of conventional and advanced MRI 
techniques employed in the studies presented in this thesis (Chapter II)), I present 
the following studies: 
(A) Pilot studies with innovative imaging techniques – this included a gamma-
aminobutyric acid (GABA) magnetic resonance spectroscopy study in 
patients with secondary progressive multiple sclerosis (SPMS) (Chapter 
III) and a novel diffusion study (neurite orientation dispersion and density 
imaging, NODDI) in the brain of patients with relapsing remitting multiple 
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sclerosis (RRMS) (Chapter IV). The main results of these investigations 
are that GABA may be a marker of neurodegeneration and NODDI may 
better characterise microstructural changes in the brain than standard 
diffusion tensor imaging. 
(B) Clinical studies with more established imaging measures including an MRI 
follow-up spinal cord study in primary progressive multiple sclerosis 
(PPMS) (Chapter V) using 1H-Magnetic resonance spectroscopy (1H-
MRS), Q-space imaging (QSI) and spinal cord area.  Another study looked 
at the development of spinal cord atrophy in a progressive MS cohort of 
patients over 1 year to determine the sample sizes required to 
demonstrate a reduction in spinal cord cross-sectional area as a primary 
outcome measure in clinical trials (Chapter VI). Both of these studies 
demonstrated spinal cord atrophy occurred over 1 year and it may be a 
useful outcome measure in phase II neuroprotective trials in early PPMS. 
In the final chapter (Chapter VII), I will summarise the results of the studies 
presented in the thesis and propose future directions for the research.  
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1.1 Introduction 
Multiple sclerosis (MS) is a chronic demyelinating disease, of the brain and spinal 
cord, with both demyelinating and degenerative components. It is the most 
common cause of neurological disability in young adults world-wide. Jean-Martin 
Charcot was the first to describe the clinicopathological features of MS in 1868. 
However there had been case presentations as early as the 1820s. Despite the 
pathological characteristic lesions being described over 150 years ago, the 
aetiology and pathophysiology of the disease course remains unclear. 
MS is a global disease with an estimated 2.1 million sufferers worldwide in 2008, 
which increased further to 2.3 million in 2013 (Browne et al., 2014). The increase 
in MS prevalence is likely to be due to increased survival of people with MS, 
improved diagnosis of MS and increased MS incidence in some countries 
(Browne et al., 2014). The prevalence of MS varies greatly, with the highest in 
North America and Europe (140 and 108 per 100,000 respectively) (Browne et 
al., 2014). The UK prevalence of MS is estimated to be around 125 per 100,000 
(Mackenzie et al., 2014).  
1.2 MS Phenotypes 
The initial phase of relapsing-remitting MS (RRMS) is characterised by episodes 
of active disease with neurological dysfunction (relapse), during which 
demyelinating lesions form in the central nervous system, interspersed with 
periods of clinical inactivity. There is a variable degree of recovery between 
relapses. The disease course for RRMS is highly unpredictable with the 
frequency of relapses as well as the accumulation of disability linked to the sex 
of the patient as well as the age at disease onset. About 85% of patients present 
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with relapses and remissions. After a variable number of years, a proportion of 
patients show a gradual deterioration in function, independent of relapse activity, 
which is called secondary progressive MS (SPMS) (Weinshenker et al., 
1989a&b). SPMS is diagnosed retrospectively by a history of gradual worsening, 
after an initial relapsing remitting course, with or without acute exacerbations 
during the progressive course (Lublin et al., 2014). There is no clear clinical, 
imaging, immunological, or pathological criteria to help determine the transition 
point from RRMS to SPMS. The median time to the development of SPMS was 
19.1 years from first diagnosis in the Lyon cohort data (Vukusic et al., 2003) and 
21.4 years in the British Columbia cohort data (Koch et al., 2010). The study by 
Koch et al. found that the main factors influencing the onset of SPMS in untreated 
RRMS patients included male gender, age at onset and motor onset symptoms, 
which were associated with both a shorter time to and a younger age at SPMS 
onset (Koch et al., 2010). A more recent study found that pre and post-
progression relapses accelerated the time to severe disability in progressive MS 
(Novotna et al., 2015).  
A minority of patients with MS (10%) have a slow accumulation of disability from 
disease onset without relapses, and are described as having primary progressive 
MS (PPMS) (Koch et al., 2009). 3-10% of patients with PPMS have relapses 
(Hawker et al., 2009; Andersson et al., 1999). Primary progressive MS differs 
from other types of MS as the age of symptom onset is typically older (fourth-fifth 
decade) compared with RRMS (second-third decade). Studies to date show that 
PPMS has an equal sex distribution. This is in contrast to RRMS which has a 
female preponderance at 2-3:1 (Compston and Coles, 2008, Miller and Leary, 
2007a). Previously it was felt that PPMS may represent a distinct, non- (or less) 
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inflammatory form of MS (Lassmann et al., 2012). However, now it is felt that 
PPMS is part of the spectrum of progressive MS phenotypes, based on clinical, 
imaging and genetic data (Lublin et al., 2014). A recent study in radiologically 
isolated syndrome (RIS) found a similar prevalence (at 12%) and age at onset of 
PPMS to the general MS population (Kantarci et al., 2015). In this RIS cohort the 
presence of spinal cord lesions and being male predicted the evolution to PPMS 
(Kantarci et al., 2015).  
MS can be divided into different sub-types (RRMS, PPMS and SPMS) as 
described above, characterised by a different clinical course defined by the 
National Multiple Sclerosis Society of the USA Advisory Committee (Lublin & 
Reingold, 1996). These definitions have recently been modified (Lublin et al., 
2014), with the inclusion of two new disease courses: clinically isolated syndrome 
(CIS) and radiologically isolated syndrome (RIS). CIS is defined as the first 
clinical presentation of a disease that shows characteristics of inflammatory 
demyelination that could be MS, but has yet to fulfil the criteria for dissemination 
in time (Miller et al., 2005). RIS is defined as the incidental imaging finding 
suggestive of demyelination without a corresponding history or physical 
examination findings typical for MS (Okuda et al., 2009). Further modifications to 
the diagnostic criteria include the use of MRI scans to detect disease activity and 
to determine if progression of disability has occurred over a given time period 
(Lublin et al., 2014). Disease activity is determined by clinical relapses and/or 
MRI activity (contrast-enhancing lesions; new or unequivocally enlarging T2 
lesions assessed at least annually) (Lublin et al., 2014). While progression is 
measured by clinical evaluation assessed at least annually (Lublin et al., 2014). 
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The progressive relapsing disease subtype has also been redefined as PPMS 
with disease activity (Lublin et al., 2014) as outlined below. 
2013 description for relapsing disease 
 
Figure 1.1: 2013 multiple sclerosis phenotype descriptions for relapsing disease. 
* Activity determined by clinical relapses and/or MRI activity (contrast-enhancing 
lesions; new or unequivocally enlarging T2 lesions assessed at least annually). 
** CIS, if subsequently clinically active and fulfilling current MS diagnostic criteria, 
becomes RRMS (Lublin et al., 2014).  
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2013 description for progressive disease   
 
Figure 1.2: 2013 multiple sclerosis phenotype descriptions for progressive 
disease. * Activity determined by clinical relapses assessed at least annually 
and/or MRI activity (contrast enhancing lesions; new and unequivocally enlarging 
T2 lesions). ** Progression measured by clinical evaluation, assessed at least 
annually. If assessments are not available, activity and progression are 
indeterminate (Lublin et al., 2014).  
 
1.3 Clinical presentation and disease course 
The symptoms and signs of MS are variable and can result from injury to any part 
of the central nervous system (CNS), from the spine to the brain. The symptoms 
and signs of MS merely reflect the functional anatomy of impaired saltatory 
conduction at affected sites (Compston & Coles, 2002). The cerebrum is almost 
always involved when assessed with MRI, however most white matter 
abnormalities cannot be linked to specific events or clinical symptoms. Some 
areas are more affected than others such as the optic nerve, cerebellum, brain 
stem and the posterior and lateral columns of the spinal cord. Typical symptoms 
in RRMS include optic neuritis, sensory symptoms, motor deficits, diplopia, 
vertigo, balance problems, and fatigue (Weinshenker et al., 1989a).  
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Cognitive impairment is very common in MS, with prevalence ranging from 40% 
to 70% (Chiaravalloti et al., 2008), and typically is more common in the 
progressive forms of MS (Chiaravalloti et al., 2008). MS detrimentally affects 
various aspects of cognitive functioning in particular attention, information 
processing speed, working memory, verbal memory and executive function 
(Rocca et al., 2015). It has been demonstrated that white matter lesions only play 
a partial role on cognitive performance compared to damage to normal appearing 
white and grey matter (Rocca et al., 2015). Cortical lesion number and volume 
are associated with cognitive deficits in MS patients, with damage to deep grey 
matter structures, such as the thalamus, having an early role in cognitive 
impairment in MS (Rocca et al., 2015). It is thought that cognitive deficits in MS 
patients may be related to a disconnection syndrome involving white matter tracts 
(Rocca et al., 2015). It has been found that some MS patients who have 
considerable disease burden do not have cognitive impairment. It is thought that 
this may be due to brain reserve and cognitive reserve (Sumowski et al., 2013). 
The theory of brain reserve suggests that people with larger maximal life-time 
brain growth are able to withstand a greater disease burden, before reaching a 
critical threshold of brain volume loss, when cognitive impairment then emerges 
(Sumowski et al., 2014). Cognitive reserve refers to enriching life experiences 
that are associated with more efficient patterns of cognitive processing, which 
helps to preserve cognition (Sumowski et al., 2014). Based on these more recent 
findings, important factors which may help predict future risk of cognitive decline 
in MS are lower maximal life-time brain growth and intellectual enrichment 
(Sumowski et al., 2014). These at risk subjects may benefit from early cognitive 
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rehabilitation and to engage in intellectual enrichment activities (Sumowski et al., 
2014).  
Fatigue is reported to affect 50% to 80% of people with MS (Krupp, 2006) and it 
may be the most disabling symptom for some people with MS (Giovannoni, 
2006). It is more common in people with PPMS and SPMS compared to RRMS 
and it tends to be worse in the afternoon (Patrick et al., 2009). The 
pathophysiology of fatigue is not fully understood but potential mechanisms 
include pro-inflammatory cytokines e.g IFN-δ, tumour necrosis factor-α and 
interleukin 1, 6 and 10 (Heesen et al., 2006), over activity of neural circuits 
(Thickbroom et al., 2008) and/or diffuse axonal damage (Tartaglia et al., 2004).  
80% of PPMS cases have spinal cord involvement, progressing to quadriparesis 
with associated autonomic dysfunction. The PPMS phenotype implies a worse 
prognosis than RRMS (Noseworthy et al., 2000). Natural history studies 
demonstrate a large variation in the rate of disability in PPMS, as measured by 
the number of years taken to reach an Expanded Disability Status Scale (EDSS) 
of 6 (Kurtzke, 1983). The evaluation of disease course in PPMS and SPMS (once 
established), are similar (Miller and Leary, 2007a). Natural history studies in 
RRMS have shown that the average annual relapse frequency is approximately 
one per year (Confavreux et al., 1980). Due to the potential for treatment during 
the RRMS phase, studies have looked at factors which predict long–term 
disability. However, to date our ability to predict the disease course remains 
weak. A study by Weinshenker et al., (Weinshenker et al., 1989a) found that a 
high number of relapses in the first two years following the onset of MS correlated 
with long–term disability. Another study found relapse frequency after 2 years 
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does not seem to predict the onset of secondary progression or times to EDSS 
6.0, 8.0 or 10, which may be related to neurodegeneration (Scalfari et al., 2010). 
The number of relapses and the location of relapses did not correlate with 
progression to SPMS (Kremenchutzky et al., 2006).  
The exact aetiology of MS is unknown but it is widely recognised that it has a 
complex causation that involves both genetic and environmental factors 
(Compston & Coles, 2008). Each of these factors are clearly implicated in the 
disease, with a complex interaction between genes and the environment 
occurring at a critical age (Compston & Coles, 2008). The four main factors 
thought to contribute to causality include (i) latitude, sunlight exposure (UVR) and 
Vitamin D, (ii) prior Epstein-Barr Virus (EBV) infection timing and adaptive 
immune response to EBV, (iii) cigarette smoking and (iv) hygiene hypothesis 
(Taylor et al, 2011).  
1.3.1 Environmental Factors 
Multiple epidemiological studies have shown a definite role for environmental 
factors in determining the disease risk for MS. The latitude gradient is the most 
obvious example of how the environment affects the risk of MS (Kurtzke, 1975). 
Kurtzke divided areas into high, medium and low risk, which correlated with 
latitude. He found that there were very few cases of MS near the equator, with 
high risk zones in northern Europe and in the USA. This has been reproduced in 
more recent studies, with increases in prevalence seen with increasing distance 
north or south of the equator (Taylor et al., 2011). MS is common in regions 
populated by northern Europeans but the risk of disease is modified depending 
on where the individual lives early in life (Compston & Coles, 2008). Migration 
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from high-risk to low-risk regions in childhood is associated with a reduced risk, 
while migration from low-risk to high-risk parts of the world is associated with an 
increased risk of developing MS compared with the population of origin 
(Compston & Coles, 2008).  
The incidence of MS has been rising around the world over the last few decades. 
This is likely due to a rising incidence in women, which may support a sex-linked 
environmental factor (Compston & Coles, 2008). Potential explanations for this 
include a rise in female smoking, later age of first pregnancy, declining birth rates 
and obesity (Koch-Henriksen & Sorensen, 2010). 
A large number of viruses but in particular Epstein Barr Virus (EBV) have been 
implicated in the pathogenesis of MS.  About 90% of the population is infected by 
EBV and the infection typically occurs in early childhood. In comparison almost 
all patients (>99%) with MS are infected with EBV and the infection mostly occurs 
in adolescence (Ascherio et al., 2000). The exact mechanism of how EBV is 
involved in the pathogenesis of MS is not fully understood. It is thought that MS 
may result from deficient control of EBV infection, resulting in EBV infected B 
cells accumulating in the central nervous system (Fernández-Menéndez et al., 
2016). EBV may have a direct role in inflammation and/or it may reactivate T cells 
contributing to the pathological process (Fernández-Menéndez et al., 2016). 
It has been proposed that EBV may be a simple confounder in epidemiological 
studies and it may not be a causative agent in MS pathogenesis. Even though 
EBV and other viral antibody titres are raised in MS subjects compared to the 
general population as outlined above, this may reflect immune dysregulation 
rather than being a true causative factor (Hunter et al., 2000). A pathological 
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study of acute and chronic MS plaques as well as CSF, did not find EBV in the B 
lymphocytes and there was no evidence of intrathecal EBV antibody production 
(Sargsyan et al., 2010). Therefore, it may be that EBV is association with other 
risk factors, such as smoking, which may alter the host’s response to EBV and 
increase the overall risk of MS (Simon et al., 2010).   
Smoking has been identified as a risk factor for the subsequent development of 
MS. Cigarette smokers have a higher risk of developing MS compared to those 
who have never smoked (Ascherio & Munger, 2007). It has been demonstrated 
that smoking is associated with more severe disease, faster disability 
progression, and faster progression to SPMS (Hernan et al., 2005; 
Manouchehrinia et al., 2013). A retrospective study found that those who smoked 
had a higher risk of conversion from CIS to clinically definite MS (Di Pauli et al., 
2008). The mechanisms underlying the association between cigarette smoking 
and the risk of developing MS are not clear but one theory is the presence of 
neurotoxic compounds in cigarettes, such as nitric oxide (Hernan et al., 2005). 
The presence of nitric oxide in MS lesions caused by smoking may accelerate 
axonal loss and the progression of disability in MS patients (Hernan et al., 2005). 
Additional environmental factors implicated in the development of MS include 
sunlight exposure and vitamin D status. The main source of Vitamin D for most 
people is sunlight (Holick et al., 2004; Ascherio et al., 2010), with people living at 
least 40o north or south of the equator having low sunlight for 4 months of the 
year and an associated reduction in Vitamin D levels (Webb et al., 1988). Places 
such as Canada, Northern Europe, New Zealand and Tasmania have the highest 
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prevalence rates of MS in the world and have lower sunshine exposure (Goodin 
et al., 2009).  
Variability in UVB exposure and vitamin D status during pregnancy was thought 
to explain why season of birth effects MS risk (Disanto et al., 2012), with births in 
November having the lowest risk of MS and births in May having the highest risk 
of MS (Willer et al., 2005). However, a recent study has demonstrated that the 
apparent seasonal patterns for month of birth thought to be specific for MS are 
expected by chance alone, as the month of births varies significantly with 
geographical location and over time in the normal population (Fiddes et al., 2013). 
Therefore, the prior association of MS with month of birth are likely due to a false 
positive association.  
Overall, a number of studies have found a higher MS risk in subjects with low 
Vitamin D levels (Munger et al., 2004; Salzer et al., 2012) as well as a poorer 
prognosis in patients with MS who have low levels of Vitamin D (Ascherio et al., 
2014; Simpson et al., 2010). One study demonstrated that Vitamin D levels in the 
first 12 months after a CIS strongly predicted MS activity and progression during 
the following four years (Ascherio et al., 2014). More recently a study found that 
higher Vitamin D levels in RRMS patients treated with interferon beta-1b were 
associated with lower rates of disease activity on MRI (Fitzgerald et al., 2015).  
It is unlikely that any one of the environmental factors discussed above is solely 
responsible for the development of MS. It is very likely that a complex interaction 
of a number of environmental factors in association with genetic factors contribute 
to the development of MS.  
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1.3.2 Genetic Factors  
The role of genetics in MS is clear given the difference in prevalence in 
populations of different ethnic backgrounds living in close proximity. Familial 
studies have demonstrated a familial recurrence rate of about 20% (Compston & 
Coles, 2002). Population based twin studies show higher clinical concordance 
rates in monozygotic (25%) than in dizygotic pairs (5%) (Willer et al., 2003; 
Mumford et al., 1994). The concordance rate for MS is similar in half-siblings 
raised together and apart (1.2% vs 1.5% respectively) which indicates that 
changes in environment have little influence on this group (Ebers et al., 1995). In 
individuals adopted early in life and who went on to develop MS later, the new 
family did not incur any extra risk of MS, while the biological parents were found 
to be at an increased risk (Ebers et al., 1995). The risk of MS changes from 3% 
in first degree relatives, to 1% in second-degree and third-degree relatives, 
indicating the risk of developing MS increases with the degree with which they 
are related to them (Dyment et al., 2006). Overall, there is no clear pattern of 
inheritance apparent in MS, but it is clear that genes play a definite role in its 
pathogenesis (Compston, 2006). 
Several genetic loci are associated with an increased risk of developing MS. Initial 
studies found a link between MS and major histocompatibility complex (MHC) 
(Compston et al., 1976), with genes for the Human Leukocyte Antigen (HLA) 
located within the MHC area, which contains a high number of polymorphisms 
(Horton et al., 2004). A number of HLA genes have been identified with an 
association between the DR2 haplotype HLADRB1*1501 in the class II region of 
the MHC on the short arm of chromosome 6 and the development of MS (Olerup 
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and Hillert, 1991). The genes inside this region encode cell-surface glycoproteins 
which are key components of the immune system (Munoz-Culla et al., 2013).  
Linkage studies have been replaced with Genome-Wide Association Studies 
(GWAS), which uses a hypothesis–free strategy that screens the whole genome 
by tagging linkage disequilibrium blocks (Munoz – Culla et al., 2013). It uses 
single-nucleotide polymorphism (SNP) data as a reference to scan the whole 
genome and identify parts of the genome associated with the disease (Munzo–
Culla et al., 2013). The main progress since the identification of the MHC, has 
been the identification of the association with variants in both IL7R and IL2R 
(Hafler et al., 2007/IMSGC 2007). To date 14 GWAS have now been completed 
in MS and the success of these studies are directly related to the number of 
samples screened. Collaboration between the International Multiple Sclerosis 
Genetic Consortium (IMSGC) and the Welcome Trust Case Control Consortium 
(WTCCC2) ended in the largest study to date and confirmed the 23 previously 
reported associations and identified 34 new association variants, and 29 of these 
had genome significance (Sawcer et al., 2011). These novel susceptibility loci 
identified modestly increase disease susceptibility in MS, such as VCAM1, PLEK, 
CD86 and IL12B, as well as replicating previously suggested associations 
(Sawcer et al., 2011).  These risk alleles tend to be involved in T-cell maturation, 
therefore suggesting the critical disease mechanisms mainly involve immune 
dysregulation (Sawcer et al., 2011).  
There are a number of limitations with the genetic analysis in MS. The IL7R 
association identified to date has a frequency of 72% in white Europeans, with 
the allele estimated to increase the risk of disease by only a factor of 1.2 (Sawcer, 
Chapter I: Introduction to multiple sclerosis 
37 
2008). Therefore, the vast majority of people carrying this allele will never develop 
MS. Overall MS is not a common disease in the whole population and studies of 
less than 600 cases and 600 controls are unlikely to identify significant 
associations (Sawcer, 2008). The work to date provides substantial evidence of 
a genetic component to MS, however like the environmental factors, it involves 
complex interactions which are very challenging to disentangle.  
1.4 Comorbidities & MS  
Comorbidities in patients with MS can be divided into 3 areas: 1) MS and diseases 
which may have a common pathogenic origin e.g. thyroid dysfunction, psoriasis 
and inflammatory bowel disease, 2) MS and diseases which occur as a 
consequence of MS e.g. psychiatric disorders and 3) MS and disease that are 
very common e.g. cardiovascular disease and cancer (Capkun et al., 2015; 
Marrie et al., 2015). The existence of comorbidities in MS have been associated 
with diagnostic delays, disability progression and progression of lesion burden on 
MRI and this is becoming more clear with time (Marrie et al., 2009; Marrie et al., 
2010; Weinstock-Guttman et al., 2013). A population-based administrative data 
study in an MS population found survival was lower (median of 7 years lower) for 
those with MS than in a population matched for age, sex-and socioeconomic 
status (Marrie et al., 2015). The study by Marrie et al., 2015 found that a number 
of conditions were associated with increased risk of mortality, specifically 
depression, diabetes, hypertension, ischaemic heart disease and chronic lung 
disease. Excluding MS-related mortality, the most common causes of death were 
due to circulatory system disease, cancer and respiratory disease (Marrie et al., 
2015). The early detection and management of comorbidities in patients with MS 
is extremely important, as it can reduce premature death and improve quality of 
Chapter I: Introduction to multiple sclerosis 
38 
life (Capkun et al., 2015). Looking at the whole care of a patient with MS, including 
physical and mental comorbidities, will improve management of this complex 
disease (Ciccarelli & Thompson, 2016).  
1.5 Pathology 
The pathological features of MS were first described by Carswell and Cruveilhier 
(Carswell, 1838, Cruveilher, 1841). They were later summarised by Frommann 
and Charcot (Frommann 1878, Charcot 1880). The sclerotic plaque has been the 
most important finding in MS, since it was first described. The pathological 
hallmarks of MS are inflammation, demyelination, remyelination, gliosis and 
neurodegeneration, which occur either focally or diffusely throughout the grey 
and white matter of the brain and spinal cord. The sclerotic plaque arises due to 
a complicated interplay of inflammation, demyelination and repair, with a variable 
degree of axonal loss (Compston & Coles, 2008).  
1.5.1 White Matter 
Oligodendrocytes in the CNS manufacture myelin. In MS, the oligodendrocytes 
are damaged by inflammatory T lymphocytes, which are not being regulated, 
resulting in immune dysregulation (Compston & Coles, 2008). Traditionally MS 
was considered to be an autoimmune inflammatory disorder, which was mediated 
by a T cell attack against CNS elements, in particular myelin. Patients with RRMS 
display a compelling autoimmune and inflammatory phenotype on laboratory and 
radiological tests (Stys et al., 2012). These features are present in all forms of 
MS but they vary both quantitatively and qualitatively between the three forms 
(RR, SP and PP) of MS (Lassmann et al., 2012), with the degree of inflammation 
Chapter I: Introduction to multiple sclerosis 
39 
higher during the early relapsing stage of the disease and lower in the later phase 
of the disease (Frischer et al., 2009).  
Pathological examination of biopsied or post-mortem brains of patients with MS 
shows characteristic perivascular inflammatory infiltrates, which consist mainly of 
lymphocytes and macrophages. Inflammatory infiltrates mainly contain CD8+ T 
lymphocytes, which are clonally expanded in active lesions (Babbe et al., 2000).  
CD4+T cells and B lymphocytes are less numerous than CD8+T cells and mainly 
accumulate in the perivascular space and meninges (Ozawa et al., 1994; Serafini 
et al., 2004). Microglial activation in the initial lesions is associated with 
demyelination and neurodegeneration with subsequent recruitment of 
macrophage as a result of myelin breakdown (Frischer et al., 2009; Lassmann et 
al., 2011).  
Early RRMS is predominantly a disease of the white matter, characterised by 
confluent plaques of demyelination. The active demyelination is associated with 
inflammation and blood-brain barrier leakage (Lassmann et al., 2014). The 
progressive stage of the disease is characterised by the gradual expansion of 
white matter lesions in the absence of blood-brain barrier leakage, with 
degeneration of chronically demyelinated axons a prominent feature in the 
progressive stages of MS and a major cause of irreversible disability (Mahad et 
al., 2015).  
1.5.2 Grey Matter 
The understanding of MS has evolved significantly over recent years. 
Traditionally it was thought that MS was solely a disease of the white matter, 
however improvements in radiology and pathology in more recent years indicates 
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that grey matter structures (that is, neuronal somas and synapses) of the brain 
are also affected (Geurts et al., 2009).  
Extensive pathology is seen in the grey matter in all types of MS. Grey matter 
pathology is characterised by demyelination with a relative absence of immune 
cell infiltrates. The number of cortical lesions increases at a significantly greater 
rate in patients with actively progressive disease and correlates with increasing 
disability (Calabrese et al., 2010a). Therefore, there is increasing evidence that 
accumulating cortical grey matter pathology plays an important role in the severity 
of both physical and cognitive disability (Calabrese et al., 2010b; Mahad et al., 
2015). This ultimately results in extensive brain tissue loss and injury (Lassmann 
et al., 2014). The degree of cortical atrophy is not constant throughout the brain, 
with marked regional variations in cortical involvement. There is more extensive 
involvement seen in the hippocampus, frontal and temporal cortices as well as 
the cingulate gyrus, and less extensive involvement in the occipital lobe and 
primary motor cortex (Gilmore et al., 2009). The predilection for the frontal lobe 
and the hippocampus is likely to account for the predominance of cognitive over 
motor disability related to cortical pathology (Gilmore et al., 2009).  
Little is known about the mechanism of lesion formation in the cortical grey matter 
and how the accumulation of cortical pathology may contribute to clinical 
progression (Reynolds et al., 2011). Post-mortem studies have shown that 
inflammatory infiltrates are commonly found in the cerebral leptomeninges in 
SPMS (Frischer et al., 2009). In a proportion of SPMS cases, large B cell 
aggregates have been identified in the subarachnoid space with some 
characteristics of ectopic B cell follicles (Frischer et al., 2009; Magliozzi et al., 
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2007). The ectopic B cell follicle-like structures can be found distributed 
throughout the cerebral meninges and they are variable in number and size 
(Magliozzi et al, 2007). They are mainly present in the cerebral sulci which 
suggests that reduced CSF flow and the microenvironment of these locations, 
favours the homing and retention of inflammatory cells which gives rise to an 
inflammatory milieu in the CSF (Magliozzi et al., 2007). MS cases with these 
meningeal lymphoid-like structures are associated with a younger age at disease 
onset, a shorter time to disease progression and wheelchair use, and shorter 
disease duration (Magliozzi et al., 2010). This raises the possibility that CSF-
mediated factors may play an important role in cortical pathology. More recently 
a similar finding in white matter has been demonstrated, where a gradient in 
magnetisation transfer ratio (MTR) abnormalities from periventricular to deep 
normal appearing white matter (NAWM) in MS patients were found, which was 
most marked in the periventricular region. This further raises the possibility of 
CSF-mediated factors are involved in the pathogenesis in MS (Liu et al., 2015). 
In the past, the majority of the evidence suggested that the disease began due to 
an immune dysregulation. This is based on the “outside-in” model of MS (Stys et 
al., 2012). The resulting inflammatory reaction, which typically follows a RR 
course in the initial stages, causes further demyelination and tissue injury (Stys 
et al., 2012).  
In more recent years, doubt has been cast on this model due to some 
inconsistencies and an “inside-out” model of MS has been proposed. This model 
proposes that the initial malfunction occurs within the CNS, like other 
neurodegenerative conditions, for example Parkinson’s and Alzheimer’s disease. 
Primary neurodegeneration, possibly involving the oligodendrocyte-myelin 
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complex, resulting in Wallerian degeneration may be the initiating event. This 
then releases highly antigenic constituents along the degenerated tracts, which 
promotes secondary autoimmune and inflammatory responses in the 
predisposed individual (Hauser et al., 2006; Trapp et al., 2008; Sato et al., 2015). 
Progressive stages of MS remain largely refractory to treatment. It is widely 
suggested that accumulating axonal loss is responsible for irreversible clinical 
progression. Pathological changes associated with clinical progression include 
inflammatory changes becoming increasingly compartmentalised in the 
perivascular and subarachnoid spaces behind a relatively intact blood-brain 
barrier (Meinl et al., 2008).  
Pathological studies have significantly enhanced our understanding of the 
mechanisms underlying MS over the last number of years. It is most likely that 
MS starts as a result of inflammation, which then initiates a number of 
neurodegenerative mechanisms as the disease progresses, including changes 
related to age.  
1.6 Diagnosis of multiple sclerosis 
Over the last 50 years, the diagnostic criteria for MS have evolved, with 
successive modifications, due to technological advances which improve the 
accuracy of diagnosis. MS cannot be diagnosed in an asymptomatic individual 
based on MRI findings alone. The criteria have evolved and more recent criteria 
allow MRI evidence of dissemination of lesions in space and time, while the 
earlier criteria required clinical evidence of dissemination. The first criteria was 
proposed by Schumacher et al in 1965 and stated that definite MS was classed 
as having objective evidence for disease affecting two or more regions of the 
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CNS white matter (dissemination in space), with episodes separated at least 1 
month apart or with progression over six months (dissemination in time), in a 
person aged 10-50 years at onset. The authors recommended routine laboratory 
tests to exclude alternative conditions and a lumbar puncture was also included, 
to look for an increase in cerebrospinal fluid (CSF) gamma globulin and 
mononuclear cells.  
Subsequent to this, the new Poser criteria (Poser et al., 1983) introduced 
laboratory features to improve the diagnostic classification in patients. This 
included visual evoked potentials (VEPs), CSF and MRI imaging. These criteria 
included the presence of unmatched oligoclonal bands (OCBs) in the CSF but 
not in the serum, indicating an immunological process in the CNS. Their presence 
is supportive of an MS diagnosis. However, they may be present in other CNS 
inflammatory conditions such as sarcoid, systemic lupus erythematosus (SLE) 
and syphilis. The age is restricted to between 10 and 59 years of age and 
progressive onset of disease is excluded from making an MS diagnosis.  
The widespread use of MRI in MS and other neurological conditions was 
subsequently reflected in the diagnostic criteria for the disease proposed by Paty 
(Paty et al., 1988). Paty included MRI in the diagnostic criteria, as well as 
computerised tomography (CT), OCBs, VEPs and somatosensory evoked 
potentials (SSEPs). The criteria developed by Paty et al, included abnormalities 
in the above parameters, as well as a history of dissemination in time and space. 
The MRI was either strongly suggestive of MS, was suggestive of possible MS or 
was not MS, based on the number of lesions seen. An MRI strongly suggestive 
of MS has four lesions or three, one of which is periventricular; for possible MS 
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two lesions must be present with one lesion in a periventricular location. If there 
is one lesion or none, then another diagnosis should be considered. The authors 
included in the criteria that a single appropriate lesion could be used to 
demonstrate dissemination in space. In individuals over 40 years of age, it was 
recommended that OCBs are a prerequisite for a diagnosis of MS due to the 
increase in non-specific lesions seen with advancing age.  
In 2001, there was a further revision of the criteria with the widespread use of 
MRI (McDonald et al., 2001) and certain imaging features suggestive of MS. The 
work of Barkhof (Barkhof et al., 1997) and Tintore (Tintore et al., 2000) had shown 
that patients with CIS with three or four of the following brain MRI features had a 
high specificity for developing clinically definite MS (Barkhof et al., 1997; Tintore 
et al., 2000): 
 Nine T2 hyperintense lesions or one gadolinium-enhancing lesion 
 At least three periventricular lesions 
 At least one infratentorial lesion 
 At least one juxtacortical lesion 
Following publication of the 2001 McDonald criteria, a number of studies 
confirmed higher sensitivity and specificity compared with the previous criteria. 
These criteria were subsequently revised in 2005, by the International Panel on 
Diagnosis of MS (Polman et al., 2005). The modified criteria again incorporated 
CSF analysis, VEPs and clinical findings as well as three of the MRI criteria as 
outlined in the 2001 criteria with some modifications. Any number of cord T2 
lesions could substitute for a brain lesion, while only one could in 2001. Cord 
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lesions were not recognised as having the same significance as an infratentorial 
lesion. The originally proposed time period of three months for dissemination in 
time (DIT) was reduced to one month for a new T2 lesion to satisfy DIT. The 
detection of a contrast-enhancing lesion, at least three months after the onset of 
the clinical event also constituted evidence for DIT.  
The European multicentre collaborative research network that studies MRI in MS 
(MAGNIMS) (Montalban et al., 2010) reviewed the requirements for 
demonstrating dissemination in space (DIS) and DIT, which proposed a new 
criterion for MS based on a single MRI scan. The proposed MRI criteria included: 
(i) one or more lesion (s) in at least two of four characteristic topographies: 
periventricular, juxtacortical, infratentorial and spinal cord, as outlined before, to 
satisfy DIS; and (ii) simultaneous presence of gadolinium-enhancing and non – 
enhancing lesions or a new enhancing lesion or T2 weighted lesion on any follow 
up scan, which provided evidence of DIT.  
These MAGNIMS criteria were subsequently incorporated into the 2010 revisions 
to the McDonald criteria (Polman et al., 2011), with the addition of symptomatic 
lesions in the brainstem or spinal cord excluded from DIS. The DIT criteria 
proposed by MAGNIMS was confirmed.  
The criteria for a diagnosis of PPMS was also included, whereby patients must 
have a one year of progression with two of the following: (i) evidence of DIS in 
the brain (≥1 T2 lesion in following locations: periventricular, juxtacortical or 
infratentorial), (ii) evidence of DIS in the spinal cord (based on ≥2 T2 lesions in 
the cord), (iii) positive unmatched OCBs (Polman et al., 2011). 
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The benefits of the 2010 McDonald criteria included the focus on lesion location 
rather than lesion count, the elimination of a mandatory interval between clinical 
attack and baseline reference scan and the acceptance of the concomitant 
presence of gadolinium-enhancing and gadolinium-nonenhancing lesions as 
evidence of DIT (Rovira et al., 2015). The new 2010 diagnostic criteria does not 
require CSF testing to support the diagnosis of MS but CSF findings may be 
helpful in certain individuals when the MRI scan is not entirely diagnostic and/or 
there are MRI features which are atypical for MS (Dobson et al., 2013). Overall, 
the 2010 McDonald criteria have improved the diagnostic process for RRMS, 
resulting in an easier and earlier diagnosis. However, there are some limitations 
for PPMS (Rovira et al., 2015), as brain MRI can be normal in people with PPMS 
and small spinal cord lesions may not be picked up on spinal MRI (Kelly et al., 
2013).  
The group made a few key recommendations which may guide future diagnostic 
criteria, including the addition of biomarkers (Awad et al., 2010, Orbach et al., 
2013), the inclusion of newer MRI sequences to detect cortical lesions and 
microstructural tissue injury in NAWM.  
Overall, MS is a very heterogeneous disease and no criteria are fully reliable on 
their own. A detailed clinical evaluation by an experienced neurologist is an 
essential part of the diagnostic process.  
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Clinical Presentation Additional requirements for a 
diagnosis of MS 
≥2 attacks; objective clinical evidence 
of ≥2  
lesions or objective clinical evidence 
of 1 lesion with reasonable historical 
evidence of a prior attack 
None 
≥2 attacks; objective clinical evidence 
of 1 lesion 
Dissemination in space (DIS), 
demonstrated by: ≥1 T2 lesion in at 
least 2 of the 4 MS-typical regions of 
the CNS (periventricular, infracortical, 
juxtacortical or spinal cord); 
Or 
Await a further clinical attack 
implicating a different CNS site. 
1 attack; objective clinical evidence of 
≥2 lesions 
Dissemination in time (DIT), 
demonstrated by:  
Simultaneous presence of 
asymptomatic gadolinium-enhancing 
and non-enhancing lesions at any 
time; 
Or 
A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference 
to a baseline scan; or await a second 
clinical attack 
1 attack; objective clinical evidence of 
1 lesion (clinically isolated syndrome) 
Dissemination in space (DIS) can be 
demonstrated by:≥1 T2 lesion in at 
least 2 areas of the CNS 
(periventricular, infracortical, 
juxtacortical or spinal cord); 
Or 
Await a second clinical attack 
implicating a different CNS site. 
DIT can be demonstrated with either: 
(A) Simultaneous presence of 
asymptomatic gadolinium-
enhancing and non-enhancing 
lesions at any time. 
(B) A new T2 and/or gadolinium-
enhancing lesion(s) on follow-
up MRI, irrespective of the 
timing of the baseline MRI  
Or 
Await a second clinical attack 
Table 1.1: 2010 Revised McDonald Criteria – Diagnosing RRMS (Polman et al., 
2011). 
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1.7 Therapy in MS 
There have been significant advances in the treatment of patients with RRMS 
over the last decade, with new and effective drugs now available e.g natalizumab, 
alemtuzumab and fingolimod. Unfortunately, the same cannot be said for 
progressive forms of MS, with all trials of anti-inflammatory agents essentially 
negative to date (Ontaneda et al., 2015), apart from one phase 2 trial in SPMS 
which significantly reduced the annualised rate of whole-brain atrophy on high 
dose simvastatin (Chataway et al., 2014). The pathological process driving 
disability progression in progressive MS is not fully understood, but it likely 
involves compartmentalised inflammation, mitochondrial dysfunction and 
neurodegeneration (Mahad et al., 2015). The lack of a clear understanding of the 
underlying pathology in progressive MS, in addition to the lack of sensitive 
outcome measures and fully validated biomarkers in progressive MS, make the 
development of effective treatments a big challenge (Ontaneda et al., 2015). The 
key to the successful development of treatments in progressive MS is in the 
development of biomarkers that are linked to the pathological processes 
underlying progression (Thompson, 2015).  
Therefore, the studies presented in Chapters III – VI aim at looking for reliable 
imaging biomarkers in progressive and relapsing MS, which may be useful in 
detecting clinically meaningful pathology which may have a role in clinical trials 
in the future. 
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This chapter will focus initially on the basic principles of magnetic resonance 
imaging (MRI). The latter part of the chapter discusses the MRI sequences 
employed in the studies described in the remainder of this thesis. 
2.1 Principles of MRI  
Magnetic resonance imaging is a non-invasive technique used to image tissues 
in the human body in vivo with high spatial resolution. Two-thirds of the human 
body is made up of water, therefore the human body is abundant with water 
hydrogen atoms. It is the nucleus of the hydrogen atom, which is fundamental to 
the generation of conventional MR and consists of a single proton surrounded by 
one electron. The proton has a net positive charge and spins on its own axis, 
resulting in the production of a small magnetic field.  These protons acquire a 
magnetic moment and can align with an external magnetic field.  
When an external magnetic field (B0) is applied to a hydrogen atom, the protons 
will align in either the same direction (parallel), or in the opposite direction (anti – 
parallel) with the magnetic field. This is similar to the way in which a compass 
oscillates about the earth’s magnetic field. Protons aligned in the magnetic field 
gyrate around their own axis in a motion known as precession. The frequency at 
which the protons precess is described by the Larmor equation, where ω0 is the 
Larmor Frequency given in Hz, B0 is the strength of the externally applied 
magnetic field given in Tesla and γ is the gyromagnetic ratio given in Hz/Tesla. 
The gyromagnetic ratio is the ratio between the magnetic dipole moment to the 
angular momentum of each MR active nucleus, which is unique for each MR 
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active nucleus. The gyromagnetic ratio is an intrinsic property of the nucleus of 
interest. 
                                                   
From this equation, the resonant frequency is proportional to the externally 
applied magnetic field and is determined by the gyromagnetic ratio. This ratio is 
different for different nuclei. The stronger the magnetic field the higher the Larmor 
frequency. For a 3 Tesla MRI scanner, the hydrogen nuclei precess at a 
frequency of 128 MHz.  
At equilibrium each hydrogen nucleus is either aligned parallel to B0, in a low 
energy state or anti-parallel to the magnetic field, in a high energy state. These 
two alignments of the hydrogen proton with the B0 result in two distinct energy 
levels. At room temperature a slight excess of protons align in the low energy 
state, this results in the net magnetisation (M) being in the direction of B0, as 
shown in Figure 2.1.  
 
Figure 2.1: Alignment of spins after the application of an external magnetic field. 
There is net longitudinal magnetisation in the direction of B0.  
 
ω0 = γ B0 
Chapter II: Principles of magnetic resonance imaging 
52 
The application of energy in the form of a radiofrequency (RF) pulse to the protons 
within an external magnetic field, induces them to flip to a higher energy state. 
Low energy spins originally aligned parallel to B0 gain enough energy to re-align 
anti-parallel to B0, resulting in the reduction of net longitudinal magnetisation. 
Both the duration and amplitude of the RF pulse determines the flip angle. The 
flip angle is the angle at which the net magnetisation deviates from B0. An 
example of this is a RF pulse with a 90o flip angle which converts all the 
longitudinal magnetisation into transverse magnetisation. This induces a voltage 
in the MR receiver coil and this forms the basis of the MRI signal.  
As the RF pulse is switched off, spins release energy to their surroundings in a 
process known as relaxation, and as a result the excited protons relax back to 
their equilibrium position, releasing electromagnetic energy which is detected by 
a coil that acts as an antenna. After the RF pulse is switched off, protons lose 
coherence and spins de-phase. This results in an increase in magnetisation in 
the longitudinal plane, with the spins returning to their original energy levels, 
aligning with B0. This is known as T1 recovery, and there is a decrease in the 
transverse plane, known as T2 decay. As transverse magnetisation decays, there 
is also decay of the voltage induced in the receiver coil. This reducing signal is 
known as free induction decay (FID).  
The RF pulse is not continuous and the time from one excitation pulse to the next 
is known as the repetition time (TR) and the time from RF pulse to maximum 
signal induction is known as the echo time (TE) (Hahn, 1950).  
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2.2 T1 – longitudinal relaxation 
Longitudinal relaxation or spin-lattice relaxation is the process whereby the 
protons return to their lower energy state and is due to spins releasing energy 
obtained from the RF pulse to the surrounding lattice and therefore to their 
original equilibrium state (Bloch, 1946). T1 is defined as the time required for 
longitudinal magnetisation to restore to 63% of its final value, as show in Figure 
2.2. 
Figure 2.2 T1 recovery curve – T1 relaxation time refers to the time taken for 
63% of the longitudinal magnetisation to recover. 
 
2.3 T2 – transverse relaxation 
Transverse relaxation or spin-spin relaxation is the process whereby protons lose 
phase coherence and the transverse magnetisation starts to disappear. It arises 
from the exchange of energy between spins. No energy is actually lost from the 
spin system but the decay of transverse magnetisation arises from the loss of 
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phase coherence between spins, which arise from magnetic field 
inhomogeneities (T2* relaxation) (Bloch 1946). T2 is defined as the time required 
for the transverse magnetisation to decrease to a value of 37% of its maximum, 
as show in Figure 2.3.     
 
Figure 2.3 T2 relaxation curve – T2 relaxation time refers to the time taken for 
transverse magnetisation to decay to 37%. 
 
2.4 Image contrast 
Contrast is of importance in MRI so that abnormalities in normal appearing tissue 
can be readily determined, such as demyelination in MS. Different tissues in the 
body have intrinsic contrast parameters that are fixed, however by altering 
parameters such as TR and TE, amongst others, extrinsic contrast can be 
changed. When viewing the image areas of high signal appear brighter and low 
signal are darker. 
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2.4.1 T1-weighted imaging 
The time constant T1 refers to the recovery of longitudinal magnetisation. As 
transverse relaxation is faster than longitudinal relaxation, T2 is always shorter 
than T1. Different tissues will have different relaxation times due to their different 
chemical constituents. For example, water is highly mobile with high inherent 
energy, while large molecules, like fat, have low inherent energy. Large 
molecules can transfer energy more efficiently, therefore T1 relaxation time is 
shorter in fat than in water. Also, molecules which are more tightly packed 
together, like fat, have greater spin-spin interactions and as a result protons in fat 
de-phase more rapidly and consequently have a shorter T2 relaxation time than 
water. The T1-weighting is determined by the TR and is characterised by short 
TE and short TR.  
2.4.2 T2-weighted imaging 
The time constant T2 refers to the time constant for decay of the transverse 
magnetisation in a uniform/homogenous magnetic field. T2 imaging decay varies 
depending on the tissue being imaged as decay is determined by the magnetic 
fields of nuclei interacting with each other. Water has a long T2 and fat has a 
short T2, due to slow dephasing of water molecules. T1 effects are diminished by 
selecting a long TR, to allow full recovery between excitations. T2-weighted 
images are characterised by long TE and long TR, in order to detect differences 
between tissues due to their difference in T2 relaxation times.  
2.4.3 Proton density imaging 
The proton density (PD) of a tissue depends on the number of protons in the 
tissue, which determines the signal of the PD weighted image. High signal is 
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produced by greater numbers of protons by increasing the transverse component 
of magnetisation. Decreasing the effects of T1 and T2, results in increased PD 
weighting of the image, which is achieved using a spin echo sequence with a long 
TR and a short TE.  
After a RF excitation pulse, the net magnetisation returns from the transverse 
plane to the longitudinal plane, and induces a voltage in the MR receiver coil. The 
magnitude of the transverse component decays and hence this reducing signal 
is known as FID, as described above. The time constant of this decay is called 
T2*. In theory one would expect the decay of the MR signal to occur with a time 
T2, however, in practice it occurs with the shorter T2*. This occurs due to the 
magnetic field inhomogeneity, imperfections in the windings of the coil itself and 
also due to the differences in magnetic susceptibility between adjacent regions. 
T2* is always shorter than T2. In a perfect magnetic field, the value of T2* can 
approach that of T2.  
2.5 Pulse sequences  
MRI pulse sequences are composed of a set of pre-defined RF pulses, re-
phasing pulses and gradient pulses. They are applied in a controlled fashion to 
form an MR pulse sequence. The main parameters of a pulse sequence are the 
TE and the TR as described above. The TE determines the amount of transverse 
magnetisation decay, therefore determining the amount of T2 weighting.  
There are two principle types of pulse sequence, called spin echo (SE) and 
gradient echo (GE).  
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2.5.1 Spin Echo Imaging 
The spin echo (SE) phenomenon was first described by Erwin Hahn in 1950 
(Hahn 1950). It was later enhanced by Carr and Purcell when they reported the 
benefit of an 180o refocusing pulse (Carr and Purcell 1954). This imaging 
sequence initially uses a 90o RF pulse, rotating the longitudinal magnetisation 
into the transverse plane, maximising the transverse magnetisation, with all the 
spins in phase. When the RF pulse is switched off, there is recovery of 
longitudinal magnetisation (T1 recovery) and decay of transverse magnetisation 
(T2 decay). It is not possible to reverse the loss of phase coherence due to the 
intrinsic effect of neighbouring spins within the tissue. However, it is possible to 
reverse the loss of phase coherence which arises due to the magnetic field 
inhomogeneities (T2* decay), by applying a second RF pulse, with an 180o flip 
angle to the de-phased nuclei, which results in flipping of the magnetic moments. 
After a time interval (TE/2), equal to the time between the first and the second RF 
pulse, the nuclei return to being in phase, and as a result the NMR signal 
increases again. This is described as a spin echo. Spin echo imaging is not 
sensitive to the presence of magnetic field inhomogeneities due to the refocusing 
following an 180o pulse. Therefore, the SE image intensity depends on T2 rather 
than on T2*. The spin echo diagram (Figure 2.4) demonstrates the timing and 
amplitude of the RF pulses.  
2.5.2 Fast spin-echo (FSE) sequences 
The fast spin echo (FSE) sequence is slightly different to the conventional spin 
echo, as multiple 180o RF pulses are applied after the initial 900 RF pulse. This 
results in a series of echoes, resulting in reduction in the total acquisition time. 
Chapter II: Principles of magnetic resonance imaging 
58 
FSE allows different TEs, therefore PD and T2 weighted images can be acquired 
from one sequence.  
 
Figure 2.4: Spin echo sequence diagram. An 180o pulse is applied at time t 
(TE/2) and an echo is detected at time 2t equal to TE. 
 
2.5.3 Gradient echo imaging 
Gradient echo sequences are an alternative means to rephase the spins 
compared to SE sequences.  It differs from SE sequences in that the initial RF 
pulse produces a flip angle which is typically less than 90o, and there is no 180o 
pulse. A flip angle less than 90o results in a reduction to the magnetisation in the 
transverse plane as not all the longitudinal magnetization is converted to 
transverse magnetization. After the RF pulse is turned off, spins in the transverse 
plane begin to dephase due to T2* effects. Rather than a RF pulse, re-phasing is 
achieved using gradients. After the excitation pulse a negative gradient is applied 
which causes rapid dephasing of the transverse magnetisation which has the 
effect of speeding up fast spins and slowing down slow spins. A positive gradient 
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is then applied which speeds up the slow spins and slows down the fast spins, 
hence spins which were previously dephasing, now begin to rephase, and after 
a certain time they will all come back into phase along the y-axis forming the 
gradient echo. The positive gradient only compensates for the dephasing caused 
by the negative gradient and it does not refocus dephasing due to the main 
magnetic field inhomogeneities. This is illustrated in Figure 2.5. 
Gradient echo imaging often suffers from signal loss due to dephasing of spins in 
the presence of magnetic field inhomogeneities. The gradient echo image 
intensity (that is the height of the echo), depends on T2* rather than on T2. As 
the dephasing of spins increases with increasing TE, gradient echo imaging is 
typically acquired with a very short TE (several milliseconds). The use of smaller 
flip angles in gradient echo imaging enables longitudinal magnetisation to recover 
faster, allowing shorter repetition times and hence lending gradient echo 
sequences for rapid in vivo MRI, reducing scan time and motion artefacts (Haase 
et al., 1985). A commonly used gradient echo sequence in investigation of 
multiple sclerosis is the T1 weighted magnetically prepared rapid acquisition 
gradient echo sequence (MP-RAGE) (Mugler and Brookeman, 1990). 
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Figure 2.5: Gradient echo sequence diagram. A radiofrequency pulse producing 
a flip angle <90o is applied, which is followed by a dephasing and rephrasing 
gradients to produce the echo.  
 
The following section will discuss advanced MRI techniques, which have been 
used in the studies in the following chapters of this thesis. 
2.6 Magnetic Resonance Spectroscopy (MRS) 
The discovery of chemical shift and spin-spin coupling in the early 1950s, was a 
result of the resonant frequency of the nuclear magnetic resonance (NMR) signal 
differing by small amounts in different molecules. This is due to differences in the 
local magnetic field surrounding each nucleus which depends on both the 
chemical structure of the molecule, as well as the magnetic properties of adjacent 
nuclei. Therefore, nuclei in different chemical environments will have different 
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resonant frequencies, allowing for the identification of both structure and relative 
concentrations of the molecules within an MR sample using MR spectroscopy 
(Proctor and Yu, 1950; Gutowsky and McCall, 1951). MRS therefore allows the 
non-invasive detection and identification of endogenous metabolites in vivo. The 
majority of in-vivo studies performed to date have used the proton (1H) nucleus 
due to its high sensitivity and favourable relaxation times (Barker et al., 2010). 
Other nuclei which are MR sensitive include phosphorus (31P) and carbon (13C). 
These nuclei have lower sensitivity, resulting in longer scan times and increased 
voxel size (Barker et al., 2010). The remainder of this section will deal with 1H-
MRS.  
2.6.1 Chemical Shift 
Nuclei are susceptible to changes within their local environment. The applied 
external magnetic field (B0) opposes the local magnetic field which arises from 
neighbouring electrons and nuclei. As a result, a current is induced which 
generates a small magnetic field to shield 1H spins from B0 which opposes the 
external magnetic field. 
The degree of shielding, and hence resonant frequency, will differ due to the 
unique chemical environment, resulting in different metabolites having slight 
shifts in resonant frequency. This phenomenon is known as chemical shift.  MRS 
is based on this principle and so nuclei within compounds can be distinguished 
on the basis of the resonant frequencies.  
The x-axis of the spectra is displayed in parts per million (ppm), of the resonance 
frequency of the metabolites of interest relative to the resonant frequency of a       
reference compound. For 1H and 13C, tetramethylsilane (TMS) is widely used as 
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a reference compound, having its resonant frequency of 0ppm. Peaks in the 
spectrum are called resonances.  
2.6.2 Shimming 
Shimming refers to the process of optimizing the magnetic field homogeneity over 
the volume of interest. It is performed by making slight adjustments to the field 
gradients prior to acquiring the data. The homogeneity of the voxel is measured 
as the linewidth (the full-width of the peak at half its height) of the water resonance 
and can be quoted in ppm or hertz (Hz). Poor shimming results in a reduction in 
the homogeneity and it produces a broad line width and good shimming produces 
a narrow linewidth. Poor shimming results in rapid T2* decay, with broad spectral 
lines, while good shimming, increases the time it takes for the signal to decay, 
resulting in a spectrum with smaller linewidths and therefore higher peaks.  
2.6.3 Spin-Spin Coupling (J-Coupling)  
One common feature of the MR spectrum is the appearance of multiplets - 
doublet or triplet peaks, which are signals associated with a single hydrogen 
environment which are split into a number of subsets. This arises when adjacent 
spins align parallel or anti-parallel to B0 and this effects the local field of the spin 
of interest (Barker et al., 2010).  This is known as spin-spin or J-coupling. The 
splitting due to coupling result in signals that have lower peak intensity and a 
broader footprint along the chemical shift axis, both of which makes coupled 
species more difficult to detect, for example Gamma-aminobutyric acid (GABA) 
(CH2) groups in the molecule and glutamate (Puts et al, 2012). 
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2.6.4 Localisation  
In single voxel spectroscopy a number of localisation techniques are used to 
excite a predefined voxel like the PRESS (Point RESolved Spectroscopy) 
(Bottomley, 1987)) or STEAM (STimulated Echo Acquisiton Mode) (Frahm et al., 
1989). Localisation techniques are used to excite predefined voxels which are 
prescribed by the operator in single-voxel MRS. Not using localising techniques 
results in contamination of the metabolite of interest by large signals, e.g lipids 
from surrounding tissues. Good localisation techniques significantly improve 
spectral quality.  
2.6.4.1 PRESS (Point RESolved Spectroscopy) 
PRESS is based on the spin-echo sequence and a 90o pulse is followed by two 
180o pulses so that the primary spin echo is refocused by the third pulse 
(Bottomley, 1987). Each of the pulses has a slice-selective gradient on one of the 
three principle axes, so that the protons within the voxel are the only ones to 
experience all three radiofrequency pulses. The signal intensity is twice as high 
as STEAM, therefore spectra can be acquired with a good signal-to-noise (SNR) 
in a relatively short time. Newer sequences allow short echo times compared with 
when PRESS was originally developed, when longer echo times were needed to 
allow for good visualisation of metabolites. 
2.6.4.2 MEGA-PRESS (MEscher-GArwood Point RESolved Spectroscopy) 
Mescher and Garwood first described the MEGA suppression scheme in 1998 
and it was found the technique could be applied to editing gamma-aminobutyric 
acid (GABA) from an MR spectrum (Mescher et al., 1998). It quickly became the 
standard technique for the measurement of GABA in MRS. It allows the GABA 
Chapter II: Principles of magnetic resonance imaging 
64 
signal at 3.02ppm to be separated from other overlying metabolites, which are at 
a stronger concentration, by utilising the known couplings within the GABA 
molecule (Mullins et al, 2014). J- coupling as described above describes the 
interaction between different hydrogen nuclei within the same molecule. MEGA-
PRESS exploits the knowledge of known couplings within a molecule by applying 
an RF pulse to one coupled spin, which consequently modifies the time evolution 
of a coupling partner and the appearance of the resulting peak in the spectrum. 
The use of MEGA-PRESS in GABA detection, is a focus of one of the pathways 
described in this thesis (Chapter III).  
GABA is present in the brain at a concentration of about 1mM (Puts et al., 2012). 
The chemical structure and MR spectrum of GABA consists of three different 
multiplets, which correspond to the three methylene (CH2) groups in the molecule 
(Puts et al., 2012). MEGA-PRESS (Mescher et al., 1998) works by collecting two 
interleaved datasets which differ in their treatment of the GABA spin system. In 
one dataset, the ON editing pulses is applied to the GABA spins at 1.9ppm, which 
selectively refocuses the evolution of J-coupling to the GABA spins at 3ppm 
(Mullins et al., 2012). While in the second dataset, the inversion pulse is applied 
elsewhere so that the J-coupling evolves freely throughout the echo time and is 
called the OFF editing pulse (Mullins et al., 2012). As the RF pulse is frequency 
selective, peaks which are not around 1.9ppm or at the resonance of the OFF 
pulse are not affected by the editing pulses. Subtraction of the refocused ON 
spectrum from the non-refocused OFF spectrum removes all the peaks from the 
spectrum and retains only those that are affected by the editing pulses. 
Subtraction occurs in the post-processing and the ON and OFF spectra are 
collected in an interleaved way to reduce the potential problem of subject and 
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hardware instabilities. The resulting edited spectrum contains signals close to 
1.9ppm, which were directly affected by the pulses and the GABA signal at 3 
ppm, which is coupled to the GABA spins at 1.9 ppm. In this way the GABA 
resonance, which had a large overlap from the tCr resonance, has been 
selectively edited from the spectrum offering clear identification of GABA at 
3.02ppm. 
In addition to this, the edited spectrum also contains, the combined Glx peaks 
(sum of glutamate and glutamine) at 3.75ppm which is coupled to the Glx 
resonances at 2.1ppm.  
One disadvantage of J-difference, is their reliance upon subtraction to remove 
overlapping signals from the spectrum, as it can result in subtraction artefacts 
which can obscure the intended edited GABA signals (Puts et al, 2012). 
2.6.5 Clinical Application of MR Spectroscopy in Multiple Sclerosis 
MRS can be seen as a complementary technique to MRI because it helps to 
enhance sensitivity to pathology; it also provides chemical and biophysical 
information about the microenvironment of tissues. MRS has the unique ability to 
characterize the chemical pathology of brain and spinal cord lesions in MS, as 
well as regions of the brain or spinal cord that are not associated with evident 
structural abnormalities on conventional MRI (Gass et al., 2015). This results in 
improved diagnosis and it helps to better define the natural history of the disease 
process (Lin et al., 2005). 
Quantitative MRI techniques, such as MRS, have been used to measure disease 
burden within focal lesions, both acute and chronic, as well as in normal 
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appearing white and grey matter of MS patients at different stages of the disease. 
1H-MRS has demonstrated that although grey and white matter may appear 
normal on conventional MRI, they may be affected in the early phases of the 
disease (Miller et al., 2003). 1H-MRS has the specificity to detect and differentiate 
between neuronal and glial abnormalities in the absence of distinct structural 
injury. 1H-MRS can be helpful in improving our  understanding in vivo of the 
neurobiological mechanisms of injury and repair in MS (Gass et al., 2015).  
Studies carried out to date in MS, have demonstrated changes in various 
metabolites, including N-acetylaspartate (NAA) (usually this refers to total NAA 
(tNAA), which is equal to the sum of NAA and N-acetylaspartate-glutamate 
(NAAG)), choline (Cho)(usually this refers to total Cho (tCho) = choline + 
phosphocholine), myo-inositol (Ins), glutamate (Glu), and creatine (Cr) (usually 
this refers to total Cr (tCr) = creatine + phosphocreatine) (De Stefano et al., 
2007a; Bakshi et al., 2008) in the brain and spinal cord, which suggest the 
presence of specific pathological abnormalities.  
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An example of an MR spectrum is shown in Figure 2.6 below.  
 
Figure 2.6: Example of a post-processed spectrum from the spinal cord of a 
healthy control. The chemical shift is on the x-axis in ppm and signal intensity on 
the y-axis. Cho – choline; Cr – creatine; Ins – myo-inositol; NAA – n-
acetylaspartate 
 
A decrease in NAA in the brain has been reported in all phases of the disease, 
including radiologically isolated syndrome, indicating neuronal dysfunction and/or 
axonal loss occurring at the earliest stage of MS (Stromillo et al., 2013). It is 
thought that NAA levels may reflect both axonal loss and metabolic dysfunction 
(Moffett et al., 2007). The discordant relationship between NAA and markers of 
structural damage (Cader et al., 2007), as well as the partial recovery of NAA 
after a relapse (Ciccarelli et al., 2010), suggests that NAA may reflect neuronal 
energy metabolism (Ciccarelli et al., 2014).  
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It has been proposed that Ins is a glial specific cell marker and increases in Ins 
are associated with astrocytic activation and proliferation (Brand et al., 1993; 
Chard et al., 2002). Increased Ins, is believed to reflect increased gliosis in 
patients with CIS which is associated with clinical conversion to MS (Fernando et 
al., 2004).  
It has been shown that Cr remains relatively constant in the ageing brain 
(Saunders et al., 1999) and it was thought that Cr remains relatively constant in 
diseases. As a result, Cr has been used as an internal reference to normalise the 
intensity of other metabolites. However, more recently it has been demonstrated 
that Cr levels are higher in the brain of MS patients (Inglese et al., 2003), therefore 
one needs to be careful if using Cr as an internal reference in MS patients. It is 
thought that increased Cr represents increased gliosis (Inglese et al., 2003).  
Cho is a normal constituent of cell membrane and myelin phospholipids. 
Increases in Cho is thought to represent myelin breakdown, which occurs in 
active demyelination (De Stefano et al., 2007b; Moore et al., 2012). In RRMS, 
one study found increased Cho in NAWM (Inglese et al., 2003), which is likely to 
reflect myelin breakdown.  
Glutamate (Glu) is the major excitatory neurotransmitter in the central nervous 
system and it is the precursor for the major inhibitory neurotransmitter GABA. Glu 
and glutamine (Gln) can be difficult to distinguish at 3T (Tkac et al., 2001), 
however a modification of the PRESS localisation at 3T enabled the separation 
of Glu and Gln in the brain (Hurd et al., 2004). Most studies carried out to date 
have quantified the glutamate + glutamine (Glx) complex (Hattori et al., 2002). 
Increased Glu has been found in acute MS brain lesions (Srinivasan et al., 2005) 
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and an association has been demonstrated between memory and glutamate 
levels in the hippocampal, thalamic and cingulate regions in RRMS patients, 
which may be related to Glu excitotoxicity and neuroaxonal loss (Muhlert et al., 
2014).  
GABA is the main inhibitory neurotransmitter in the CNS and it is produced from 
glutamate by glutamic acid decarboxylase (GAD) within GABAergic neurons 
(Chang et al., 2003). GABA is then metabolised to succinic acid semialdehyde by 
GABA transaminase (GABA-T) and then to succinate within astrocytic 
mitochondria (Chang et al., 2003). A number of clinical studies have been carried 
out to date using MRS to quantify GABA. Altered GABA concentrations in the 
brain have been detected in a number of conditions including epilepsy 
(MacDonald et al., 2010), schizophrenia (Reynolds et al., 2002) and depression 
(Hasler et al., 2007). One study carried out in MS found reduced motor function 
was associated with increased GABA levels in the sensorimotor cortex and 
increased motor activation on functional MRI in patients with RRMS 
(Bhattacharyya et al., 2013). Chapter III of this thesis will present the results of 
an MRS study, which quantified GABA in a number of regions in the brain in a 
cohort of patients with SPMS.  An example a post processed MRS GABA 
spectrum is shown in Figure 2.7. 
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Figure 2.7: Example of an MRS GABA post-processed spectrum from the left 
sensorimotor cortex from a healthy control. GABA - gamma-aminobutyric acid; 
tNAA – total N-acetylaspartate.  
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2.7 Diffusion Imaging 
2.7.1 Basic principles  
Diffusion can be defined as the random translational movement of molecules in 
a fluid system, including biological tissue (Le Bihan et al., 2001). When the 
concentration of fluid is uniform, diffusion is described statistically, by measuring 
the probability of a molecule travelling a given distance in a given diffusion time 
(Wheeler-Kingshott et al., 2003). In an isotropic fluid, such probability has a 
Gaussian distribution and the molecules are free to diffuse in any direction without 
restrictions (Wheeler-Kingshott et al, 2003). In biological tissue, white matter 
tracts contain closely packed, myelinated axons, orientated in a similar direction. 
Typically, diffusion of water molecules within axons and in the extracellular space 
tends to occur parallel to fibres, rather than perpendicular to the fibres, as the cell 
membranes and extracellular structures act as barriers (Wheeler-Kingshott et al., 
2003). This ordered, directional diffusion is called anisotropic diffusion. By 
measuring the degree of anisotropic diffusion, it provides useful biological 
information on the tissue’s microstructure.  A reduction in anisotropy reflects 
disruption to the microstructural integrity of white matter tracts, therefore allowing 
the diffusion of water molecules to occur more freely other than in the main 
orientation of the tract. 
2.7.2 Effects of diffusion on the MRI signal 
Diffusion of protons can affect the MR signal (Wheeler-Kingshott et al., 2003). 
Normally in tissue, there is a delay between the excitation and the refocusing of 
the magnetisation, when spins are diffusing due to thermal agitation. When there 
is no motion or diffusion of water molecules, the dephasing which occurs after the 
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first pulse is exactly rephrased after the 180o pulse. If there is random motion of 
the spins between dephasing and rephasing, then the refocusing of the spins is 
incomplete. This results in loss of transverse magnetisation and a reduction in 
the signal amplitude. Typically, the effects of diffusion are nearly always present, 
but these effects tend to be very small and do not contribute significantly to the 
signal attenuation in a standard spin-echo sequence. The amount of signal 
attenuation in a diffusion-weighted sequence depends on the diffusion properties 
of the tissue, the sequence parameters which determine the magnetic field 
gradients and the time during which the diffusion process takes place. 
2.7.3 Pulsed gradient spin echo 
The pulsed gradient spin echo (PGSE) was proposed by Stejskal and Tanner 
(Stejskal et al., 1965) to apply diffusion weighting to an MRI acquisition. It consists 
of a 90o and 180o spin echo pair of radiofrequency pulses, then large and equal 
gradient pulses are applied on either side of the 180o refocusing pulse. The first 
gradient pulse induces a phase shift for all spins and then the second gradient 
pulse reverses this phase shift. As a result, the phase shift for static spins is 
cancelled and spins which have changed location due to diffusion of molecules 
during the time period between the two gradients (∆ in figure 2.8), are not fully 
refocussed by the second gradient pulse and this determines the signal 
attenuation. The net displacement of water molecules is called the apparent 
diffusion coefficient (ADC). By manipulating the strength of the gradient (G), the 
pulse width (δ) and the diffusion time (∆), the degree of weighting or the b-factor 
can be controlled. The b-factor has units of s/mm2. Values of up to 1000s/mm2 
are required to obtain good contrast. Two acquisitions are performed, one without 
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superimposed diffusion gradient (b value = 0) and one with a diffusion gradient 
(b value ≠ 0).  
 
Figure 2.8: Pulsed gradient spin echo sequence for diffusion weighting. ∆ 
represents the interval between centres of the two diffusion gradients 
corresponding to the diffusion time, δ represents the pulse width and g is the 
magnitude of the diffusion-weighting gradient.  
 
2.7.4 Diffusion tensor 
The diffusion tensor model is a superior mathematical model of water diffusion 
within white matter tracts than the simple ADC, as it also provides information 
about the direction of diffusion, therefore it can characterise multi directional 
diffusion. The diffusion tensor model is represented mathematically by a 3x3 
tensor, which is a matrix of values. The diffusion tensor is made up of nine values, 
with each value corresponding to a gradient orientation and a cell orientation 
(Basser et al., 1994). However, only six elements need to be measured to 
estimate the full diffusion tensor as it is symmetric around the diagonal (Basser 
et al., 1994).  
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The diffusion tensor records the full direction of molecules, from which fractional 
anisotropy (FA) (a measure of the directional dependence of apparent diffusion, 
ranging from 0, when diffusion is equal in all directions and 1, when the apparent 
diffusion is along one direction only), mean diffusivity (MD) (the average 
diffusivity), radial diffusivity (RD) (index of diffusivity perpendicular to the main 
axis of the diffusion tensor i.e. perpendicular to the main fibre direction, increased 
RD relates to demyelination and decreased RD relates to remyelination) and axial 
diffusivity (AD) (diffusion parallel to the main axis) (Basser et al., 1996) are 
derived.  These diffusion tensor imaging (DTI) measures have been used as 
measures of microstructural tissue changes. Pathological processes, which lead 
to a reduction in the barriers that restrict diffusion, can result in an increase in 
apparent diffusion coefficient (ADC) values (Gass et al., 2015). The structure, for 
example myelin in the brain, alters the direction of movement of the water 
molecules, providing information about the microstructure of tissues along a 
diffusion direction (Filippi et al., 2003). A reduction in FA can arise due to a 
reduction in neurite density, an increase in the dispersion of neurite orientation 
dispersion, in addition to other microstructural changes (Beaulieu et al., 2002). 
In general MS lesions have an increased ADC to reflect expanded free water 
content within lesions due to a combination of oedema, demyelination and axonal 
loss (Horsfield et al., 1998). FA tends to decrease in MS lesions which is likely to 
be due to a reduction in white matter tract integrity and with an increase in the 
extracellular space as a result of disruption to myelin and axonal structures 
(Hygino da Cruz et al., 2011). Abnormalities in NAWM have been detected with 
DTI, with increases in ADC and MD and a decrease in FA (Ciccarelli et al., 2003) 
(increased diffusivity and reduced anisotropy). This is represented in Figure 2.9. 
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Figure 2.9: Example of an AD, RD, FA and MD maps from an MS patient with 
reduced FA and increased diffusivity seen in lesional tissue (white arrows). These 
images are from the DTI data acquired as part of the NODDI study in Chapter IV 
of this thesis.  
 
Overall, the simple measures associated with DTI (FA, MD, RD, AD), provide 
crude measurements of the underlying complex environment (Assaf et al., 2000, 
Assaf et al., 2008). Animal studies suggest that axial diffusivity is a marker of 
neuroaxonal damage and radial diffusivity is a marker of demyelination (Song et 
al., 2003; Zhang et al., 2009; Budde et al., 2009), although this has to be applied 
with caution when interpreting these measures in the human brain. However, it 
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has been suggested that a number of physical parameters can influence diffusion 
metrics such as demyelination, axonal density and fibre orientation, therefore 
making the diffusion tensor an imperfect model (Wheeler-Kingshott et al., 2014).  
The main limitations of the DTI model are that it based on a single fibre orientation 
in each voxel, therefore it fails in areas of heterogenous white matter, such as 
fibre crossing (Alexander et al., 2001) and the DTI microstructural indices lack 
specificity. Another limitation of the diffusion tensor model is that diffusion is 
generally not Gaussian and it does not reflect the real displacement behaviour of 
water molecules due to the presence of membranes and myelin (Enzinger et al., 
2015). Longer diffusion times, which are typical in clinical application, increases 
the likelihood of hindrance and restriction due to the underlying tissue 
microstructure, which interferes with the ideal Gaussian behaviour of free water 
(Enzinger et al., 2015). As a result of this, a number of more complex DWI 
techniques have been proposed, which are thought to reflect more accurately 
what actually happens at the tissue level (Enzinger et al., 2015). These newer 
diffusion techniques can be divided into (i) a model free and (ii) a model based 
methods. Quite a number of these newer diffusion techniques have been 
developed and as part of this thesis, I chose to study a model free diffusion 
technique – Q-space imaging (QSI) and a model based diffusion technique – 
neurite orientation dispersion and density imaging (NODDI), with the NODDI 
method designed and optimised to be performed in clinical settings (Zhang et al., 
2012). These two newer diffusion techniques have been used in two of the 
studies presented in Chapters IV and V, and these techniques will be discussed 
in the following section.  
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2.7.5 Q-Space Imaging 
The diffusion tensor model, described above, assumes that the displacement 
distribution function has a Gaussian probability of displacement, related to the 
diffusion of water molecules (Schneider et al., 2014a). QSI is a model free 
diffusion weighted imaging technique (Callaghan et al., 1988), which employs a 
Fourier transformation of the signal attenuation curve to determine the 
displacement distribution without assuming a Gaussian distribution.  
Diffusion weighted imaging (DWI) is typically performed in the low b – value 
range, usually < 1500s/mm2, where the signal decay is essentially 
monoexpotential (Farrell et al., 2008). In the CNS, the degree to which diffusion 
is reduced, compared to free water arises due to microstructural barriers, which 
includes multiple compartments in vivo (Farrell et al., 2008). When restriction 
between compartments is large, the exchange is slow on the MR time scale and 
as a result the signal attenuation will become non-monoexpotential (Farrell et al., 
2008). This effect is seen with higher b – values (>1500s/mm2). When the signal 
attenuation curve is Fourier transformed, it is possible to obtain the probability 
density distribution of the diffusion from which summary statistics are derived, 
specifically the full width of half maximum (FWHM) and zero displacement 
probability (P0).  These steps are outlined in Figure 2.10. 
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Figure 2.10: Steps involved in Q-space analysis. (A) The signal attenuation curve 
from the raw Q-space data is Fourier transformed. (B) This gives the probability 
density function. (C) Summary statistics (P0 and FWHM) are derived from the 
probability density function.  
 
FWHM and P0 describes the height and width of the displacement distribution 
function. Typically, a high P0 and a low FWHM is an indicator of more hindered 
diffusion, while a low P0 and a wide FWHM indicates freer or less hindered 
diffusion (Farrell et al., 2008). As Q-space metrics are contributed to from areas 
with non-Gaussian diffusion, it is thought to be a more sensitive technique for 
detecting restricted diffusion (Assaf et al., 2000; Assaf et al., 2002). Therefore, 
high b-value Q-space imaging, which measures slower diffusion within 
compartments, such as intra-axonal fluid, may contribute more to Q-space 
metrics than standard DTI (Schneider et al., 2014b) and may be more specific for 
axonal injury (Assaf et al., 2005).  
2.7.5.1 Clinical application of Q-space imaging in MS 
Patient studies on clinical scanners have been limited to date due to hardware 
limitations with the large gradients and short gradient pulses. Increasing the 
gradient pulses to compensate for the low gradients has enabled experiments on 
clinical scanners (Assaf et al., 2005; Latt et al., 2007). One study found that Q-
space imaging was more sensitive at detecting pathophysiological changes 
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within lesions and NAWM, when compared to DTI in the brain of MS patients 
(Assaf et al., 2002). The study by Assaf et al., 2002 found broadening of the 
FWHM and a decrease in the amplitude (P0) was more pronounced in lesional 
tissue, than NAWM and when compared to control tissue. Chapter V of this thesis 
will present the results of longitudinal changes in Q-space metrics in a cohort of 
patients with PPMS.  
2.7.6 NODDI (Neurite Orientation Dispersion and Density Imaging)   
Newer MRI sequences are needed to evaluate the microstructural changes in the 
brain and spinal cord, in order to give us a better understanding of the 
pathological changes taking place in MS. The quantification of neurite 
morphology in respect to its density and orientation distribution, gives us an 
insight into the structural basis of brain function (Zhang et al., 2012). A new 
technique called NODDI which has recently been developed at UCL (Zhang et 
al., 2012) addresses this. DTI provides sensitivity to tissue microstructure, but 
lacks specificity for individual tissue microstructural features. NODDI is designed 
to overcome the limitations of DTI, achieving higher sensitivity and specificity 
(Zhang et al., 2012). Diffusion is based on water displacement patterns, which is 
influenced by the underlying tissue microstructure. Diffusion MRI measures these 
displacement patterns, and therefore provides information on different 
microstructural environments (Zhang et al., 2012). During a typical diffusion MRI 
scan, two types of diffusion are seen, either hindered or restricted and these 
relate to two kinds of microstructural environments (Assaf et al., 2000). The 
NODDI model consists of three compartments: intra-neurite, extra-neurite and 
cerebrospinal fluid (CSF). The extra-neurite compartment refers to the space 
around neurites (refers to both axons and dendrites), which is occupied by 
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various types of glial cells, the extracellular matrix and neuronal somas in grey 
matter. Diffusion in this compartment is hindered but not restricted. Restricted 
diffusion is the diffusion of water with a non–Gaussian pattern of displacement, 
with restricted geometries and this describes the water in the intra-neurite 
compartment. The intra-neurite compartment is modelled as a set of cylinders of 
zero radius, which reflects the restricted diffusion perpendicular to axons and free 
diffusion along their length. The CSF component is modelled using isotropic 
diffusion. The differentiation of intra-neurite and extra-neurite water forms the 
basis of measuring neurite morphology with diffusion MRI (Zhang et al., 2012).  
The NODDI model provides three summary statistics: Orientation dispersion 
index (ODI), neurite density index (NDI) and isotropic volume fraction (isoVF).  
Eamples of these NODDI metrics as shown in the NODDI maps in Figure 2.11. 
ODI quantifies the variability of neurite orientations (Zhang et al., 2011). ODI 
values range from 0 – 1, with increasing ODI reflecting increasing variability of 
the underlying neurite orientations. As ODI approaches 0, neurites are all parallel; 
as ODI approaches 1, neurites are uniformally randomly orientated as can be 
seen in Figure 2.12. 
NDI is used to estimate neurite density and, with axonal loss a likely pathological 
substrate for disability in MS, NDI may be a useful marker of axonal loss in MS. 
Normal brain development is associated with an increase in the dispersion of 
neurite orientation distribution (Conel, 1939), while the aging brain is associated 
with a reduction in the dendritic density of the brain (Jacobs et al., 1997). Based 
on this, the NODDI model, may provide additional information to DTI, in a clinical 
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feasible setting and it may help to explain the key factors which contribute to 
physical disability.  
 
Figure 2.11: Example of NODDI maps from an MS patient (A) orientation 
dispersion index (ODI), (B) neurite density index (NDI) and (C) isotropic volume 
fraction (isoVF).  
 
Figure 2.12: Orientation dispersion index (ODI), which is the spread of neurite 
orientations, ranging from 0 (on the left) and 1 (on the right). (Figure reproduced 
with permission from Dr. Francesco Grussu).  
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2.7.6.1 Clinical application of NODDI in MS 
To date one pilot study has been carried out in the brain of MS patients 
(Schneider et al., 2014b). Results from this study found reduced NDI and ODI in 
MS lesions compared to healthy control white matter tissue and reduced NDI and 
increased ODI in NAWM of MS patients compared to normal white matter in 
controls, reflecting axonal loss and loss of fibre integrity in MS lesions (Schneider 
et al., 2014b). More recently the NODDI technique has been successfully applied 
to the spinal cord in healthy controls (Grussu et al., 2015b). NODDI in the brain 
has been used in the study presented in Chapter IV of this thesis, in patients with 
RRMS.  
2.8. Brain atrophy   
2.8.1 Background  
Brain atrophy is a global marker of neuroaxonal loss (Fillipi & Agosta, 2010). Brain 
volume loss is well recognised in MS from the very earliest stages and in a 
complex disease like MS, it reflects a generalised process involving various tissue 
compartments (Giorgio et al., 2008). It is reported that brain volume loss occurs 
at a rate of 0.5-1.0% per year in MS patients (Bermel et al., 2006), compared to 
healthy controls who have a rate of brain volume loss of 0.1-0.3% per year (Coffey 
et al., 1992; Pfefferbaum et al., 1994). The brain volume loss in controls is likely 
related to changes associated with age. The mechanisms which lead to brain 
atrophy are not fully understood and may arise due to a combination of 
demyelination, inflammation, and axonal damage and loss which may lead to 
retrograde neurodegeneration (Giorgio et al., 2008). A number of pathological 
studies have found that neuroaxonal damage and loss may occur independent of 
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demyelination, and this may be related to the presence of an abnormal glia-
axonal interaction in the absence of very little inflammation (Garbern et al., 2002).  
2.8.2 Technical  
In order to capture temporal patterns of structural brain changes, adequate MRI 
protocols as well as accurate and robust image analysis tools are required. Brain 
atrophy is generally measured on 2D/3D T1-weighted images. A number of MRI 
based methods are available to detect brain atrophy. 
Segmentation based methods are suitable for single time point analysis and are 
designed to analyse regional volumes. Brain parenchymal fraction (BPF) is one 
example which assesses global brain atrophy, which provides a ratio of volume 
of parenchymal brain tissue to the total volume within the outer surface of the 
brain, and it has been demonstrated that this measure is highly reproducible with 
a coefficient of variation of less than 0.2% (Rudick et al., 1999). Segmentation 
based methods are not recommended for longitudinal analysis.  
Registration based methods are sensitive to changes over time and are therefore 
recommended for longitudinal studies. An example of a registration based 
method is SIENA (structural image evaluation using normalisation of atrophy) 
(Smith et al., 2001). This method assesses brain volume changes by estimating 
directly the local shifts in brain edges across the entire brain. Firstly, the brain 
and skull are extracted from the two time points, the two brains are aligned to 
each other and both brains are then resampled into the halfway space between 
the two images, in order to avoid bias (Smith et al., 2004). Tissue type 
segmentation is then performed in order to find the brain/non-brain edge points 
and perpendicular edge displacement is then estimated at these edge points 
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(Smith et al., 2004). The mean edge displacement is then converted into a global 
estimate of percent brain volume change (PBVC) between the two time points 
(Giorgio et al., 2008). Another well-established registration based method is 
Boundary Shift Integral (BSI) (Freeborough & Fox, 1997), which is similar to 
SIENA as it uses linear registration to align the baseline and repeat images and 
then tracks the shift of the brain boundary location (Prados et al., 2015).  
It has been demonstrated that registration based techniques are more precise 
and sensitive compared to segmentation based methods for longitudinal data 
analysis (Anderson et al., 2007).  
Prior to any brain atrophy measurements, be it registration or segmentation 
based methods, lesion filling of the hypointense lesions on T1-weighted scan is 
performed in order to prevent misclassification of tissue during brain volume 
calculations. One study found 52% of lesion voxels were misclassified as grey 
matter (Chard et al., 2010), and as a result, an increase in lesion volume causes 
a false increase in grey matter volume.  
2.8.3 Clinical application 
Global brain atrophy has been demonstrated at all stages of MS (Bermel et al., 
2006). It has been demonstrated that those patients with CIS who have 
significantly greater ventricular enlargement develop MS when compared to 
those that remain stable (Dalton et al., 2002). Global brain atrophy measures 
predict disability and disability progression (Fisher et al., 2002). More recently it 
has been found that grey matter, but not white matter volumes, decreased with 
advancing disease in MS (Roosendaal et al., 2011) and disability and cognitive 
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impairment are better predicted by grey matter than white matter volume or T2 
lesion volume (Roosendaal et al., 2011). 
Regional measures of brain atrophy also vary with frontal, temporal and parietal 
lobes the most frequently involved cortical grey matter regions in MS patients 
(Calabrese et al., 2007).  Atrophy of the deep grey matter structures also occurs, 
with the thalamus the most consistently involved grey matter region in MS. 
Thalamic atrophy occurs within the first five years of MS onset, when most 
patients are minimally disabled (Henry et al., 2009) and it is also associated with 
conversion from CIS to clinically definite MS over 2 years (Zivadinov et al., 2013). 
Thalamic atrophy is associated with cognitive dysfunction, motor disability, 
fatigue and pain syndromes (Minagar et al., 2013).  
Brain atrophy has been used as an outcome measure in clinical trials in MS. 
Patients participating in clinical trials often have active disease with clinical 
relapses and evidence of gadolinium enhancing lesions on MRI. Resolution of 
this inflammation results in an initial accelerated decrease in brain volume during 
the first year of treatment, which is termed pseudoatrophy (Zivadinov et al., 2008). 
It is not known if the effects of pseudoatrophy continue to occur after one year. 
This needs to be further investigated to determine the full extent of pseudoatrophy 
after the initiation of certain therapies which may be related to resolution of 
inflammation as opposed to neurodegeneration (De Stefano and Arnold, 2015).  
Some of the newer disease modifying agents available (natalizumab, dimethyl-
fumarate, fingolimod, alemtuzumab) for the treatment of RRMS, have 
incorporated brain volume as an outcome measure and have shown to improve 
brain atrophy accrual when compared to placebo or another treatment (Vidal-
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Jordana et al., 2015; Miller et al., 2007b; Miller et al., 2015; Radue et al., 2012; 
Coles et al., 2008; Cohen et al., 2012). To date only one phase II clinical trial in 
SPMS have had positive effects on brain atrophy (Chataway et al., 2014).  
2.9 Spinal cord imaging 
Most of the above techniques can also be applied to the spinal cord; however 
overall spinal cord imaging is technically very challenging. The spinal cord is a 
small structure, motion artefacts can arise in the cervical cord due to cardiac 
systole (Mikulis et al., 1994) and truncation artefact can arise at the interface 
between high and low signal which can cause misrepresentation at the interface 
of the CSF/spinal cord surface within the image, which overall can degrade the 
image quality (Bronskill et al., 1988). Motion artefacts can be significantly reduced 
with the use of cardiac triggering and saturation bands. As well as this, fast 
imaging techniques have made spinal cord imaging more reliable which has, 
overall improved the quality of spinal cord data (Filippi and Rocca, 2011). The 
technical improvements which have been made to spinal cord imaging, have 
resulted in more spinal cord imaging studies taking place in MS. Lesions in the 
spinal cord are most commonly seen in the cervical cord and they are mostly 
located peripherally. Up to 90% of patients with MS have asymptomatic spinal 
cord lesions, whilst 30-40% of CIS subjects have asymptomatic lesions 
(Lycklama et al., 2003).   
2.9.1 Spinal cord 1H-MR spectroscopy  
Over the last decade, improvements in data acquisitions and post-processing, 
have made spinal cord spectroscopy possible. As discussed previously, NAA is 
a marker of neuroaxonal integrity and in the spinal cord a number of studies have 
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demonstrated reduced NAA in both acute and chronic lesions (Ciccarelli et al., 
2007; Marliani et al., 2010; Abdel-Aziz et al., 2015).  
One study demonstrated that following a spinal cord relapse, NAA levels are 
initially low and the NAA levels starts to recover as the patient recovers from the 
relapse (Ciccarelli et al., 2010). Cord area was then used as a surrogate marker 
of axonal density and it was found that changes in NAA levels were not entirely 
a result of axonal loss, but may also reflect mitochondrial dysfunction. These 
findings suggest that the recovery of NAA is partially explained by the recovery 
of mitochondrial function (Ciccarelli et al., 2010).  
Ins is a marker of glial function. One study demonstrated marginally increased 
Ins at the start of a spinal cord relapse, which correlated with disability (Ciccarelli 
et al., 2007). Reduced Ins was found in the spinal cord of patients with 
neuromyelitis optica when compared to MS patients, reflecting astrocytic loss, in 
keeping with the pathological hallmark of neuromyelitis optica (astrocytic 
necrosis) (Ciccarelli et al., 2013).  
Glx (the sum of glutamate and glutamine) represents the excitatory 
neurotransmitter pool. In the cervical cord Glx was lower in patients with PPMS 
compared to controls, which may be explained by neuro-axonal degeneration 
(Abdel-Aziz et al., 2015).  
2.9.2 Q-space imaging in the spinal cord  
Very few Q-space imaging studies have been performed in the spinal cord of MS 
patients. The change in the shape of the displacement distribution function in MS 
lesions in the spinal cord represents the loss of axonal and/or myelin barriers to 
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diffusion, as demonstrated in one study in patients with RRMS (Farrell et al., 
2008). This study demonstrated the feasibility of using high b-value Q-space 
imaging in four patients with MS in the spinal cord, as well as improved detection 
of abnormal diffusion compared to apparent diffusion coefficient (ADC) 
measurements (Farrell et al., 2008). A study in healthy controls demonstrated 
good reproducibility in perpendicular and parallel diffusivity in the ascending and 
descending tracts in the cervical cord (Schneider et al., 2011). More recently, 
Abdel-Aziz et al., 2015 found significantly higher perpendicular diffusivity in the 
whole cervical cord, anterior, posterior and lateral columns of the cervical cord in 
early PPMS compared to healthy controls. This is likely to reflect a breakdown of 
myelin and axonal membranes, which act as a microstructural barrier to 
perpendicular diffusivity (Abdel-Aziz et al., 2015).  They also found Q-space 
imaging metrics were more sensitive at detecting microstructural injury within the 
spinal cord than standard ADC measures (Abdel Aziz et al., 2015).  
2.9.3 Spinal Cord Atrophy  
2.9.3.1 Background 
Irreversible and progressive disability in MS is thought to be due to ongoing 
neuroaxonal loss and demyelination in white matter lesions (Trapp et al., 1998), 
NAWM (Evangelou et al., 2000) and grey matter (Kutzelnigg et al., 2005). Spinal 
cord involvement in MS often results in progressive locomotor disability. 
Demyelinating plaques are the characteristic feature of MS in the spinal cord. 
However, spinal cord neuropathological studies have demonstrated that axonal 
loss rather than plaques represent the main pathological substrate of irreversible 
physical disability (DeLuca et al., 2006; Lovas et al., 2000). It is reported that 
axonal density can be reduced by as much as 65% in the spinal cord in patients 
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with MS (Lovas et al., 2000). To date, clinical trials of anti-inflammatory therapies 
in progressive MS have generally been negative (Fox et al., 2012). There is an 
urgent need to develop biomarkers to measure important events in the neuronal 
injury pathway and correlate these with clinical disability (Fox et al., 2012) in 
progressive MS in order to facilitate development of neuroprotective agents.  
MRI is the most sensitive technique for detecting in vivo measurements of spinal 
cord cross sectional area. A reduction in spinal cord cross sectional area can be 
used as an approximate marker of axonal loss (Losseff et al., 1996: Bot et al., 
2004). Demyelination can also contribute to reduction in cord volume (Bot et al., 
2004). To date only a few clinical trials have used spinal cord cross sectional area 
as an exploratory endpoint in clinical trials due to the challenges in developing 
sensitive and reproducible methods (Kearney et al., 2014a). The rate of cord 
atrophy in MS is thought to be ~1% per year with substantial inter-subject 
variation (Rashid et al., 2006). As these changes are overall quite small, a very 
reproducible method is required to detect these changes longitudinally.  
2.9.3.2 Technical  
Initially spinal cord area was measured using manual outlining of the axial images 
of the cord (Kidd et al., 1993). A semiautomatic edge-detection method was then 
developed (Losseff et al., 1996). This method involved drawing two regions of 
interest, one around the spinal cord and one around the outer border of the CSF. 
A mean signal intensity of the cord and CSF was calculated and a signal intensity 
threshold halfway between the cord and CSF was used to define the edge of the 
spinal cord (Losseff et al., 1996).  The newest method, the active surface model, 
is more automated and allows rapid measurement of spinal cord area (Horsfield 
et al., 2010). This method involves the placement of cord markers centrally in the 
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cord on a number of axial slices. Then an outline of the cord is created 
automatically, allowing for the detection of atrophy in the cervical cord as shown 
in Figure 2.13. The C2/C3 region is used to measure spinal cord area using the 
active surface model as the CSF space is wide at this level so the cord tends to 
lie centrally, there is little variability in cross-sectional area at this level and it is 
not a common site for disc protrusion (Losseff et al., 1996). As well as this, post-
mortem work has demonstrated that as a result of flexion and extension of the 
head, the spinal cord can move up to 1.8 cm. However, this effect is least evident 
in the high cervical region (Reid, 1960).  
 
Figure 2.13: Example of an axial 3D-FFE image (resolution 0.5 x 0.5 x 5 mm3) 
through the C2/3 intervertebral disc from a healthy control showing the cord 
volume using the active surface model.   
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A highly reproducible method is required to detect these small changes in the 
spinal cord over time in order for it to be a feasible outcome measure in clinical 
trials.   The active surface model (ASM) is a rapid and reproducible semi-
automatic measure of spinal cord area (Horsfield et al., 2010). The active surface 
model has been demonstrated to be more reproducible than the Losseff 
technique (Losseff et al., 1996), with lower inter and intra-observer coefficients of 
variation compared to the Losseff technique (inter-observer coefficient of 
variation = 1.07% for the ASM versus 7.95% for the Losseff technique; intra-
observer coefficient of variation = 0.44% for the ASM versus 2.15% for the Losseff 
technique) (Horsfield et al., 2010). The feasibility of spinal cord cross sectional 
area quantification in the context of a multicentre study has been demonstrated 
using the active surface model in subgroups of MS patients (Rocca et al., 2011).  
2.9.3.3 Clinical application 
Spinal cord atrophy is seen in all stages of MS, with volume loss most marked in 
the progressive forms of MS. Cord atrophy has been detected in patients with a 
CIS, even in the absence of spinal cord symptoms (Brex et al., 2001). Several 
studies in MS subjects with a long disease duration found that cord atrophy is 
independently related to disability (Daams et al., 2014) (Kearney et al., 2014b) 
(Kidd et al., 1993). The study by Losseff et al., 1996, found a strong correlation 
between EDSS score and cord area with a reduction in cord area associated with 
increased levels of disability. It has been demonstrated both in-vivo (Bergers et 
al., 2002) and ex-vivo (Ganter et al., 1999), that cord atrophy occurs 
independently of focal lesions. It has been found that the rate of spinal cord 
atrophy does not correlate with the rate of brain atrophy which raises the 
possibility of independent disease processes causing brain and spinal cord 
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atrophy (Lukas et al., 2015).  Cord atrophy has the potential to be used as an 
imaging biomarker to monitor disease progression in MS, as well as a primary 
outcome measure in neuroprotective clinical trials to evaluate the effects of 
treatment. Chapter VI of this thesis presents the results of a study which 
investigated the changes in spinal cord atrophy in a progressive MS cohort.   
2.10 Conclusion 
The following Chapters III-VI will present the results of studies which have used 
a number of the above advanced imaging techniques in MS. 
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3.1 Introduction 
There is a need to understand the mechanisms of neurodegeneration in 
progressive MS (Fox et al., 2012), as described in Chapter I. SPMS develops 
after an initial RRMS course (typically 10-15 years), with or without acute 
exacerbations during the progressive course (Lublin et al., 2014). This results in 
irreversible and continuous neurological decline. There is a decrease in the 
development of new inflammatory lesions, but disability accumulation continues, 
which is likely to be due to ongoing neuroaxonal loss, the mechanisms for which 
include degeneration of chronically demyelinated white matter axons (Trapp et 
al., 1999) and progressive cortical demyelination (Kutzelnigg et al., 2005). SPMS 
results in significant motor and cognitive impairment in affected patients. 
Cognitive dysfunction is common, with prevalence rates of between 43% and 
70% (Langdon et al., 2012), affecting information processing speed (Amato et al., 
2010), episodic memory and executive function (Strober et al., 2009). The 
pathological processes underlying clinical disability in MS are complex, and 
include neuronal and glial changes with associated structural and metabolic 
abnormalities. These abnormalities may be detected in vivo by metabolic and 
molecular imaging (Ciccarelli et al., 2014). A recent study found that in MS 
patients, reduced concentrations of grey matter Glu, the main excitatory 
neurotransmitter of the human brain, correlated with worse memory function 
(Muhlert et al., 2014), suggesting that abnormalities in the neurotransmitter 
pathways may play a role in neurodegeneration, which underpins disability in MS. 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
brain (DeFelipe, 1993) and is produced from glutamate by L-glutamic acid 
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decarboxylase within GABAergic neurons (Chang et al., 2003), as described in 
Section 2.6.5. GABA is needed for normal brain function, synaptic plasticity, 
cortical adaptation and reorganisation (Stagg, 2014). Altered GABA 
concentrations, either increases or decreases, have been detected in a number 
of conditions, including epilepsy (MacDonald et al., 2010), and schizophrenia 
(Reynolds et al., 2002). GABAergic inhibition may be one of the mechanisms 
involved in use-dependent plasticity in the intact human motor cortex (Stagg et 
al., 2011; Levy et al., 2002). Changes in GABA concentration in the sensorimotor 
cortex during motor learning have been demonstrated (Floyer-Lea et al., 2006). 
One pilot study in RRMS (Bhattacharyya et al., 2013) found that reduced motor 
performance correlated with increased GABA levels in the sensorimotor cortex. 
The increased GABA concentration was also associated with increased motor 
activation on functional MRI. Despite limitations, these in vivo results suggest that 
cortical reorganisation occurring in the sensorimotor cortex in patients with 
RRMS, as reflected by increased functional MRI response, is linked with 
increased GABA levels, and is a possible compensatory mechanism that 
maintains motor function (Bhattacharyya et al., 2013).  
Magnetoencephalography (MEG) is a method of providing measures of neural 
activity and it is thought to reflect the effects of synchronous post-synaptic activity 
(Hari et al., 2010). The peak frequency of gamma oscillations in the primary motor 
cortex measured using MEG, which was induced by a button press task was 
positively correlated with GABA concentrations in this region in controls (Gaetz 
et al., 2011). This has also been demonstrated in the visual cortex 
(Muthukumaraswamy et al., 2009). This suggests that the frequency of gamma 
oscillations is determined by the GABA/glutamate ratio, with a low ratio 
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associated with efficient inhibition of relevant neural activity, therefore producing 
more precise task performance (Atallah & Scanziani, 2009; Takei et al., 2016). In 
vivo quantification of GABA using 1H-MR spectroscopy is challenging due to the 
spectral overlap of GABA with more abundant metabolites, such as N-acetyl-
asparate (NAA) at 2 ppm (Puts and Edden, 2012). MEGA-PRESS (MEscher-
GArwood Point RESolved Spectroscopy) is a spectral editing method that allows 
the discrimination of GABA from these metabolites (Mescher et al., 1998), as 
described in Section 2.5.6; it also allows quantification of tNAA, which, when 
reduced, indicates neuronal loss and/or metabolic dysfunction (Moffett et al., 
2007), and Glx, which has been found to be reduced in the spinal cord of PPMS 
patients compared to healthy controls, suggesting dysfunction in the 
glutamatergic pathway and neuroaxonal loss (Abdel-Aziz et al., 2015). 
Single voxel MRS using MEGA-PRESS has been used in a number neurological 
conditions to date as mentioned above. Specifically, the sensorimotor cortex has 
been studied in RRMS and demonstrated the MEGA-PRESS sequence is a 
reproducible method for the detection of GABA in this region (Bhattacharrya et 
al., 2013). One study carried out in controls successfully measured GABA in the 
hippocampus using the same protocol used in this study and also demonstrated 
good reproducibility of the measure in this region (Solanky et al., 2013b).  
Thus, the finding of: (i) reduced concentrations of Glu, which is the precursor of 
GABA, as observed in post-mortem (Wegner et al., 2006) and in vivo MR 
spectroscopy  studies in progressive multiple sclerosis (Sastre-Garriga et al., 
2005); (ii) reduced GABA-related gene transcripts and density of inhibitory 
neuronal processes in the motor cortex of autopsied MS brains (Dutta et al., 
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2006); and (iii) impaired compensatory mechanisms occurring in SPMS 
compared with RRMS (Rocca et al., 2005), lead us to hypothesise that GABA 
levels are reduced in SPMS patients when compared with  healthy controls and 
that they correlate with increased clinical disability. This is the first in-vivo study 
performed to date, to investigate reduced GABA levels in SPMS and its 
association with clinical disability. In order to test these two hypotheses, I 
measured the concentrations of GABA in the prefrontal cortex, right hippocampus 
(involved in visual and verbal memory) and left sensorimotor cortex using MEGA-
PRESS MR spectroscopy. I investigated whether there was an association 
between memory function and GABA concentration in the grey matter regions of 
the prefrontal cortex and hippocampus, and between sensory and motor function 
and GABA concentration in the left sensorimotor cortex. I examined if these 
associations were independent of imaging measures of structural damage, such 
as those sensitive to axonal loss and demyelination, derived from the same 
areas, and of tNAA and Glx, obtained within the same spectroscopic voxels. 
3.2 Materials and methods 
3.2.1 Subjects 
Patients with a diagnosis of SPMS who were not taking any medication that 
affects the GABAergic systems (e.g. Baclofen), for a minimum of 6 months prior 
to the time of scanning, and with an EDSS of between 4.0 - 6.5, were recruited 
into this cross-sectional stand-alone study. Healthy controls were also recruited. 
All the SPMS patients recruited into this study were recruited from the MS clinics 
ran on a weekly basis at The National Hospital of Neurology and Neurosurgery, 
Queen Square London. All healthy controls recruited into this study, were work 
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colleagues, friends and family as well as friends and family of the MS patients. 
Written informed consent was obtained for participants in the study, which was 
approved by our local research ethics committee (Study reference: 
05/Q0502/101).  
I recruited the SPMS patients from the MS clinics at Queen Square, I obtained 
the consent on the day of the scanning and I carried out all the clinical and 
cognitive testing on the day of the scan. The radiographers at the Institute of 
Neurology performed the actual MRI scans (Marios Yiannakas, Chichi Ugorji and 
Luke Hoy). I carried out the post-processing in TARQUIN and reviewed the 
results of each patient individually. If there were any issues with the data, I 
discussed and reviewed the results with Dr Bhavana Solanky, the Physicist who 
optimised the protocol. I assimilated the data in a spreadsheet, including all 
clinical, cognitive and MRI date. Dr. Dan Altmann and Dr. Carmen Tur performed 
the statistical analysis for this study. I interpreted the results from the statistical 
analysis performed and the results are presented below. 
3.2.2 Cognitive Tests 
Patients and controls were assessed using a range of cognitive tests. Speed of 
information processing was assessed using the Symbol-Digit Modalities Test 
(SDMT) (Lezak et al., 2004), and the 3-second Paced Auditory Serial Addition 
Test (PASAT) (Rao et al., 1990), for which z-scores were obtained with reference 
to published norms (Fischer et al., 1999). Executive function was measured using 
the Stroop colour-word interference test (Trenerry et al., 1989) and Hayling 
sentence completion test (Burgess and Shallice., 1997).  Verbal memory was 
assessed using The California Verbal Learning Test – II (CVLT-II) for immediate 
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and delayed recall (Delis et al., 2000) and visuospatial memory was assessed 
using the Brief Visuospatial Memory Test Revised (BVMT-R) (Benedict et al., 
1997). Working memory was assessed using the digit span from the Wechsler 
Adult Intelligence Scale-III (Wechsler et al., 1997). Premorbid IQ was measured 
using the National Adult Reading Test (Nelson, 1982). Levels of anxiety and 
depression were measured using with the Hospital Anxiety and Depression Scale 
(HADS) (Zigmond et al., 1983).  
Failure of a test (SDMT, Stroop, PASAT, Hayling Sentence Completion, Digit 
Span, CVLT-II and BVMT-R), was defined as a score of two or more SDs below 
the mean of the controls. Patients with significant cognitive impairment were 
defined as those showing failure on at least two tests.  
3.2.3 Clinical Assessments 
All patients were assessed using the EDSS (Kurtzke, 1983). All patients and 
controls were also assessed using the 9-Hole Peg Test (9-HPT) (Goodkin et al., 
1988), Timed 25-Foot Walk Test (TWT) (Cutter et al., 1999), and the Medical 
Research Council (MRC) scoring system for muscle strength of the right upper 
and lower limb (Medical Research Council, 1943; Dyck et al., 2005). Z-scores 
were calculated for the 9-HPT and TWT from normative values displayed in the 
National Multiple Sclerosis Society Task Force database (Fischer et al., 1999).  
Mean grip strength from the right upper limb was measured using the Jamar 
hydraulic dynamometer (Sammons Preston. Incorporated, Bolingbrook, IL, USA) 
(Svens and Lee, 2005). The average of two trials for the TWT and the average of 
two trials for the 9-HPT were calculated (Fischer et al., 1999).  Vibration 
perception thresholds (VPTs) were measured using the biosthesiometer (Bio-
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Medical Instrument Company, Newbury, Ohio) from both the right lateral 
malleolus and the right ulnar styloid process. Mean VPTs were calculated and 
used in the analysis. The right upper and lower limb scores from the motor and 
sensory tests were only included in the analysis as GABA concentration was 
estimated in the left sensorimotor cortex.  
3.2.4 Magnetic Resonance Imaging Protocol 
All scans were performed using a 3T Achieva system (Philips Medical Systems, 
Best, Netherlands) with a 32-channel head coil.  
3.2.4.1 Structural MR Imaging  
All participants underwent structural imaging, which included: (i) axial PD / T2-
weighted imaging using a 2D dual-echo turbo spin echo (TSE) sequence (TR = 
3500 ms; TE = 19/85 ms; flip angle α = 90o; FOV = 240 x 180 mm2; with spatial 
resolution of 1x1x3mm3); (ii) 3D MPRAGE (T1-weighted magnetisation-prepared 
rapid acquisition gradient-echo sequence) (TR = 6.9 ms; TE = 3.1 ms; flip angle 
α = 8o; FOV = 256 x 256 mm2; voxel size = 1 x 1 x 1 mm3); and (iii) axial 2D DIR 
(double inversion recovery) scan (voxel-size = 1 x 1 x 3 mm3, TR = 16000 ms; 
TE = 9.9 ms).  
We outlined hyperintense lesions in all SPMS participants on the axially acquired 
T2-weighted images using a semi-automated edge finding tool in JIM v. 6, then 
recorded the volume of T2-weighted lesions in millilitres for each subject. 
Hypointense lesions on the T1-weighted volume scan were marked and filled with 
values consistent with NAWM signal intensity to prevent misclassification of 
tissue during segmentation (Chard et al., 2010).  Segmentation of the lesion-filled 
image was then performed using SPM8 (statistical parametric mapping; 
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Wellcome Trust Centre for Neuroimaging, University College London (UCL) 
Institute of Neurology, London). The brain parenchymal fraction (the sum of white 
and grey matter relative to total intracranial volume) was then recorded for each 
subject. For calculation of brain tissue volumes, the grey matter, white matter and 
CSF masks were obtained by segmentation of the volumetric T1-weighted scans. 
DIR lesions were marked for each patient following consensus recommendations 
(Geurts et al., 2011).  
3.2.4.2 Single-Voxel Spectroscopy 
Sagittal T1-, coronal T2- and axial PD-weighted scans were used for voxel 
placement in the three grey matter regions (prefrontal cortex, right hippocampus 
and left sensorimotor cortex). 
Due to the significant overlapping signals of GABA with other metabolites, non-
invasive measures of GABA in the brain were acquired using the widely used 
MEGA-PRESS editing sequence (Mescher et al., 1998), with parameters TR= 
2000ms, TE = 68ms, MOIST water suppression, pencil-beam automated 
shimming, and editing pulses centred at 1.9 and 7.5ppm on each alternate scan. 
The dimensions and averages for the volume of interest were as follows: (1) right 
hippocampus: dimensions 30 x 19.2 x 16 mm3, volume = 9.22 mls, 576 averages; 
(2) prefrontal cortex: dimensions 28 x 30 x 22 mm3, volume = 18.48 mls, 432 
averages; and (3) left sensorimotor cortex: dimensions 35 x 34 x 22 mm3, volume 
= 26.18 mls, 400 averages. The acquisition and analysis protocol used in this 
study followed recently published guidelines for GABA-edited MR spectroscopy 
at 3 T using MEGA-PRESS (Mullins et al., 2014). Example placements of each 
volume of interest can be seen in Figure 3.1. 
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A non-water suppressed scan was also acquired with the same parameters (24 
averages in one block), to provide an internal water reference to metabolite 
concentrations. TARQUIN (Totally Automatic Robust Quantification in NMR), was 
used to estimate the concentrations of GABA, tNAA and Glx (Wilson et al., 2011).  
Figure 3.1: Placement of MR Spectroscopy (MRS) voxels (left) with their 
example MRS spectra (right) in the prefrontal cortex (A), right hippocampus (B) 
and the left sensorimotor cortex (C).  
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3.2.5 Spectral Quantification 
Spectral quantification was carried out using TARQUIN, which provides a fully 
automatic analysis of in-vivo spectra (Wilson et al., 2011). The analysis package 
uses a linear combination of basis functions to fit spectra (Wilson et al., 2011). 
For MEGA-PRESS data, TARQUIN uses a simple predefined basis set which 
models the GABA peak as two single Gaussian peaks (Mullins et al., 2014). The 
reliability of TARQUIN has been demonstrated to be comparable to other spectral 
quantification methods e.g LCmodel (O’Gorman et al., 2011). The non-water 
suppressed scan was used as an internal reference of known concentration to 
find the absolute concentrations of GABA.  
Spectral quality was assessed using Cramér-Rao-Lower-Bounds (Rao, 1946) 
values provided by TARQUIN, which represent the minimum possible variance 
on a fit parameter. Only data that had Cramér-Rao-Lower-Bounds values of 
≤20% were included in the analysis. From the participants, datasets for 6 controls 
and 14 patients had to be excluded from the hippocampus due to Cramér-Rao-
Lower-Bounds values larger than 20% (Near, 2014), and one patient’s dataset 
was excluded from the hippocampus due to time constraints. The hippocampus 
is technically very challenging due to its small size, the strong susceptibility to 
effects of nearby cranial air and bone, as well as the pulsatile cerebrospinal fluid 
surrounding it (Solanky et al., 2013b). In the prefrontal cortex, datasets from 3 
controls and 1 patient were excluded due to Cramér-Rao-Lower-Bounds values 
greater than 20%. In the sensorimotor cortex, 2 controls and 1 patient were 
excluded due to Cramér-Rao-Lower-Bounds values greater than 20% and 4 
patient datasets were not acquired due to time constraints.  
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The fractional content of grey matter and white matter within each spectroscopic 
voxel was calculated. In order to count the number of T2 and DIR lesions within 
each spectroscopic voxel, we created a binary mask of the spectroscopic 
voxel by using the absolute scan geometry of the PD/T2 and DIR volumes as a 
reference.  
3.2.6 Statistical analysis 
3.2.6.1 Differences in cognitive and clinical performance and metabolite 
concentrations between groups 
Differences between patients and controls were examined using independent-
sample t-tests. For GABA measures, differences were examined for each region 
separately using multiple linear regression to adjust for age, gender, grey matter 
and white matter fraction. Since the concentrations of tNAA and Glx can also be 
estimated within the same voxel using the same protocol, we completed the 
investigation by looking at these metabolites in the model.  
3.2.6.2 Associations between clinical disability and regional GABA levels in 
patients and controls 
Associations between GABA levels and clinical disability were examined in 
patients and controls combined using multiple regressions of the clinical variables 
on GABA predictors with interaction terms (i.e. group x GABA measure) to allow 
different associations between patients and controls to be estimated. These 
models allowed adjustment for covariates, such as age, gender, and premorbid 
IQ (when appropriate). Potential confounders, such as grey matter lesions within 
the spectroscopic volume of interest, anxiety and depression were also examined 
by including these as covariates. Grey matter lesions within the spectroscopic 
volume of interest were not included in the final model, as they did not contribute 
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to the model. In these models, variables describing executive function and 
information processing speed were regressed on prefrontal GABA concentration, 
those describing memory (visual and verbal) functions on hippocampus GABA 
concentration, and those describing right upper and lower limb motor and sensory 
ability on sensorimotor cortex GABA concentration.  
In patients only, to assess independence of GABA concentration from tNAA or 
Glx as predictors, tNAA or Glx was added to models with GABA in cases where 
GABA was significantly or borderline significantly associated with a clinical score.  
Where regression residuals showed deviation from normality, we used bias-
corrected nonparametric bootstrap with 1,000 replicates to obtain confidence 
intervals (CIs) and p-values. Significance was set at 5% level. All analyses were 
performed in Stata 13.1 (Stata Corporation, College Station, Texas, USA). 
3.7 Results 
3.7.1 Participant demographics and characteristics 
Thirty patients with SPMS (mean age = 51.3 years (SD9.6), 23 females, median 
EDSS=6 (range 4 – 6.5)) and 17 healthy controls (mean age = 46.3 years 
(SD11.7), 9 females) were studied. Overall patients had a short duration of 
progressive disease (mean duration of progressive disease = 4 years) and a 
moderate level of disability. Further details on patient demographic 
characteristics and disability are summarised in Table 3.1.   
3.7.2 Clinical disability 
As expected, patients had significantly slower processing speed on the SDMT (p 
< 0.001) and had worse verbal memory than controls, with significantly worse 
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immediate (p = 0.01) and 30 minute delayed recall (p = 0.02) of the list, after 
adjusting for age and gender (Table 3.1). In contrast, patients and controls did 
not differ in their executive function (Stroop p = 0.65, Hayling sentence completion 
p = 0.08), working memory (p = 0.26), visuospatial memory (p = 0.23), premorbid 
IQ (p = 0.09), or on the PASAT (p = 0.14). 63% of patients (n = 19) were 
categorised as cognitively preserved, with only 37% (n = 11) categorised as 
cognitively impaired.  
Patients performed significantly worse on all motor and sensory tests, when 
compared to controls, specifically, grip strength (p = 0.001), muscle strength (p = 
0.001), 9-HPT (p = 0.001), TWT (p = 0.001) and VPTs (p = 0.001), after adjusting 
for age and gender (Table 3.1).   
Physical 
disability tests 
 
Controls Patients Adjusted 
difference* 
(95% CI) 
P-value  
Median EDSS 
(range) 
NA 6 
(4 – 6.5) 
- - 
Mean 9-HPT 
(right arm, z 
score)  
1.19 
(0.53) 
-0.33 
 (1.29) 
-1.69 
(-2.36 to -1.01) 
<0.001 
Mean TWT  
(z score)  
0.41 
(0.02) 
0.06 
(0.33) 
-0.340 
(-0.52 to -0.16) 
<0.001 
Mean Grip 
Strength (right 
upper limb, kg 
force)  
28.13  
(13.53) 
12.83  
(6.99) 
-11.99 
(-18.12 to -5.85) 
<0.001 
Mean Vibration    
perception 
Threshold (VPT) 
(right upper and 
lower limb)  
7.83 
 (3.64) 
18.24  
(10.88) 
10.86 
(4.59 to 17.13) 
<0.001 
Mean MRC 
Strength (right 
upper and lower 
limb) 
70.00  
(0.00) 
61.38 
(4.81) 
-8.52  
(-11.22 to -5.83) 
<0.001 
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Cognitive Tests Controls Patients Adjusted 
difference* 
(95% CI) 
P-value 
Mean Anxiety 
(HADS) 
5.12 
(3.79) 
7.10 
(5.45) 
2.36 
(-0.81 to 5.54) 
0.14 
Mean Depression 
(HADS) 
3.47 
(1.81) 
5.67 
(3.51) 
2.45 
(0.51 to 4.39) 
0.0 
Mean Digit Span 
(scaled score)  
11.47  
(2.74) 
10.73  
(3.32) 
-1.12  
(-3.10 to 0.84) 
0.25 
Mean Stroop 
(seconds to 
complete)  
127.69  
(25.77) 
148.22  
(78.72) 
10.35 
(-35.09 to 55.78) 
0.65 
Mean SDMT 
(total score)  
60.00 
(12.35) 
45.63 
(14.06) 
-15.27 
(-23.30 to -7.24) 
<0.001 
List Learning Controls Patients Adjusted 
difference* 
(95% CI) 
P-value 
Mean Learning 
(total words)  
62.00 
(12.28) 
53.94 
(10.18) 
-8.30 
(-16.72 to 0.11) 
0.05 
Mean Recall after 
distraction  
14.18 
(1.83) 
11.69 
(3.14) 
-2.73 
(-4.64 to -0.82) 
0.01 
Mean 30 minute 
delayed recall  
14.18 
(2.60) 
11.69 
(3.14) 
-2.69 
(-4.87 to -0.52) 
0.02 
Mean PASAT (z 
score) 
0.15 
(1.07) 
-0.38 
(1.24) 
-0.53 
(-1.25 to 0.18) 
0.14 
Mean Visual 
recall – BVMT-R  
28.73 
(7.73) 
25.69 
(9.22) 
-3.49 
(-9.38 to 2.39) 
0.23 
Mean Hayling 
Sentence 
Completion 
5.93 
(1.27) 
5.43 
(1.25) 
-0.72 
(-1.51 to 0.08) 
0.08 
 
Table 3.1: Mean (SD) demographics, clinical and cognitive performance of 
patients and controls. * A linear regression model was used adjusting for age 
and gender.  
3.7.3 Structural MRI Measures 
Total grey matter DIR lesions in patients ranged from 0 – 32, with a median of 16 
lesions. The median number of grey matter lesions within each of the 
spectroscopic volumes of interest was 0 (Table 3.2).  
Patients showed significant whole brain white matter atrophy when compared 
with controls (white matter fraction: 0.32 vs. 0.34, p < 0.0001), after adjusting for 
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age and gender. There was no significant difference in total brain grey matter 
fraction (p = 0.74), or in the grey matter or white matter tissue volumes within the 
spectroscopic voxels between patients and controls (all p values>0.05) (Table 
3.2).  
Chapter III: GABA concentration in progressive multiple sclerosis 
109 
  
 
Controls Patients Adjusted 
difference* 
(95% CI) 
P-
value 
Total brain GMF 0.47 
(0.02) 
0.47 
(0.01) 
0.001 
(-0.01 to 0.01) 
0.74 
Total brain WMF 0.34 
(0.01) 
0.32 
(0.02) 
-0.02 
(-0.03 to -0.01) 
0.001 
BPF 0.81 
(0.02) 
0.80 
(0.02) 
-0.02 
(-0.03 to -0.004) 
0.01 
GMF in the 
hippocampus 
spectroscopic VOI 
0.54 
(0.10) 
0.58 
(0.09) 
0.05 
(-0.03 to 0.12) 
0.21 
WMF in the 
hippocampus 
spectroscopic VOI 
0.44 
(0.09) 
0.38 
(0.08) 
-0.06 
(-0.13 to 0.01) 
0.07 
GMF in the 
prefrontal cortex 
spectroscopic VOI                        
0.50 
(0.06) 
0.50 
(0.03) 
0.02 
(-0.01 to 0.05) 
0.24 
WMF in the 
prefrontal cortex 
spectroscopic VOI                          
0.35 
(0.07) 
0.33 
(0.08) 
-0.02 
(-0.08 to 0.03) 
0.33 
GMF in the 
sensorimotor cortex 
spectroscopic VOI 
0.32 
(0.04) 
0.35 
(0.10) 
0.03 
(-0.02 to 0.09) 
0.26 
WMF in the 
sensorimotor cortex 
spectroscopic VOI 
0.58 
(0.07) 
0.53 
(0.14) 
-0.05 
(-0.13, 0.03) 
0.18 
DIR lesions 
(median (range)) 
Controls Patients   
Total brain grey 
matter lesions 
NA 16 
(0 – 32) 
- - 
Grey matter lesions 
in the prefrontal 
spectroscopic   VOI 
NA 0 lesions 
(range 0-4) 
- - 
Grey matter lesions 
in the hippocampal 
spectroscopic VOI 
NA 0 lesions 
(range 0 -
1) 
- - 
Grey matter lesions 
in the sensorimotor 
cortex spectroscopic 
VOI 
NA 0 lesions 
(range 0 - 
2) 
- - 
 
 
Table 3.2:  MRI measures in patients and controls. * Adjusted for age and gender. 
WMF-white matter fraction; GMF-mrey matter fraction.  
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3.7.4 GABA concentration in the hippocampus and sensorimotor cortex 
was lower in patients than controls 
Patients had significantly reduced GABA concentration in the hippocampus 
(lower by 0.41mM (95% CIs -0.79, -0.01, p = 0.04)), and in the sensorimotor 
cortex (lower by 0.39mM (95% CIs -0.67, -0.10, p = 0.01)), when compared with 
healthy controls, after adjusting for age, gender, grey matter and white matter 
fractions within the spectroscopic voxel (Table 3.3). However, there was no 
significant difference in GABA concentration in the prefrontal cortex (p = 0.096) 
between patients and controls.  
Patients also showed a significantly reduced tNAA concentration in the 
sensorimotor cortex (lower by 2.46mM (p = 0.01)), when compared with healthy 
controls, after adjusting for age, gender, grey matter and white matter fractions 
within the spectroscopic voxel. There were no significant differences in tNAA 
levels in the hippocampus (p = 0.51) and prefrontal cortex (p = 0.58) between 
groups after adjusting for the above-mentioned covariates (Table 3.3).  
There were no significant difference in Glx in the prefrontal cortex, hippocampus 
and sensorimotor cortex between patients and controls (Table 3.3).  
  
Chapter III: GABA concentration in progressive multiple sclerosis 
111 
 
 Controls Patients Adjusted difference 
(95% CI) 
P-value 
Hippocampus     
GABA 1.46 
(0.47) 
1.08 
(0.33) 
-0.41 
(-0.792 to -0.014) 
0.04 
tNAA 5.52 
(1.645) 
3.62 
(2.74) 
-1.08 
(-4.51 to 2.35) 
0.51 
Glx 8.12 
(4.59) 
7.03 
(3.57) 
1.01 
(-12.47 to 14.43) 
0.86 
Sensorimotor 
Cortex 
    
GABA 1.51 
(0.46) 
1.17 
(0.35) 
-0.39 
(-0.67, -0.10) 
0.01 
tNAA 9.14 
(1.99) 
7.28 
(2.76) 
-2.46 
(-4.17, -0.74) 
0.01 
Glx 4.86 
(1.89) 
4.32 
(2.24) 
-0.71 
(-2.36, 0.93) 
0.38 
Prefrontal 
Cortex 
    
GABA 0.89 
(0.25) 
0.98 
(0.22) 
0.13 
(-0.02, 0.29) 
0.10 
tNAA 
 
7.76 
(3.25) 
7.93 
(2.34) 
0.57 
(-1.54, 2.67) 
0.59 
Glx 5.48 
(1.57) 
5.32 
(1.62) 
0.03 
(-1.21, 1.27) 
0.97 
Table 3.3:  Comparison of GABA, tNAA and Glx concentration (mean (SD) in 
mM) in the prefrontal cortex, right hippocampus and left sensorimotor cortex 
between the control group and the patient group. P-values given for adjusted 
group comparisons after correcting for age, gender, GMF and WMF within the 
spectroscopic VOI.  
 
3.7.5 Associations between GABA levels in the sensorimotor cortex and 
clinical scores 
In patients, worse motor function in the right upper and lower limb was 
significantly associated with lower GABA levels in the sensorimotor cortex, after 
correcting for age and gender. In particular, for each unit decrease in GABA 
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levels, there was a predicted -10.86 (95% CIs -17.79, - 4.48) decrease in grip 
strength (kg force) (p < 0.001) and -8.74 (95% CIs -13.94, -3.02) decrease in 
muscle strength of the right upper and lower limb (p < 0.006), according to the 
corresponding regression models. In addition, per unit decrease in GABA levels, 
there was a predicted borderline significant decrease in the 9-HPT of -1.26 (95% 
CIs -2.78, 0.26) (p < 0.10). These significant associations did not show any 
substantial change (i.e., their regression coefficients did not change) when tNAA 
and Glx levels in the sensorimotor cortex were included into the model. Repeating 
the regression models including age, gender, depression, and premorbid IQ did 
not change the pattern of results. There were no significant associations between 
GABA concentration in the sensorimotor cortex and the remaining physical 
disability scores, such as EDSS, TWT, and VPTs, and between GABA 
concentration in either the hippocampal or prefrontal volumes of interest and any 
of the cognitive tests. 
3.7.6 Associations between tNAA levels in the sensorimotor cortex and 
clinical scores 
In patients, lower tNAA in the sensorimotor cortex was also significantly 
associated with worse motor function, after correcting for age and gender. For 
each unit decrease in tNAA levels, there was a predicted -1.20 (95% CIs -0.48, -
1.98) decrease in grip strength (p < 0.02), -0.94 (95% CIs -0.73, -1.83) decrease 
in muscle strength (p < 0.05) and -0.14 (95% CIs -0.12, -0.30) decrease in 9-HPT 
(p < 0.04) according to the corresponding regression models. When the models 
regressing clinical scores on tNAA were adjusted for GABA, the direction and 
magnitude of the regression coefficients for tNAA completely changed (for grip 
strength: -1.20 vs. 0.56; muscle strength: -0.94 vs. 0.18; 9-HPT: -0.14 vs. 0.02), 
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while the direction and magnitude of those for GABA remained similar, before 
and after adjusting for tNAA (-10.86 vs. -15.26, -8.74 vs. -10.31, and -1.26 vs. -
1.30, respectively). There was no significant association between tNAA 
concentration in the sensorimotor cortex and EDSS, TWT and VPTs. 
3.8 Discussion 
This study provides evidence that (i) GABA levels are reduced in the 
hippocampus and sensorimotor cortex in patients with SPMS and (ii) lower GABA 
concentration in the sensorimotor cortex correlates with reduced motor function 
of the contralateral limbs. We will discuss each of these results in turn. 
3.8.1 Evidence of GABAergic dysfunction in SPMS 
The observed reduced GABA levels in the hippocampus and sensorimotor cortex 
in patients with SPMS when compared with healthy controls raises the possibility 
that GABA may be a marker of neurodegeneration in the brain. The reduction in 
GABA levels may reflect a combination of reduced GABA receptor levels and 
decreased density of inhibitory interneuron processes in the motor cortex in 
patients with progressive MS, which have been described by a previous 
histological study (Dutta et al., 2006). A positron emission tomography (PET) 
imaging study in MS using 11C-flumazenil (Freeman et al., 2010), which binds the 
benzodiazepine site on the GABAA receptor, reported that the uptake of 11C-
flumazenil was lower (indicating reduced GABAA receptor levels) in the cortex of 
patients with MS (RRMS and SPMS) compared with healthy controls (Freeman 
et al., 2010), suggesting the loss of dendrites and synapses as seen in post-
mortem analysis (Wegner et al., 2006), which may precede the development of 
measurable brain atrophy. A previous study reported reduced Glu levels in grey 
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matter (cingulate and parietal cortices) in RRMS patients compared to controls, 
suggesting that a reduced availability of the precursor glutamate may contribute 
to reduced synthesis of GABA. The significant decrease in tNAA concentration in 
the sensorimotor cortex in patients compared to controls confirms that there was 
significant neuronal loss and/or dysfunction in this region, since tNAA is a well-
established marker of neuroaxonal integrity, viability and metabolism (Moffett et 
al., 2007).   
In addition to being a marker of neurodegeneration, decreases in GABA levels 
may contribute to the ongoing neurodegenerative process in progressive MS. 
Although spectroscopic measurements in vivo do not allow us to draw firm 
conclusions about possible changes in the neurotransmitter pool and/or 
GABAergic pathway, there is some evidence from preclinical studies that MR 
spectroscopy-derived GABA levels reflect extra-synaptic GABA tone, rather than 
synaptic GABA activity (Mason et al., 2001). Therefore, the observed reduced 
GABA levels may reflect a reduction in inhibitory innervation of cortical neurons, 
which, in turn, upregulates the firing rate of demyelinated axons, resulting in 
higher energy demands, as proposed by Dutta et al., 2006; this may ultimately 
result in progressive axonal loss and neurodegeneration. Additionally, there is 
evidence that GABA mediates neuroprotection by delaying neuronal death (Saji 
& Reis, 1987). 
There was no difference in GABA levels in the prefrontal cortex between patients 
and controls, indicating a regional variation in altered GABA levels. This is likely 
to reflect regional variation in both the reduced synaptic density and neuronal 
loss, and in the possible role of altered GABA concentration, as a mechanism of 
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plasticity and functional reorganization, as explained below. Overall the GABA 
concentration was lower in controls than in patients in the prefrontal cortex, but 
this did not reach statistical significance. The study carried out by Bhattacharyya 
et al., 2011 found reduced GABA in the sensorimotor cortex in controls compared 
to RRMS patients. It has been demonstrated that in healthy controls, reduced 
GABA levels were observed in the prefrontal cortex during a working memory 
task and it is thought that this is related to synaptic plasticity (Michels et al., 2012). 
In the healthy brain, reduced GABA levels are thought to be associated with 
facilitating long-term potentiation like plasticity (Stagg et al., 2011), which may 
reflect the results in the prefrontal cortex in this study. The higher GABA levels in 
the SPMS patients in the prefrontal cortex may reflect loss of some of the adaptive 
mechanisms associated with plasticity.  
3.8.2 Association between lower GABA levels and physical disability 
In this study, there were associations between decreased muscle strength and 
worse performance on the 9-HPT, and lower sensorimotor GABA concentration. 
This suggests that greater loss of inhibitory neurons (and their processes) is an 
important contributor to clinical disability. Additionally, reduced GABA levels may 
represent a mechanism through which progressive axonal degeneration leads to 
progressive neurological disability. Patients with SPMS may have a loss of 
compensatory mechanisms associated with cortical reorganisation and 
adaptation, due to a reduction in synapses and neurons, resulting in the loss or 
deterioration in function.  
The observed correlation between worse 9-HPT scores and lower GABA levels 
in the sensorimotor cortex is in contrast to a study by Bhattacharyya et al (2013), 
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as previously mentioned. Bhattacharyya et al., found that a worsening of 
performance on the 9-HPT was associated with increased GABA levels in 
patients with RRMS.  These conflicting findings may reflect differences between 
patient populations (SPMS compared to RRMS). Patients with SPMS may have 
loss of the compensatory mechanisms associated with cortical reorganisation 
(Rocca et al., 2005), as a result of ongoing loss of inhibitory GABA 
neurotransmission, ultimately resulting in progressive neurodegeneration and 
progressive disability. In contrast, in RRMS, reduced GABA levels are associated 
with improved motor performance, as a result of adaptation of cortical grey 
matter. The inclusion, in the Bhattacharyya’s study, of patients currently taking 
GABAergic medications at the time of scanning is a limitation.  
I found no significant associations between GABA levels in the sensorimotor 
cortex and VPTs, TWT or EDSS. This may be due to the role of regions other 
than the sensorimotor cortex in contributing to the clinical function that is captured 
by these scores, the small range of EDSS (4-6.5) in the patient group, and the 
impact of changes in regionally specific GABA levels on function.  
It is surprising that patients’ performance on cognitive tests were not associated 
with GABA levels in relevant brain regions. It is difficult to say why I did not see a 
relation between memory function and GABA levels in the prefrontal cortex and 
hippocampus grey matter regions, but this may be due to a number of reasons. 
First, the patients recruited into this study were relatively early in their progressive 
disease course (mean duration = 4 years) and had no significant grey matter 
atrophy. Second, 63% of patients (n = 19) were categorised as cognitively 
preserved, with only 37% (n = 11) categorised as cognitively impaired. Third, a 
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sample size calculation with 80% power, at 5% significance, requires an N of 85 
to detect a significant association between GABA levels and the cognitive tests, 
which is substantially more than the number recruited into this study. Finally, 
GABA differences may be more widespread and so have an effect in relation to 
memory that is not evident in the single volume of interest studied.  
3.8.3 Association between lower tNAA levels and physical disability 
The observed reduction in tNAA in the sensorimotor cortex in patients compared 
to controls is in keeping with previous studies of reduced tNAA in MS (Kirov et 
al., 2013; Achnichts et al., 2013). tNAA is a well-established marker of neuronal 
loss and/or metabolic dysfunction as discussed in Section 2.6.5 (Moffett et al., 
2007). tNAA correlated with grip strength, muscle strength and the 9-HPT. 
Several studies in MS have demonstrated consistent correlations with tNAA and 
physical disability (De Stefano et al., 1997; Aboul-Enein et al., 2010). These 
studies confirm neuroaxonal damage as a mechanism of disability in MS. 
Nevertheless, the fact that tNAA was not a significant factor in the models 
including GABA, and that the regression coefficients for GABA did not materially 
change when adjusting for tNAA, indicates that the relationship between lower 
GABA and poorer clinical performance is confirmed and independent of the levels 
of tNAA.  
3.8.4 Limitations and future directions 
One limitation of this study is the shape of the spectroscopic volumes of interest 
and the linear relationship between the volume of interest and spectroscopic 
signal to noise ratio. As the regions of interest were small, it was necessary to 
use volumes of interest that encompassed the grey matter of interest, rather than 
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being completely contained within the specific region, in order to achieve reliable 
measurements of metabolite concentrations in acceptable acquisition times. 
Whilst every effort was made to limit the MR spectroscopy voxel to hippocampal 
grey matter, the size and shape of the volumes of interest meant this included 
some white matter from surrounding tissue, and small parts of neighbouring 
medial temporal lobe structures. This was necessary in order to attain a sufficient 
signal to noise ratio, in an acceptable acquisition time. The correction for white 
matter fraction and grey matter fraction within the spectroscopic voxel in the 
statistical models will have reduced the possibility that differences in these 
measures between groups were responsible for differences in GABA. One study 
(Bhattacharyya et al., 2011) measured GABA in the sensorimotor cortex with 
similar grey matter fraction (37+/-7%) and white matter fraction (52+/-12%) as to 
those reported in Table 3.2. They found that the concentrations of GABA within 
the grey matter and white matter were up to nine times greater in grey matter 
compared to white matter (2.87+/-0.61mM versus 0.33+/-0.11mM) 
(Bhattacharyya et al., 2011), which suggests that the majority of the GABA 
concentration quantified with MR spectroscopy derives from the grey matter. 
From a technical point of view, the spectral editing cannot separate the GABA 
signal from the macromolecule component, which may be clinically relevant 
(Cudalbu et al., 2012). A number of approaches have been proposed to separate 
GABA from co-edited macromolecule signals, including metabolite nulling (Behar 
et al., 1994), and symmetric editing-based suppression of macromolecules 
(Henry et al., 2001). Each of these methods have significant detrimental effects 
on the quality of the data as well as the acquisition time (Mullins et al., 2014), and 
macromolecule contamination is frequently accepted as a limitation of this most 
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commonly applied approach (Mullins et al., 2014). It has also been reported in 
the literature, that occipital cortex GABA concentration is modulated during the 
menstrual cycle, with reduced GABA during the follicular phase of the cycle 
(Epperson et al., 2002). I did not correct for menstrual cycle in our analysis, but 
note that this variable would not be relevant as 14 out of 23 female patients and 
4 of 9 female controls were menopausal. 
3.8.5 Conclusion 
Using 1H-MR spectroscopy, I provide the first in vivo evidence that GABA 
neurotransmission in the hippocampus and sensorimotor cortex is reduced in 
patients with SPMS when compared with healthy controls. Lower GABA levels in 
the sensorimotor cortex of MS patients are associated with reduced motor 
performance. These findings raise the possibility that altered GABA 
neurotransmission may be a marker of neurodegeneration, but it may also 
suggest that GABA is a mechanism of neurodegeneration in progressive MS 
patients. If I put these findings together with the evidence that GABA may mediate 
neuroprotection, targeting GABA may be a productive strategy that should be 
further explored in multiple sclerosis.  
After discussing metabolic imaging in SPMS in this Chapter, the next Chapter 
looks at a novel quantitative MRI technique, to explore its ability to detect more 
global microstructural changes in the brain of patients with RRMS. 
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4.1 Introduction 
In order to give us a better understanding of the pathological changes taking 
place in lesional tissue and normal appearing tissue newer MRI sequences are 
needed to evaluate the microstructural changes in the brain. A new technique 
called NODDI (neurite orientation dispersion and density imaging) has been 
developed to address this. NODDI is designed to overcome the limitations of DTI, 
achieving higher sensitivity and specificity (Zhang et al., 2012). It provides new 
opportunities to study diseases, such as MS, which alter neural tissue 
microstructure. 
DTI provides sensitivity to tissue microstructure, but lacks specificity for individual 
tissue microstructural features. The NODDI model consists of three 
compartments: intra-neurite, extra-neurite and cerebrospinal fluid (CSF), as 
described in Section 2.7.6. The intra-neurite compartment is modelled as a set of 
cylinders of zero radius, which reflects the restricted diffusion perpendicular to 
axons and free diffusion along their length. The extra-neurite compartment is 
modelled as simple Gaussian anisotropic diffusion as in the DTI model, where 
diffusion is hindered but not restricted.  The extra-neurite compartment refers to 
the space around neurites (refers to both the axons and dendrites), which is 
occupied by various types of glial cells, the extracellular matrix and neuronal 
somas in grey matter. Lastly the CSF compartment is modelled using isotropic 
diffusion and it is designed to capture CSF contamination and account for other 
potential sources of free water such as oedema.  
The NODDI model provides three summary statistics: Orientation dispersion 
index (ODI), neurite density index (NDI) and the isotropic volume fraction (isoVF). 
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ODI quantifies the variability of neurite orientations (Zhang et al, 2011). Values 
range from 0 to 1, with increasing ODI implying increasing variability of the 
underlying neurite orientations. For instance, for ODI approaching 0, neurites are 
all parallel; on the other hand, for ODI approaching 1, neurites are uniformally 
randomly oriented. Unlike DTI, NODDI estimates orientation dispersion and 
neurite density, with both contributing to conventional DTI metrics such as FA 
(Schneider et al., 2016). One study carried out in epilepsy found that the NODDI 
metrics increased the contrast over DTI for the detection of focal cortical 
abnormalities (Winston et al., 2014). NDI is used to estimate neurite density and, 
as axonal loss is a likely pathological substrate for disability in MS (Bonati et al., 
2011) and cervical myelopathy (Freund et al., 2011), NDI may be a useful marker 
of axonal loss in vivo in patients with these disorders. 
To date a number of preliminary studies using NODDI in MS have been 
performed by our group here at UCL. These studies have found increased ODI 
and reduced NDI in NAWM in RRMS patients when compared to white matter in 
control subjects (Schneider et al., 2014b; Schneider et al., 2016; Brownlee et al., 
2016). The increase in ODI is thought to reflect loss of fibre coherence (i.e. an 
increase in dispersion) in the NAWM of RRMS patients (Schneider et al., 2014b), 
while a reduction in NDI is thought to arise due to axonal loss and/or 
demyelination (Grussu et al., 2015a). In lesions, a reduction of both ODI and NDI 
and an increase in isoVF have been demonstrated when compared to NAWM in 
MS subjects (Schneider et al., 2016; Schneider et al., 2014b). The reduction in 
ODI in lesions, has been preliminary confirmed by histology in the spinal cord 
(Grussu et al., 2015a; Grussu et al., 2016). Significantly lower NDI in NAWM has 
been found in SPMS when compared to RRMS (Brownlee et al., 2016), with lower 
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NDI significantly associated with EDSS, suggesting NDI may reflect reduced 
density of axons and/or demyelination in NAWM which may contribute to disability 
in MS (Brownlee et al., 2016). A number of studies carried out by our group at 
UCL have found similar results in MS patients using the NODDI protocol used in 
this study and have demonstrated that this is a reproducible method (Schneider 
et al., 2014b).  
It has been demonstrated that in traumatic spinal cord injury patients there is 
disruption in the axonal architecture and information flow between the spinal cord 
and brain is interrupted, which results in significant clinical disability (Dietz et al., 
2011). As well as spinal cord atrophy, cortical atrophy and cortical reorganisation 
of the primary motor and sensory cortex have been demonstrated in the brain of 
spinal cord injury patients (Freund et al., 2011).  
One study investigated the relationship between microstructural white matter 
changes measured with standard DTI using voxel based morphometry, spinal 
changes and brain activation in spinal cord injury patients (Freund et al., 2012). 
This study found significant differences (reduced FA) in the corticospinal tract of 
the spinal cord injury subjects compared to controls, specifically in the pyramids, 
the internal capsule, the cerebral peduncle and the hand area (Freund et al., 
2012). These results suggest that microstructural changes in the brain are 
specific to the sensorimotor cortex in spinal cord injury (Freund et al., 2012). To 
date, NODDI has not been applied to cervical myelopathy patients. 
In this study I recruited a cohort of patients with RRMS, a cohort of cervical 
myelopathy patients and a healthy control group, to undergo the same brain 
NODDI protocol, in order to (i) investigate differences between groups and (ii) 
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look at the relationship between NODDI parameters and disability in both patient 
groups, and thus obtain insights into the factors that may contribute to disability. 
To complete the analysis, standard DTI parameters were also obtained from the 
same dataset.  
My objectives were as follows:  
(i) To determine if ODI, NDI and isoVF (NODDI summary statistics) applied 
to the brain can help differentiate between MS patients and controls. 
(ii) To determine if ODI, NDI and isoVF (NODDI summary statistics) applied 
to the brain can help differentiate between cervical myelopathy patients and 
controls. 
(iii) To correlate these MRI measures with physical disability in these two 
patient cohorts.   
4.2 Materials & Methods 
4.2.1 Study  
I recruited subjects with RRMS, cervical myelopathy and healthy controls into the 
study. Inclusion criteria for RRMS patients were: age between 18-65 years; and 
absence of a relapse or a course of corticosteroids in the three months prior to 
imaging. Inclusion criteria for cervical myelopathy patients were aged between 
18-65 years, previous cervical decompression (with or without an implant) at the 
level of C3/C4 or C4/C5 in the previous five years, and with or without signal 
change in the cervical cord. Exclusion criteria for cervical myelopathy patients: 
presence of a spinal implant at C2/C3.  
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All the RRMS patients recruited into this study were recruited from the MS clinics 
ran on a weekly basis at The National Hospital of Neurology and Neurosurgery, 
Queen Square London. The cervical myelopathy patients were obtained from Mr. 
David Choi, Consultant Neurosurgeon at The National Hospital of Neurology and 
Neurosurgery, Queen Square, as these patients were under his care for their 
cervical myelopathy. All healthy controls recruited as part of this study, were work 
colleagues, friends and family as well as friends and family of the MS patients.  
Written informed consent was obtained for participants in the study, which was 
approved by our local research ethics committee (Study Reference: 
14/LO/0608).  
For this study one of my clinical research colleagues, Dr Luke Kipp helped out 
with getting the consent on the day of the scan and doing the clinical 
assessments. Overall he performed 20-30% of the assessments and I performed 
the remainder of the assessments on the subjects recruited into this study. The 
radiographers at the Institute of Neurology performed the actual MRI scans 
(Marios Yiannakas, Chichi Ugorji and Luke Hoy). For the NODDI analysis, I used 
the relatively automated scripts which were developed by Dr Ferran Prados, Dr 
Torben Schneider and Dr Francesco Grussu, for the processing of the NODDI 
data. I assimilated the data in a spreadsheet, including all clinical, cognitive and 
MRI date. Dr. Carmen Tur performed the statistical analysis for this study. I 
interpreted the results from the statistical analysis performed and the results are 
presented below.  
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4.2.2 Cognitive Assessments 
All patients (both MS and myelopathic) and controls were assessed using a range 
of cognitive tests. Speed of information processing was assessed using the 
SDMT (Lezak et al., 2004), and the 3-second PASAT (Rao et al., 1990), for which 
z-scores were obtained with reference to published norms (Fischer et al., 1999). 
Verbal memory was assessed using the CVLT-II for immediate recall (Delis et al., 
2000) and visuospatial memory was assessed using the BVMT-R (Benedict et 
al., 1997).  
4.2.3 Clinical Assessments 
All patients (MS and cervical myelopathy) and controls were also assessed using 
the 9-HPT (Goodkin et al., 1988) and TWT (Cutter et al., 1999). Z-scores were 
calculated for the 9-HPT and TWT from normative values displayed in the 
National Multiple Sclerosis Society Task Force database (Fischer et al., 1999).  
The average of two trials for the TWT and the average of two trials for the 9-HPT 
were calculated (Fischer et al., 1999). MS patients were also assessed using the 
EDSS (Kurtzke, 1983). Cervical myelopathy patients were also assessed using 
the ASIA (American Spinal Injury Association) impairment scale (Maynard et al., 
1997).  
4.2.4 MRI protocol 
Subjects were scanned at 3T using a Philips Achieva MRI system with RF multi-
transmit technology (Philips Healthcare, Best, the Netherlands). Brain scans 
were performed using a 32 – channel coil. A polystyrene filled bag was placed 
behind the neck of all participants to minimise motion artefacts.  
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The following scans were performed: 
For calculation of brain T2 lesion volumes, PDT2 weighted images were acquired 
using a dual-echo turbo spin echo (TSE) sequence [parameters; TR = 4900ms; 
TE = 15/85ms; flip angle α = 90o; FOV = 240 x 180mm2; voxel size = 0.5 x 0.5 x 
2mm3].  
For calculation of brain tissue volumes, a 3D T1-weighted magnetisation – 
prepared gradient – echo sequence was used [TR = 6.9ms; TE = 3.1ms; flip angle 
α = 8o; FOV = 256 x 256mm2; voxel size = 1 x 1 x 1mm3; NEX = 1; 180 sagittal 
contiguous slices].  
The brain NODDI diffusion-weighted images were acquired using a spin echo-
planar imaging sequence. The imaging parameters were; FOV = 192 x 222mm2; 
TR = 12000ms; TE = 91ms; flip angle α = 90o, voxel size = 2.5 x 2.5 x 2.5 mm3, 
b-values 300/1000/2855s/mm2 with 6/30/60 isotropically distributed gradient 
directions and 10 interleaved non-diffusion weighted (b=0) images. 
4.3 Image Post Processing 
4.3.1 T2 hyperintense lesions 
T2 hyperintense lesions were manually outlined from the T2-weighted images 
using the semi-automated edge finding tool from (JIM v6.0, Xinapse systems, 
Aldwincle, UK). Afterwards the volume of T2-weighted lesions in millilitres was 
recorded for each subject.   
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4.3.2 Brain segmentation 
The PD-weighted lesion masks were co-registered to the 3D-T1 images using a 
pseudo-T1 image generated by subtracting the PD from the T2-weighted image 
(Hickman et al., 2002). Lesion masks were transformed from native space to 
3DT1 space using linear interpolation. The 3DT1 images were filled using a non-
local patch match lesion filling technique (Prados et al. 2014).  
For brain extraction, tissue segmentation and parcellation, we used Geodesical 
Information Flows (GIF) (Cardoso et al., 2015). In brief, GIF is a segmentation 
technique that uses imaging databases as sources of information. GIF is able to 
propagate voxel-wise annotations, such as tissue segmentation or parcellation, 
between morphologically dissimilar images by diffusing and mapping the 
available examples through intermediate steps. A spatially-variant graph 
structure connecting morphologically similar subjects is introduced over the 
database of images, enabling the gradual diffusion of information to all the 
subjects, even in the presence of large-scale morphological variability. The 
database of images used for this study has 95 neuroanatomically labelled MRI 
brain scans following the Neuromorphometrics protocol. GIF is part of NiftySeg 
(http://niftyseg.sf.net) software package and is available as an online tool at 
http://cmictig.cs.ucl.ac.uk/niftyweb.  
4.3.4 NODDI processing 
Each diffusion-weighted image was corrected for eddy current-induced 
distortions and subject movements using FSL (FMRIB, Oxford, UK) (Andersson 
et al. 2016). For the NODDI fitting, the Matlab (The MathWorks, Inc., Natick, 
Massachusetts, USA) NODDI toolbox using the default settings was used to 
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generate ODI, NDI and isoVF maps (http://nitrc.org/projects/noddi_toolbox) 
(Zhang et al., 2012). The NODDI maps were then registered to the segmented 
tissue masks and T2 lesion masks to extract the tissue specific NODDI values. 
To complete the analysis, standard DTI parameters were obtained from the same 
dataset using the open-source Camino toolbox (Cook et al., 2006), 
(http://camino.cs.ucl.ac.uk/), using only the b=0 and b=1000s/mm2 data for each 
subject. Specifically, we derived the following DTI metrics: fractional anisotropy 
(FA), radial diffusivity (RD), axial diffusivity (AD) and mean diffusivity (MD).  
4.4 Statistical Analysis 
Linear regression models were used to look for differences in clinical scores 
between patient groups and controls, correcting for age, gender and BPF, with 
the clinical score used as the dependent variable.  
Differences in NODDI measures and standard DTI measures in NAWM, cortical 
grey matter and deep grey matter were examined between RRMS and controls 
and cervical myelopathy patients and controls using multiple linear regression 
adjusting for age, gender and the specific tissue fraction (WMF or GMF), with the 
MRI measure used as the dependent variable and group as the independent 
variable. The models were also repeated adjusting for T2 lesion load but it was 
not included in the final model, as it did not contribute to the model.  
Paired t-tests were used to look at the differences in NODDI metrics between T2 
lesions and normal appearing white matter in the RRMS group.  
Associations between NODDI metrics and clinical disability were examined in 
RRMS patients using multiple linear regressions, correcting for age, gender and 
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the specific tissue fraction (WMF or GMF), with the clinical disability score used 
as the dependent variable and the MRI measure as the independent variable.  
Statistical significance was considered when p values were below 0.05. All 
analyses were performed using SPSS 21 (IBM).  
4.5 Results 
4.5.1 Participant demographics and characteristics   
Twenty-five patients with a diagnosis of RRMS (mean age = 39.4 years (SD 6.6), 
20 females, median EDSS 2.5 (range 1.0 – 6.5)), 15 cervical myelopathy patients 
(mean age = 48.9 years (SD 7.3), 7 females) and 20 healthy controls (mean age 
= 36.6 years (SD 12.5), 13 females) were recruited into the study. Overall the MS 
patients had a mean duration of disease of almost eight years (Table 4.1) and a 
median EDSS of 2.5. Seven of the cervical myelopathy patients had signal 
change in the cervical cord. Further details on patient demographic 
characteristics and disability are summarised in Table 4.1.   
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 RRMS Cervical 
myelopathy 
Controls 
N 25 15 20 
Mean age (yrs) 39.4 (6.6) 48.9 (7.3) 36.6 (12.5) 
Gender (M:F) 5:20 8:7 7:13 
Mean disease 
duration (yrs) 
7.96 (5.59) - - 
Median EDSS 
(range) 
2. 5 (1.0 – 6.5) - - 
Mean ASIA – 
motor  
- 98.60 (2.35) - 
Mean ASIA – pin 
prick  
- 110.93 (1.71) - 
Mean ASIA – 
light touch  
- 109.20 (4.16) - 
Mean T2 lesion 
volume (mls) 
12.67 (13.68) - - 
WMF 0.30 (0.01) 0.32 (0.01) 0.31 (0.02) 
GMF 0.45 (0.01)* 0.44 (0.01) 0.46 (0.01) 
BPF 0.75 (0.02)* 0.76 (0.01) 0.77 (0.01) 
Table 4.1: Mean (SD) demographics and clinical characteristics of patients and 
controls. * p<0.05, significant difference between RRMS and controls after 
performing a linear regression model correcting for age and gender.  
 
4.5.2 Clinical disability 
Patients with RRMS had significantly slower processing speed on the SDMT 
(p<0.02), worse visual (p<0.01), and verbal memory (p<0.04), and were 
significantly impaired in the TWT (p<0.01) when compared to controls, after 
correcting for age, gender and BPF. There was no significant impairment in the 
PASAT (p<0.06) and 9-HPT (p<0.07) (Table 4.2).  
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Patients with cervical myelopathy had worse verbal memory (p<0.03) when 
compared to controls, after adjusting for age, gender and BPF (Table 4.3). They 
did not differ from controls in the TWT, 9-HPT, PASAT, SDMT and BVMT-R. 
There was no significant difference demonstrated between the RRMS and 
cervical myelopathy patients in any of the clinical and cognitive assessments.   
Physical disability 
tests 
 
RRMS Healthy 
controls 
Adjusted difference* 
Estimate RC (95% CI) P-value 
Mean 9-HPT (z 
score) 
0.31 
(0.39) 
0.50 
(0.05) 
-0.09  
(-0.19 to 0.01) 
0.07 
Mean TWT (z 
score) 
0.17 
(0.93) 
0.79 
(0.54) 
-0.34   
(-0.58 to -0.09) 
0.01 
Cognitive Tests RRMS Controls Estimate RC (95% CI) P-value 
 
Mean SDMT (total 
score) 
54.56 
(11.19) 
62.13 
(10.15) 
-3.72  
(-6.74 to -0.71) 
0.02 
Mean PASAT (z 
score) 
-0.42 
(1.18) 
0.29 
(0.80) 
-0.33  
(-0.67 to 0.02) 
0.06 
Mean Visual recall 
– BVMT-R  
22.28 
(7.50) 
28.29 
(3.87) 
2.91 
(0.80 to 5.02) 
0.01 
Mean Californian 
Verbal Learning 
test – CVLT-II 
(Immediate Recall) 
57.80 
(11.33) 
63.27 
(8.19) 
-3.36   
(-6.59 to -0.14) 
0.04 
Table 4.2: Mean (SD) clinical and cognitive performance of RRMS patients and 
controls. * A linear regression model was used adjusting for age, gender and 
brain parenchymal fraction (BPF). RC – regression coefficient. 
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Physical 
disability tests 
 
Cervical 
myelopathy  
Healthy 
controls 
Adjusted difference* 
Estimate RC 
(95% CI) 
P – 
Value 
 
Mean 9-HPT (z 
score) 
0.20 (0.56) 0.50 (0.05) -0.21 
(-0.54 to 0.12) 
0.21 
Mean TWT 
(z score)  
0.41 (0.11) 0.79 (0.54) -0.21 
(-0.53 to 0.10) 
0.18 
Cognitive Tests Cervical 
myelopathy 
Controls Estimate RC 
(95% CI) 
P – 
Value 
Mean SDMT (total 
score) 
52.80 (8.56) 62.13 
(10.15) 
-4.06 (-10.77 to 
2.65) 
0.23 
Mean PASAT (z 
score) 
-0.19 (1.03) 0.29 (0.80) -0.25 
(-1.00 to 0.50) 
0.50 
Mean Visual recall 
– BVMT-R 
24.64 (7.70) 28.29 (3.87) -2.37 
(-8.01, 3.27) 
0.39 
Mean Californian 
Verbal Learning 
test – CVLT-II 
(Immediate Recall) 
52.13 
(12.64) 
63.27 (8.19) -10.41 
(-19.61 to -1.22) 
0.03 
Table 4.3: Mean (SD) clinical and cognitive performance of cervical myelopathy 
subjects and controls. * A linear regression model was used adjusting for age, 
gender and BPF.  
  
4.5.3 Difference in MRI metrics between RRMS and controls 
There was a significant decrease in NDI in the NAWM in RRMS patients 
compared to controls (regression coefficient (RC) -0.02, 95% confidence intervals 
(CI) -0.04 to -0.002, p = 0.03) after correcting for age, gender and WMF (Figure 
4.1 & Table 4.4). There was no significant difference in any of the other NODDI 
parameters (Figure 4.1 & Table 4.4) or standard DTI parameters in the NAWM, 
cortical and deep grey matter (Table 4.4).  
There was a significant decrease in the GMF (p=0.01) and brain parenchymal 
fraction (BPF) (p=0.02) in RRMS patients compared to controls after correcting 
for age and gender (Table 4.1).  
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(A) Normal appearing white matter 
(B) Cortical grey matter 
(C) Deep grey matter 
(D) Normal appearing white matter and T2 lesions 
 
Figure 4.1: Boxplots of the NODDI metrics (ODI, NDI and isoVF) in: (A) normal 
appearing white matter (NAWM), (B) cortical grey matter (CGM), (C) deep grey 
matter (DGM) in RRMS and cervical myelopathy patients when compared to 
healthy controls, and (D) in NAWM compared to T2 lesions in RRMS patients 
only. P values adjusted for age, gender and WMF or GMF.  
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MRI 
Metric 
 
RRMS 
N = 25 
Controls 
N = 20 
P-value Adjusted difference  
(95% CI) 
Normal appearing white matter 
ODI 0.27 (0.02) 0.27 
(0.02) 
0.60 0.003 
(-0.009 to 0.015) 
NDI 0.5733 
(0.0264) 
0.5949 
(0.0280) 
0.03* -0.02 
(-0.04 to -0.002) 
isoVF 0.08 (0.02) 0.08(0.02) 0.79 0.001 
(-0.012 to 0.009) 
FA  0.42 (0.02) 0.43 (0.02) 0.12 -0.009 
(-0.02 to 0.003) 
MD 
(mm2/s) 
0.00078 
(0.00003) 
0.00076 
(0.00002) 
0.11 1.42 x 10-5 
(-0.000001 to 0.00003) 
AD  
(mm2/s) 
0.0012 
(0.00003) 
0.0011 
(0.00002) 
0.37 9.33 x 10-6 
(-0.00001 to 0.00003) 
RD  
(mm2/s) 
0.00059 
(0.000030) 
0.00057 
(0.000029) 
0.07 1.66 x 10-5 
(-0.0000001 to 0.00004) 
Cortical grey matter 
ODI  0.47 (0.01) 0.47 (0.01) 0.73 0.001 
(-0.006 to 0.008) 
NDI 0.44 (0.02) 0.44 (0.01) 0.24 -0.006 
(-0.017 to 0.005) 
isoVF 0.12 (0.03) 0.10(0.03) 0.11 0.01 
(-0.003 to 0.031) 
FA  0.19 (0.01) 0.19 (0.01) 0.34 -0.003 
(-0.010 to 0.004) 
MD 
(mm2/s) 
0.00096 
(0.000044) 
0.00092 
(0.00005) 
0.06 2.88 x 10-5 
(-0.000001 to 0.00006) 
AD  
(mm2/s) 
0.0011 
(0.00005) 
0.0011 
(0.00005) 
0.08 2.84 x 10-5 
(-0.000001 to 0.00006) 
RD  
(mm2/s) 
0.00086 
(0.00004) 
0.00084 
(0.00005) 
0.07 2.90 x 10-5 
(-0.000001 to 0.00006) 
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Deep grey matter 
ODI  0.38 (0.01) 0.38 (0.02) 0.64 0.002 
(-0.007 to 0.012) 
NDI 0.50 (0.02) 0.48 (0.03) 0.28 0.01 
(-0.009 to 0.028) 
isoVF 0.10 (0.03) 0.08 (0.02) 0.09 0.013 
(-0.002 to 0.028) 
FA  0.27 (0.02) 0.26 (0.02) 0.57 0.003 
(-0.009 to 0.016) 
MD 
(mm2/s) 
0.00089 
(0.000052) 
0.00086 
(0.00005) 
0.22 1.95 x 10-5 
(-0.00001 to 0.00005) 
AD 
(mm2/s) 
0.0011 
(0.00006) 
0.0011 
(0.00007) 
0.27 2.15 x 10-5 
(-0.00002 to 0.00006) 
RD 
(mm2/s) 
0.00077 
(0.00005) 
0.00074 
(0.00004) 
0.22 1.85 x 10-5 
(-0.00001 to 0.00005) 
Table 4.4: Mean (SD) of diffusion MRI measures in RRMS patients and controls. 
P-values based on linear regression models comparing RRMS to controls, 
adjusting for age, gender and the specific tissue fraction for the region (either 
WMF or GMF). * Significant p-value. 
 
Figure 4.2: Example of NODDI maps from a control (top row) and a patient with 
RRMS (bottom row) (27-year-old male, with an EDSS of 3.5), (A) orientation 
dispersion index (ODI), (B) neurite density index (NDI) and (C) isotropic volume 
fraction (isoVF). Visually there is a reduction in NDI in the normal appearing white 
matter of the RRMS subject when compared to the control. Absolute values of 
NDI in the NAWM in the control is 0.5839 and 0.5642 in the RRMS patient.   
Chapter IV: Application of NODDI, a novel diffusion MRI technique in RRMS 
137 
4.5.4 Difference in MRI metrics between cervical myelopathy subjects and 
controls 
There was a significant increase in ODI in the cortical grey matter in cervical 
myelopathy patients when compared to controls (RC 0.005, 95% CI 0.001 to 
0.008, p=0.02) (Figure 4.1 & Table 4.5). There was a significant decrease in MD 
(RC -2.17 x 10-5, 95% CI -0.00004 to -0.00001, p=0.02), AD (RC -2.56 x 10-5, 
95% CI -0.00004 to -0.00001, p=0.009) and RD (RC -1.97 x 10-5, 95% CI -
0.00004 to -0.00001, p=0.02) in the cortical grey matter of the brain in cervical 
myelopathy patients compared to controls after correcting for age, gender and 
GMF (Table 4.5).  
MRI Metric 
 
Cervical 
Myelopathy 
N = 15 
Controls 
N=20 
P-value Adjusted 
difference 
(95% CI) 
Normal appearing white matter 
ODI  0.26 (0.01) 0.27 
(0.02) 
0.31 -0.003 
(-0.009 to 0.003) 
NDI 0.60 (0.03) 0.60 (0.03) 0.69 0.003 
(-0.011 to 0.016) 
isoVF 0.08 (0.01) 0.08 (0.02) 0.94 0.002 
(-0.006 to 0.005) 
FA  0.44 (0.02) 0.43 (0.02) 0.24 0.005 
(-0.003 to 0.013) 
MD  
(mm2/s) 
0.00075 
(0.00002) 
0.00076 
(0.00002) 
0.15 -6.16 x 10-6 
(-0.00001 to 
0.000001) 
AD  
(mm2/s) 
0.0011 
(0.00002) 
0.0011 
(0.00002) 
0.41 -4.02 x 10-6 
(-0.00001 to 
0.00001) 
RD  
(mm2/s) 
0.0005 
(0.00003) 
0.00057 
(0.00003) 
0.15 -7.23 x 10-6 
(-0.00002 to 
0.000001) 
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Cortical grey matter 
ODI 0.48 (0.009) 0.47 (0.007) 0.02*  0.005 
(0.001 to 0.008) 
NDI 0.45 (0.014) 0.44 (0.01) 0.68 0.001 
(-0.005 to 0.007) 
isoVF 0.10 (0.02) 0.10 (0.03) 0.21 0.007 
(-0.004 to 0.018) 
FA  0.19 (0.009) 0.19 (0.007) 0.52 -0.001 
(-0.005 to 0.003) 
MD 
(mm2/s) 
0.00090 
(0.00004) 
0.00092 
(0.00005) 
0.02* -2.17 x 10-5 
(-0.00004 to -
0.00001) 
AD 
(mm2/s) 
0.00106 
(0.00004) 
0.00108 
(0.000052) 
0.009* -2.56 x 10-5 
(-0.00004 to -
0.00001) 
RD 
(mm2/s) 
0.00082 
(0.00004) 
0.00084 
(0.000049) 
0.02* -1.97 x 10-5 
(-0.00004 to -
0.00001) 
Deep grey matter 
ODI  0.38 (0.017) 0.38 (0.017) 0.17 0.005 
(-0.002 to 0.012) 
NDI 0.49 (0.02) 0.48 (0.03) 0.92 0.001 
(-0.010 to 0.011) 
isoVF 0.09 (0.02) 0.08 (0.02) 0.45 0.003 
(-0.006 to 0.012) 
FA  0.26 (0.01) 0.26 (0.019) 0.31 -0.003 
(-0.010 to 0.003) 
MD 
(mm2/s) 
0.00084 
(0.00005) 
0.00086 
(0.000052) 
0.06 -2.00 x 10-5 
(-0.00004 to 
0.000001) 
AD 
(mm2/s) 
0.0011 
(0.00007) 
0.0011 
(0.00007) 
0.06 -2.77 x 10-5 
(-0.00005 to 
0.000001) 
RD  
(mm2/s) 
0.00074 
(0.00005) 
0.00073 
(0.00005) 
0.09 -1.606 x 10-5  
(-0.00003 to 
0.000001) 
Table 4.5: Mean (SD) of diffusion MRI measures in cervical myelopathy patients 
and controls. P-values based on linear regression models comparing cervical 
myelopathy subjects to controls, adjusting for age, gender and the specific tissue 
fraction for that region (either WMF or GMF). * Significant p-value. 
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4.5.5 Differences between MRI parameters in T2 lesions and normal 
appearing white matter in RRMS 
There was a significant decrease in NDI (p=0.0001, 95% CI -0.22 to -0.17) and 
ODI (p=0.0001, 95% CI -0.06 to -0.03) and a significant increase in isoVF 
(p=0.001, 95% CI 0.02, 0.08) in T2 lesions compared to NAWM in RRMS patients 
(Table 4.6, Figure 4.1 & 4.3).   
There was a significant decrease in FA (p=0.0001, 95% CI -0.10 to -0.07) and a 
significant increase in MD (p=0.0001, 95% CI 0.0003 to 0.0004), AD (p=0.0001, 
95% CI 0.0003 to 0.0004) and RD (p = 0.0001, 95% CI 0.0003 to 0.0004) in T2 
lesions when compared to NAWM in RRMS patients (Table 4.6).  
MRI metric T2 lesions Normal 
appearing white 
matter 
P-value 
ODI 0.23 
(0.03) 
0.27 
(0.02) 
0.0001 
NDI 0.38 
(0.06) 
0.57 
(0.03) 
0.0001 
isoVF 0.13 
(0.07) 
0.08 
(0.02) 
0.001 
FA 0.33 
(0.05) 
0.42 
(0.02) 
0.0001 
MD 
(mm2/s) 
0.001 
(0.0001) 
0.0008 
(0.00003) 
0.0001 
AD 
(mm2/s) 
0.0015 
(0.0001) 
0.0011 
(0.00003) 
0.0001 
RD 
(mm2/s) 
0.00089 (0.0001) 0.00059 
(0.00003) 
0.0001 
Table 4.6: Mean (SD) of NODDI MRI measures in T2 lesions and in NAWM in 
RRMS patients. P-values based on paired sample t-tests comparing T2 lesions 
to NAWM in RRMS patients. 
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Figure 4.3: Example of NODDI maps from T2 lesions of an MS subject. (A) Axial 
T2 scan with T2 hyperintense lesions outlined in red, (B) an NDI map of the T2 
lesions demonstrating a reduction in NDI and (C) an ODI map of the T2 lesions 
demonstrating a reduction in ODI.   
 
4.5.6 Associations between MRI metrics and clinical disability scores in 
patients with RRMS and cervical myelopathy 
A) NODDI metrics 
There was no significant association between NDI in the NAWM and any clinical 
scores despite a significant reduction in NDI in RRMS patients when compared 
to controls.  
NDI and isoVF were associated with clinical scores: (i) there was a significant 
association between NDI in the deep grey matter and scores obtained in the 
CVLT-II, such that, per unit decrease in NDI, there was a predicted decrease in 
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verbal memory (CVLT-II) of -169.96 (95% CI -335.04 to -4.85, p = 0.04), after 
correcting for age, gender and GMF in RRMS patients, (ii) isoVF in the cortical 
grey matter was independently associated with EDSS and TWT after adjusting 
for age, gender and GMF. In particular, per unit increase in isoVF, was associated 
with a predicted 44.80 (95% CI 10.51 to 79.10, p=0.01) increase in EDSS and a 
predicted -26.64 (95% CI -45.15 to -8.13, p=0.008) decrease in TWT and, (iii) 
isoVF in the deep grey matter was independently associated with the TWT, such 
that, per unit increase in isoVF, was associated with a predicted -26.48 (95% CI 
-48.68 to -4.29, p=0.02) decrease in TWT, after correcting for age, gender and 
GMF.     
There was no significant association between the NODDI metrics and clinical 
disability scores in cervical myelopathy patients.  
B) DTI metrics 
There was a significant association between the TWT and RD (RC -
16,831.79mm2, 95% CI -27,775.97 to -5,887.68, p=0.005), AD (RC -
12,159.29mm2, 95% CI -20,137.64 to -4,180.93, p=0.005) and MD (RC -
15,440.53mm2, 95% CI -25,232.51 to -5,648.56, p=0.004) in the cortical grey 
matter and between the TWT and RD (RC -19,858.36mm2, 95% CI -33,825.13 to 
-5,891.58, p=0.008), AD (RC -14,394.52mm2, 95% CI -26,425.81 to -2,363.23, 
p=0.042) and MD (RC -20,087.56mm2, 95% CI -33,753.69 to -6,421.44, p=0.007) 
in the deep grey matter in RRMS patients.   
In the cervical myelopathy patients, there was no significant difference in RD, AD 
and MD in the deep grey matter when compared to controls, but there was a 
significant association between visual memory assessed using the BVMT-R and 
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RD (RC -160,973.95mm2, 95% CI -298,895.95 to -23,051.46, p=0.03), AD (RC -
116,451.31mm2, 95% CI -213,991.13 to -18,911.50, p=0.024) and MD (RC -
148,562.93mm2, 95% CI -270,199.16 to -26,926.70, p=0.02) in the deep grey 
matter in cervical myelopathy patients, such that an increase in diffusivity in the 
deep grey matter is associated with a reduction in visual memory scores.  
The very high regression coefficients obtained in this analysis arose due to the 
very small numbers obtained for the diffusivity measures e.g 0.0007 or 0.0008 
mm2/s.  
4.6 Discussion 
NODDI is a multi-compartment, model-based diffusion weighted MRI technique, 
which reflects in-vivo neuronal morphology, such as the density and dispersion 
of neurites. NODDI has the potential to provide specific biomarkers of tissue injury 
in MS and in clinically feasible settings.  
In this pilot study, I aimed to investigate differences in NODDI metrics between 
RRMS and controls and cervical myelopathy patients and controls and to look at 
the relationship between NODDI parameters and disability in both patient cohorts, 
in order to obtain insights into the key factors that may contribute to disability. 
Based on this pilot study, there was a significant decrease in NDI (believed to 
reflect a reduction in the density of axons and/or demyelination) in NAWM in 
RRMS patients compared to controls. In T2 lesions, there was a significant 
decrease in NDI and ODI and a significant increase in isoVF compared to NAWM 
in the RRMS cohort, which is thought to reflect axonal loss and/or demyelination, 
reduction in neural tissue complexity and increased free water respectively. In 
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cervical myelopathy patients, there was a significant increase in ODI in cortical 
grey matter when compared to controls.  
Despite no significant change in NDI in the deep grey matter between MS patients 
and controls, there was a significant correlation between NDI in the deep grey 
matter and verbal memory in MS patients, raising the possibility that NODDI 
measures may reflect pathological abnormalities which may be responsible for 
cognitive impairment. I will discuss each of these results in turn. 
4.6.1 Difference in MRI metrics between RRMS and controls 
4.6.1.1 Normal appearing white matter 
There was a significant reduction in NDI in NAWM in RRMS patients compared 
to controls. NDI represents the amount of neural tissue occupied by neurites and 
a reduction in NDI is likely to represent axonal loss in NAWM in MS. This is in 
keeping with the results presented by Schneider et al., 2014b and Brownlee et 
al., 2016. Interestingly, a recent histological-MRI study performed by our 
colleagues (Grussu et al., 2015a), has shown that reduced NDI can also occur in 
the presence of demyelination, without axonal loss. Demyelination increases the 
amount of MRI-visible water. As a result, NDI, which is the ratio of the amount of 
water inside axons to the total MRI visible water, also decreases, even if there is 
no evidence of axonal loss, due to loss of myelin (Grussu et al., 2015a). 
Therefore, these findings from the histological study raise the possibility that NDI 
is unable to distinguish between demyelination of axons and axonal loss.  
There was a trend towards increased ODI in the NAWM in RRMS patients 
compared to controls, but this did not reach statistical significance. An increase 
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in ODI is thought to arise due to a loss of fibre coherence, with consequent 
increased dispersion of the orientation of the neurites (Schneider et al., 2014b).  
There was no significant difference in any of the standard DTI metrics in the 
NAWM. Results from previous studies carried out in RRMS have found significant 
decreases in FA, increases in RD (diffusivity along the principle diffusion 
direction), AD (diffusivity across the principle diffusion direction) and MD (mean 
amount of diffusion) in NAWM in MS subjects compared to controls, which is 
thought to arise due to axonal loss and/or demyelination (Roosendaal et al., 
2009). A previous post-mortem study in MS brains found that myelin content and 
to a lesser extent axonal loss are associated with FA and MD (Schmierer et al., 
2007). It has been suggested that standard DTI may be sensitive to 
microstructural changes in the brain but lacks specificity, which may account for 
the fact that multiple DTI indices have been implicated in explaining the same 
pathological process in MS (Pierpaoli and Basser, 1996). These findings suggest 
NODDI is sensitive to microstructural changes in the NAWM, which was not 
detected by any of the DTI indices.  
4.6.1.2 T2 lesions 
In T2 lesions, there was a reduction in ODI and NDI and an increase in isoVF, 
and these results are in keeping with the results presented by Schneider et al., 
2014. A reduction in ODI may arise for a number of reasons: (i) in MS lesions 
small axonal fibres are more likely to be lost, compared to large fibres, therefore 
a reduction in ODI may be due to the presence of axons with less undulations 
and therefore a reduction in overall neural tissue complexity (DeLuca et al., 2006; 
Muhlert et al., 2013; Grussu et al., 2015a) and (ii) as a result of axonal loss, there 
is expansion of the extracellular space and gliosis, raising the possibility that 
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gliosis may alter neurite architecture and therefore cause a reduction in ODI 
(Klawiter et al., 2011). Results from an ex-vivo study found similar results of 
reduced ODI in MS spinal cord lesions (Grussu et al., 2015a). An increase in 
isoVF may arise due to higher CSF contamination as a result of lesional tissue 
being adjacent to the ventricles with associated tissue loss, increasing the free 
diffusion compartment represented by isoVF, and also the presence of oedema 
at the site of lesions may lead to an increase in isoVF.  
There was a significant decrease in FA, with significant increases in RD, AD and 
MD in T2 lesions compared to NAWM in RRMS subjects. Reduction in FA and 
increased MD in NAWM has previously been demonstrated in RRMS with the 
highest degree of diffusion abnormalities found in T1-hypointense lesions 
(Werring et al., 1999; Werring et al., 2000; Filippi et al., 2001). Increases in RD, 
and AD reflects increased movement of water perpendicular and parallel to the 
main diffusion direction, as you would expect as a result of axonal loss and/or 
demyelination (Schmierer et al., 2007).  
Work carried out by Grussu et al., (Grussu et al., 2015a) found that a decrease 
in FA can be related independently by an increase in ODI or by a decrease in 
NDI. These two contrasting effects have very different biological meaning, which 
cannot be distinguished by using FA alone and therefore indicates that DTI FA is 
a somewhat non-specific measure of tissue integrity (Grussu et al., 2015a). Thus 
NODDI metrics have the potential to disentangle two of the main microstructural 
changes contributing to FA - the density and the orientation complexity of 
neuronal processes (Grussu et al., 2015a).  
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4.6.2 Difference in MRI metrics between cervical myelopathy subjects and 
controls 
There was a significant increase in ODI in cortical grey matter in cervical 
myelopathy patients when compared to controls but there was no difference in 
any of the other NODDI metrics in this patient population. To explain this, it may 
be useful to look at spinal cord injury, which results in the disintegration of axons, 
which disrupts pathways mediating efferent and afferent information flow 
between the brain and spinal cord (Freund et al., 2011). It has been demonstrated 
that following spinal cord injury, there is the development of spinal cord atrophy 
(Lundell et al., 2011), cortical atrophy (Wrigley et al., 2009) and cortical 
reorganisation (within the sensorimotor cortex) (Kokotilo et al., 2009). It has been 
suggested that cortical reorganisation in spinal cord injury may arise from 
regenerative sprouting of axons in order to reintegrate injured neurons 
(Henderson et al., 2011). The increase in ODI may reflect a loss of fibre 
coherence (i.e. more dispersed) due to increased synaptic complexity, which may 
occur as an adaptive mechanism to preserve function. Overall the size of the 
myelopathy cohort is small and greater numbers will be required to confirm these 
findings.  
There was a significant decrease in the standard DTI metrics, specifically RD, AD 
and MD in the cortical grey matter, in cervical myelopathy patients compared to 
controls. Decreases in RD, AD and MD are thought to reflect a reduction in the 
movement of water perpendicular and parallel to the principle diffusion direction 
and a reduction in mean diffusion respectively. It is difficult to say why these 
changes occurred as overall the sample size for the cervical myelopathy patients 
is very small. One study carried out in spinal cord injury patients (where the 
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subjects were more physically impaired than our cohort of myelopathy patients in 
this study) found an increase in RD in the corticospinal tract which was likely due 
to axonal loss and/or demyelination (Freund et al., 2012). Our findings in the brain 
are in the opposite direction to these results (decrease in MD, AD and RD). The 
decrease in MD, AD and RD may arise due to increased synaptic complexity in 
the cortical grey matter, in keeping with the ODI results. These mechanisms are 
presently only speculative and requires further investigation.  
4.6.3 Associations between MRI metrics and clinical disability scores in 
RRMS 
There was no significant reduction in NDI in the deep grey matter in MS patients 
compared to controls, although this may be due to the small sample size; there 
was a significant association between a reduction in neurite density in the deep 
grey matter and impaired verbal memory. I know cognitive dysfunction in MS is 
associated with grey matter pathology. The findings in this study may reflect 
axonal loss and/or demyelination contributing to cognitive dysfunction, raising the 
possibility that this NODDI metric may detect pathological changes occurring in 
the deep grey matter that contributes to cognitive disability. isoVF in the cortical 
grey matter was associated with EDSS and TWT and in the deep grey matter 
with TWT in MS patients, which is likely to reflect higher CSF contamination, 
increasing the free diffusion compartment, which may arise due to atrophy of the 
cortical and deep grey matter. This is reflected in the significant decrease in GMF 
in RRMS patients when compared to controls.  
RD, AD and MD in the cortical and deep grey matter was significantly associated 
with the TWT z-scores in MS patients, reflecting an increase in perpendicular, 
Chapter IV: Application of NODDI, a novel diffusion MRI technique in RRMS 
148 
parallel and mean diffusivity respectively, which may arise due to axonal loss 
and/or demyelination. A number of DTI studies in cortical and deep grey matter 
in MS patients have found increased diffusivity in these regions, associated with 
clinical (Vrenken et al., 2006) and cognitive disability (Rovaris et al., 2002).  
4.6.4 Associations between MRI metrics and clinical disability scores in 
cervical myelopathy patients 
Cervical myelopathy patients were significantly impaired on testing of verbal 
memory when compared to controls. There appears to be quite limited data to 
explain this but one study carried out in cervical myelopathy patients before and 
after decompression surgery demonstrated improvements in cognitive function 
after surgery (Hoshimaru et al., 2010). There is also evidence of cognitive 
impairment in spinal cord injury patients ranging from reduced attention, 
executive function, learning ability and processing speed (Davidoff et al., 1992; 
Roth et al., 1989; Murray et al., 2007). One study in an animal model of spinal 
cord contusion demonstrated cognitive deficits which they suspected were 
related to microglial activation (Wu et al., 2014). It is an interesting finding that 
needs to be further explored. There was no significant association with any of the 
NODDI indices and physical or cognitive function tests in the cervical myelopathy 
patients. There were significant associations between RD, AD and MD in the 
deep grey matter and visual memory in the cervical myelopathy patients, such 
that an increase in diffusivity in the deep grey matter is associated with impaired 
visual memory. The DTI metrics may be detecting pathological changes in these 
regions which may explain some of the previous documented cognitive difficulties 
in cervical myelopathy patients but this needs further investigation.  
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4.7 Conclusion 
Based on this pilot study, there was a significant reduction in NDI and ODI in T2 
lesions and in NDI in NAWM in RRMS. In cervical myelopathy patients there was 
a significant increase in ODI in cortical grey matter. It is likely that NODDI can 
provide additional information on neural tissue microstructure and tissue 
complexity which standard DTI cannot disentangle and it may be a useful imaging 
technique to complement other imaging modalities. 
4.8 Limitations 
Overall, the numbers recruited into this study is small, and this might explain the 
lack of significant results in more of the NODDI metrics in the RRMS cohort. The 
recruitment for this study is ongoing, to increase the number of RRMS and 
cervical myelopathy patients recruited into the study. NODDI in the spinal cord is 
also being acquired as part of this study. This may provide more information in 
relation to intrinsic changes occurring in the cervical cord in both MS and cervical 
myelopathy patients and how this influences the NODDI metrics.  
In the MS patients only, I performed the EDSS, which is a well known clinical 
assessment carried out in MS. While in the cervical myelopathy patients I carried 
out the ASIA scale only and not the EDSS. The ASIA was designed for spinal 
cord injury patients to capture specifically the degree of sensory and motor 
impairment in the upper and lower limbs in these patients. In hindsight, I probably 
should have performed the EDSS in the cervical myelopathy patients as well, to 
compare the degree of disability between the two patient groups. The remainder 
of the clinical and cognitive assessments were the same in both groups.  
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In Figure 4.1 (A), there was an outlier in ODI in normal appearing white matter in 
the RRMS group and in Figure 4.1 (B) there was an outlier in ODI in cortical grey 
matter in the control group and the RRMS group. When the statistical analysis 
was initially performed, it was re-ran again excluding these outliers and it did not 
change the pattern of results. Therefore, it was felt that these outliers were not 
contributing significantly to the overall results and so I did not exclude them in the 
final model.  
In Table 4.2, two of the clinical and cognitive assessments, specifically the 9-HPT 
(p=0.07) and PASAT (p=0.06), were very close to reaching statistical significance 
in RRMS patients compared to controls. It is very likely that these tests would 
have reached significance if a few more subjects were recruited into the study.  
Another limitation of this study is the fact that the DTI metrics were obtained from 
recycled NODDI data. In one sense this is good as it reduces the scan time for 
the patients, however, the DTI metrics were acquired with a TE which is longer, 
than the TE you would use if acquiring only DTI.  The same echo time was used 
for each b-shell in order to achieve the same T2-weighting for the three tissue 
compartments (Grussu et al., 2015b). The signal decreases as you increase the 
TE, therefore the signal to noise ratio may be sub-optimal for the DTI data 
(Grussu et al., 2015b).  
Longitudinal changes in NODDI metrics have not yet been investigated in MS to 
date. The next Chapter will explore the longitudinal changes in a number of 
advanced spinal cord imaging techniques, in order to establish whether changes 
are seen over time in these MRI metrics and if they can predict disability 
progression in a cohort of patients with early PPMS. 
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5.1 Introduction 
PPMS is characterised by sustained disability progression from disease onset 
and, as mentioned earlier, the rate of deterioration, both clinically and 
radiologically is variable (Khaleedi et al., 2008; Ingle et al., 2003; Confavreux et 
al., 2003). To date, MRI is not well established as a prognostic marker in PPMS. 
Biomarkers, which are linked to the pathological processes underlying 
progression, are key to the successful development of treatments in progressive 
MS (Thompson, 2015).  
High b-value Q-space imaging (QSI) is one such advanced quantitative MRI 
(qMRI) technique. It is a model free diffusion weighted imaging (DWI) technique 
(Callaghan et al., 1998), which is thought to be specific for axonal injury (Assaf et 
al., 2005), with better sensitivity for detecting pathological changes in lesions and 
NAWM, compared to standard diffusion tensor imaging (DTI) (Assaf et al., 2002). 
QSI has been discussed in more detail in Section 2.7.5.  
One study demonstrated the feasibility of using high b-value Q-space imaging in 
four patients with MS in the spinal cord, as well as improved detection of abnormal 
diffusion compared to apparent diffusion coefficient (ADC) measurements (Farrell 
et al., 2008). A study in healthy controls demonstrated good reproducibility in 
perpendicular and parallel diffusivity in the ascending and descending tracts in 
the cervical cord (Schneider et al., 2011). 
 1H-MRS quantifies metabolites, which can reflect quite specific microstructural 
processes occurring in the spinal cord and can complement standard structural 
MRI (Ciccarelli et al., 2014), discussed in Section 2.6.5 and Section 2.9.1. 
Metabolites frequently quantified in the spinal cord include: tNAA - a marker of 
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neuronal structure and neuronal metabolism (Moffett et al., 2007), Ins - a marker 
of astrocytic activation and proliferation (Brand et al., 1993), tCr – a marker of 
gliosis, and tCho - a marker of membrane phospholipids, which are released 
during myelin breakdown (Henning et al., 2008).  More recently, the glutamate-
glutamine (Glx) complex, a marker of neuronal integrity and the excitatory 
neurotransmitter has been successfully quantified in the spinal cord (Solanky et 
al., 2013a) (Abdel-Aziz et al., 2015).  
In our recent study in early PPMS (Abdel-Aziz et al., 2015), we demonstrated 
significant changes in spinal cord spectroscopy (1H-MRS) (significantly reduced 
tNAA and Glx) and Q-space metrics (significantly increased perpendicular 
diffusivity in all spinal cord columns) between patients and controls, and 
interpreted these abnormalities as indicating neurodegeneration. This raises the 
possibility that these imaging metrics may be reliable imaging biomarkers of 
spinal neurodegeneration, and may have a role in predicting clinical outcome and 
treatment responses in PPMS.  
The aim of the study was to investigate if (i) changes in advanced MRI techniques 
occur over 1 year in the baseline cohort reported by Abdel-Aziz et al., 2015, (ii) if 
changes in these MRI metrics correlate with clinical changes over 1 year and (iii) 
if baseline MRI metrics predict clinical status at 1 year.  
In addition to using these advanced pathologically specific MRI techniques, I 
selected clinical function tests, which are more sensitive at detecting clinical 
changes mediated by spinal pathways than conventional clinical tests used in MS 
studies.  
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5.2 Materials and Methods 
5.2.1 Study participants 
Twenty-one patients with an established diagnosis of PPMS (Polman et al., 2005) 
(13F, median EDSS 5 (range 3-6.5)) and 24 healthy controls (21F) were recruited 
into the initial study at baseline (Abdel-Aziz et al., 2015) and invited to come back 
after 1 year. Two patients were not scanned at one year due to the insertion of 
devices which would have been affected by the MRI scan – in one the insertion 
of an intrathecal baclofen pump and in the other a cardiac device. Six healthy 
control subjects did not undergo the one-year follow-up study - four subjects had 
moved away and two subjects were not contactable. Patients were clinically 
assessed on the day of the MRI at baseline and at 1 year.  
All the PPMS patients recruited into this study were recruited from the MS clinics 
ran on a weekly basis at The National Hospital of Neurology and Neurosurgery, 
Queen Square, London. All healthy controls recruited into this study were work 
colleagues, friends and family as well as friends and family of the MS patients.  
All subjects recruited into the study provided written informed consent prior to 
taking part in the study, which was approved by the local research ethics 
committee (Study Reference: 10/H0713/74).  
Dr. Abdel-Aziz carried out all the baseline study in the PPMS cohort as reported 
in Abdel-Aziz et al., 2015. I then completed the 1 year follow-up study for this 
cohort of patients. Dr Abdel-Aziz obtained the consent at baseline. I then 
contacted (by phone and e-mail) the patients and healthy controls at 1 year and 
arranged for them to comeback for the 1 year follow-up. I carried out all the clinical 
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testing on the day of the scan. The radiographers at the Institute of Neurology 
performed the MRI scans at the two time points (Marios Yiannakas, Chichi Ugorji 
and Luke Hoy). I carried out the post-processing for the spectroscopy data using 
the LCModel and reviewed the results of each patient individually. I also 
performed the Q-space analysis, spinal cord and brain atrophy measurements. If 
there were any issues with the data, I discussed and reviewed the results with Dr 
Bhavana Solanky and Dr Torben Schneider, the Physicists who optimised the 
protocol. I assimilated the data in a spreadsheet, including all clinical, cognitive 
and MRI date. Dr. Dan Altmann and Dr. Carmen Tur performed the statistical 
analysis for this study. I interpreted the results from the statistical analysis 
performed and the results are presented below.  
5.2.2 Clinical Assessments 
All patients were assessed using standard clinical assessments commonly 
performed in MS studies including the EDSS (Kurtzke et al., 1983), 9-HPT 
(Goodkin et al., 1988), TWT (Cutter et al., 1999), ASIA impairment scale 
(Maynard et al., 1997), Multiple Sclerosis Walking Scale – 12 (MSWS – 12) 
(Hobart et al., 2003) and Modified Ashworth Scale (MAS) (Bohannon and Smith, 
1987). For the statistical analysis, the average of two trials of the TWT and the 
average of four trials of the 9-HPT (averaged as reciprocals of the mean times 
from two trials for each hand) (Fischer et al., 1999) were calculated. The MAS 
values from 16 muscle groups in the upper and lower limbs were converted from 
a 0-4 scale (which includes a value of 1+ between scores of 1 and 2), to a 0-5 
scale, with the resulting values summated to obtain an overall score ranging from 
0-80 (Stein et al., 2007).  
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I also used a number of clinical measures which are more sensitive at detecting 
correlations between MRI abnormalities in the spinal cord and clinical disability 
(Oh et al., 2013; Zackowski et al., 2009), specifically grip strength from both upper 
limbs was measured using the dynamometer (mean grip strength from both limbs 
was used in the analysis) (Sammons Preston. Incorporated, Bolingbrook, IL, 
USA) (Svens and Lee, 2005), Vibration perception thresholds (VPTs) were 
measured from all 4 limbs at the lateral malleoli and ulnar styloid processes, using 
the biosthesiometer (mean VPTs were calculated and then used in the analysis) 
(Bio – medical Instrument Company, Newbury, Ohio) and postural stability was 
assessed using a modified version of a recently developed protocol for 
quantifying stance stability (Bunn et al., 2013). Individuals were requested to 
stand relaxed and still, facing a blank wall at a distance of 1m, for 40s long trials. 
Three trials each of four conditions were recorded, consisting of two stance 
widths (inter – malleolar distance of 32cm and 4cm) and two visual conditions 
(eyes open (EO) and eyes closed (EC)). Body sway was measured using a 3-D 
orientation sensor (MTx: Xsens, Enschede, NL), which was fixed to the skin, just 
below the C7 spinous process. The device measured the instantaneous angular 
position of the trunk in the anteroposterior (pitch) and mediolateral (roll) planes.  
Summary measures were made in these signals using custom scripts written in 
Matlab (The Mathworks, Natick, MA USA). The amount of angular motion was 
then calculated separately from the roll and pitch body sway data and from the 
combined motion given by square root (pitch-motion2 + roll-motion2), termed total 
sway. All three signals were summarized by summing the sample – to – sample 
absolute change in signal and then dividing by the duration of the trial to yield 
average angular speeds of body sway reported in degrees/second. The mean of 
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the three trials per condition were used for statistical analysis. An index of 
exacerbation of sway on eye closure was obtained from the Romberg quotient 
calculated as sway eyes closed/sway eyes open at both stance widths.  
5.2.3 MRI Protocol  
The MRI protocol at 1-year follow-up was exactly the same as that used for the 
baseline study (Abdel-Aziz et al., 2015). All scans were performed using a 3T 
Achieva system (Philips Medical Systems, Best, Netherlands). To reduce motion 
artefacts during scanning and improve image quality, an MR compatible cervical 
collar was worn by all subjects (Yiannakas et al., 2012). The scans performed 
included single voxel 1H-MRS and Q-space imaging of the cervical cord, PD/T2 
of the brain and cervical cord, volumetric 3D-T1 of the brain and 3D fast-field 
echo for cervical cord area measurement.  
5.2.3.1 MRS protocol 
Using the manufacturer’s 16 – channel neurovascular coil (Philips Healthcare 
Systems), single voxel MRS was performed using a recently optimised protocol 
(Solanky et al., 2013a). Conventional turbo spin – echo sequences (TSE) were 
used to acquire structural images for radiological reading and to guide voxel 
placement. T2w images were acquired in the coronal plane [parameters: TR = 
4000ms; TE = 100ms; FOV = 160 x 250 mm2; voxel size = 0.6 x 0.6 x 3.0 mm3; 
NEX = 2; 13 contiguous slices] and PD/T2w images were acquired in the sagittal 
plane using a dual echo TSE [parameters: TR = 4000ms; TE = 15/80ms; FOV = 
256 x 160mm2; echo train length (ETL) = 12; voxel size = 1.0 x 1.0 x 3.0 mm3; 
NEX = 2; 12 contiguous slices].   
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For spectroscopy, volumes of interest (VOI) with dimensions of approximately 5.4 
x 7.76 x 55mm3 (2.3mls) were prescribed using the reference images. The 
dimensions of the VOI were adjusted in the anterior-posterior (AP) direction 
dependent on the size of each volunteer’s spinal cord (Ciccarelli et al., 2007; 
Marliani et al., 2010). Care was taken in positioning of the voxel at baseline and 
then at 1 year follow-up. The same voxel sizes were used at both time points for 
each subject and the voxel was centred on C2/C3 at each time. MRS data was 
acquired using a point resolved spectroscopy (PRESS) localisation sequence, 
previously published (Solanky et al., 2013a) [parameters: TE = 30ms; 376 
averages with triggered first order iterative shimming, multiple obtained 
insensitive suppression train (MOIST) water suppression, 4 outer volume 
suppression (OVS) slabs in the AP and rostrocaudal directions and cardiac gating 
(TR = 3RR ~ 3000ms) using a peripheral pulse unit (350ms delay)]. An example 
of a spectroscophy voxel placement is shown in Figure 5.1. 
5.2.3.2 Spinal cord atrophy protocol 
The cervical cord was imaged in the axial plane, perpendicular to the longitudinal 
axis of the cord, to measure the cord mean cross – sectional area (CSA) and for 
confirmation of lesion location. The imaging volume was centred on the C2/3 
intervertebral disc, using a fat – suppressed 3D slab-selective fast field echo 
(FFE) sequence [parameters; TR = 23ms; TE = 5ms; flip angle α = 7o; FOV = 240 
x 180mm2; voxel size = 0.5 x 0.5 x 5 mm3; NEX = 8; 11 axial contiguous slices]. 
In order to match the position and orientation of the volumetric scan to the 
spectroscopy voxel, the prescription values used for the MRS acquisition were 
copied and manually entered by the operator when setting up the 3D-FFE scan. 
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5.2.3.3 QSI protocol 
Using the manufacturer’s 32 – channel head coil (Philips Medical Systems, Best, 
Netherlands), each subject underwent a cardiac gated DWI acquisition 
[parameters; voxel size = 1 x 1 x 5 mm3 (interpolated in k-space to a 0.5 x 0.5mm2 
in-plane resolution), FOV = 64 x 64 mm2; TR = 9RR, TE = 129ms], performed 
with the volume centred on the C2/C3 disc to ensure similar coverage as the 
spectroscopy voxel. 12 axial contiguous slices covering a 60mm length of the 
cervical cord, typically giving coverage of the C1-C3 spinal segments. The 32 
channel head coil was used because it gave superior SNR during QSI sequence 
optimisation experiments (Schneider et al., 2011). A ZOOM (zonal oblique multi-
slice) sequence in combination with outer-volume suppression was used to 
minimise artefacts (Wilm et al., 2007). Thirty DWI volumes with equally spaced 
Q-values (Farrell et al., 2008) and two non-diffusion weighted (b0) volumes were 
acquired with diffusion weighting in two perpendicular (x and y) and one parallel 
(z) direction to the main axis of the spinal cord [parameters: diffusion pulse 
duration δ = 11.4ms, diffusion time ∆ = 75ms, gradient strength G linearly 
increased in 31 steps from 0 to 87.5mT/m in x and y direction and 62mT/m in z 
direction]. An example of the diffusion weighted image volume is shown in Figure 
5.1.  
5.2.3.4 Brain MRI protocol 
For calculation of brain T2 lesion volumes, PDT2 weighted images were acquired 
using a dual-echo TSE sequence [parameters; TR = 3500ms; TE = 15/85ms; flip 
angle α = 90o; FOV = 240 x 180mm2; voxel size = 1 x1 x 3mm3; NEX = 1; 50 axial 
contiguous slices]. For calculation of brain tissue volumes, a 3D T1-weighted 
magnetisation – prepared gradient – echo sequence was used [TR = 6.9ms; TE 
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= 3.1ms; flip angle α = 8o; FOV = 256 x 256mm2; voxel size = 1 x 1 x 1mm3; NEX 
= 1; 180 sagittal contiguous slices].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Example of the spectroscopy voxel placement in the coronal (A) and 
sagittal planes (B) and the diffusion weighted image volume in the sagittal (C) 
and coronal plane (D) in the cervical cord.  
A B 
C D 
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5.3 Image Post Processing 
5.3.1 Spinal cord metabolite quantification 
Metabolite concentrations were quantified using the user-independent LCModel 
(version 6.3) package (Provencher, 1993) and a set of basis spectra, comprising 
seventeen metabolites including macromolecules, as previously described 
(Solanky et al., 2013a). tNAA, tCho, tCr, Ins and Glx concentrations were 
quantified using the unsuppressed water signal obtained from the same voxel as 
a reference (Gasparovic et al., 2006) and formed the focus of our analysis. 
Corrections for T2 values were not performed because the TE used is relatively 
short, compared to the T2 relaxation times of the metabolites under study 
(Wansapura et al., 1999; Edden et al., 2007) and therefore, it is expected that 
changes in T2 would be negligible. Measuring T2 values for each metabolite 
would not have been possible in a patient cohort within clinically feasible scan 
times.  
5.3.2 Spectral Quality 
Overall spectral quality was assessed using the full width at half maximum 
(FWHM) and signal – to – noise ratio (SNR) provided by LCModel. CRLB values 
were used to confirm the reliability of each metabolite. CRLB values of <20% for 
tNAA, tCr, tCho and Ins and <30% for Glx were used to confirm the reliability of 
the spectral fit (Provencher et al., 2014). Poor quality spectra were excluded from 
the analysis with poor water suppression or FWHM > 0.13 and SNR < 3. The 
FWHM and SNR estimated by the LCModel (mean +/-SD) were 0.110+/-0.027 
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ppm and 3.874+/-0.859 respectively for the 1-year data. The mean CRLBs values 
for each metabolite were: tNAA (12.76%), tCr (13.46%), Ins (11.12%), Glx 
(13.70%) and Cho (13.46%).  
5.3.3 Spinal cord cross sectional area measurement  
Image segmentation and CSA measurements were performed using the 3D-FFE 
dataset in Jim 6.0 Software (Xinapse systems, Northants, England). Three 
contiguous 5mm axial slices, centred on the C2/3 disc were segmented using the 
active surface model (Horsfield et al., 2010). The mean cross – sectional area of 
the three slices was then calculated.  
5.3.4 Spinal cord QSI and ROI analysis 
The QSI indices represent the diffusion properties of water and can be derived 
from the displacement probability density function (dPDF). This is the average 
probability of a spin moving a certain distance during a given diffusion time.  A 
tall, narrow dPDF is associated with a low apparent diffusion coefficient, 
suggesting more hinderance or restriction of diffusing water molecules. A broad, 
low dPDF suggests a high apparent diffusion coefficient with more free diffusion 
of water molecules and/or a more unrestricted diffusion (Farrell et al., 2008; 
Cohen & Assaf, 2002; Schneider et al., 2014a).  
Assuming axial symmetry of diffusion along the main axis of the spinal cord, the 
two perpendicular (x,y) diffusion directions were averaged before analysis to 
increase the signal – to – noise ratio. The measurements were then extrapolated 
in to 128 data points in q-space to avoid cut-off artifacts (Cohen & Assaf, 2002) 
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and the voxel-wise dPDF was computed using inverse Fast Fourier 
Transformation.  
Data was corrected for motion using “reg_aladin” from the NiftyReg toolbox 
(Ourselin et al., 2000). Registration was performed between the interleaved b=0 
acquisitions of the xy and z protocol using the first b=0 of the xy protocol as 
reference. The estimated registration was then applied to the intermediate DWI 
images. The quality of the motion correction was assessed in each subject and 
mis-registered slices/subjects were excluded from the study.  
Voxel maps of the FWHM and the zero displacement probability (P0) were 
calculated from the dPDF. The FWHM represents the width of the displacement 
distribution function and the P0 represents the height of the displacement 
distribution function. We also acquired conventional apparent diffusion coefficient 
(ADC) maps, from the low b – value part of the decay curve (b < 1100s/mm2), for 
both the xy and z directions, using a constrained non – linear least squared fitting 
algorithm.  
To look at region specific differences in QSI metrics, the full length (60mm) of the 
cervical spinal cord was initially extracted, excluding the CSF and other tissue 
types. Four regions of interest were created using the ROI tool in JIM 6.0 and 
drawn on the average b0 image on each axial slice. From this the ADC and QSI 
indices were measured from the anterior, posterior, right lateral and left lateral 
columns of the spinal cord, as well as over the whole cord. There were no 
statistical differences between q-space indices between the right and left lateral 
columns, so the mean values from both columns were calculated for each of the 
q-space indices.  
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5.3.5 Brain T2 Lesion Volumes and grey matter and white matter volumes 
Brain T2 lesion volume (T2LV) was calculated by outlining lesions on T2 – 
weighted MRI scans using a semi – automated edge finding tool (JIM v. 6.0) by 
a single observer (NC). Total lesion volume was recorded in mls for each subject. 
Hypointense lesions on the T1-weighted volume scan were marked and filled with 
values consistent with NAWM signal intensity to prevent misclassification of 
tissue during segmentation (Chard et al., 2010).  Segmentation of the lesion-filled 
image was then performed using the ‘new_segment’ function in SPM8 (statistical 
parametric mapping; Wellcome Trust Centre for Neuroimaging, University 
College London (UCL) Institute of Neurology, London). This reduces the impact 
of lesion-associated segmentation bias on GM and WM segmentation (Chard et 
al., 2010). WM and GM fractional (WMF and GMF) volumes, relative to total 
intracranial volume, were calculated.  The sum of white and grey matter relative 
to total intracranial volume (BPF) was also recorded for each subject.  
5.3.6 Brain atrophy 
To avoid segmentation errors due to white matter lesions, an automated lesion-
filling technique was employed (Chard et al., 2010). Lesions masks were created 
based on the 3D-T1 weighted sequences without reference to previously created 
masks on T2-weighted images. 
Probabilistic whole brain segmentations were obtained using STEPS1, a multi-
atlas segmentation propagation technique, which uses an atlas library of 682 non-
MS patients with associated manual segmentations, of which the 30 most similar 
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brain templates were used during a locally-weighted label fusion process 
(Cardoso et al., 2013). 
Using these brain masks, Structural Image Evaluation using Normalization of 
Atrophy (SIENA) were calculated. SIENA is a registration based method which 
computes atrophy between two aligned scans as the perpendicular edge 
displacement at each edge point. The mean edge displacement is converted into 
a global estimate of Percent Brain Volume Change (PBVC) between two time-
points, using self-calibration based on registering both time points to the half-way 
space between them (Smith et al., 2002).  
5.4 Statistical Analysis 
Analyses were performed in Stata 13.1 (Stata Corporation, College Station, 
Texas, USA).  
Multiple linear regression models were used to (i) estimate differences between 
patients and controls in terms of change in MRI metrics over time, (ii) estimate 
association between MRI and clinical changes over the same period of time, in 
patients only, and (iii) predict clinical outcomes at one-year follow-up based on 
the MRI metrics at baseline. All models were adjusted for age and gender. Where 
regression residuals showed deviation from normality, we obtained confidence 
intervals and p-values using a bias-corrected non-parametric bootstrap with 1000 
replicates.  
Additionally, to estimate the association between changes in certain highly 
correlated clinical measures such as postural stability measures and changes in 
MRI data, we used multivariate multiple linear regression models, which allowed 
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us to predict several clinical dependent variables at the same time. To build our 
multivariate multiple linear regression models we used the Stata command 
‘Structural Equation Modelling’.  
Among the advantages of the multivariate regression there were: i) for each MRI 
predictor (changes over one year), we performed a single joint test, which 
reflected its ability to jointly predict changes in a set of postural stability measures, 
with which the MRI predictor showed associations all in the same direction. This 
reduced the risk of type I error derived from multiple testing; ii) under the 
assumptions of missing-at-random and multivariate normality, all available data 
points contributed to the model. This reduced the potential bias from exclusion of 
patients without complete data on all variables, thus reducing the risk of type II 
error. These models allowed us to reduce the risk of type I and type II errors. 
Similar models were built to predict postural stability outcomes at one year of 
follow-up with MRI variables. All multivariate models were also adjusted for age 
and gender. Statistical significance was set at 5%.  
To build the multivariate models used to predict changes in postural stability 
measures with changes in MRI metrics over one year, we followed these steps:  
1) A non-parametric correlation analysis between each clinical variable (changes 
over one year in a given postural stability measure) and each MRI measure was 
performed and the sign of the Spearman’s correlation coefficient was recorded 
2) A parametric correlation analysis was performed and only those correlations 
where the sign of the Spearman’s and the Pearson’s correlation coefficients were 
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equal were kept for further analyses (those correlations with different signs were 
discarded).    
3) Postural stability measures were divided into 4 sets, depending on the distance 
between feet (32 cm or 4 cm) and whether they were obtained with eyes open or 
closed.  
4) For each set of postural stability variables, the signs of the correlation 
coefficients describing the association between a given MRI metric and the 
individual clinical measures within the set were examined. In order to comply with 
the requirements of multivariate linear regression, where all dependent variables 
were assumed to behave in a similar biological manner, only those sets with all 
signs equal were kept for further analyses. 
5) For each set of postural stability variables selected in step 4), a multivariate 
analysis was carried out: the clinical variables (change over one year) were jointly 
considered as dependent variables and a joint test for each set of postural 
stability variables was performed. Whenever the joint test was significant (at 5% 
significance level) we considered there was evidence that the changes in a given 
MRI metric were associated with overall changes in postural stability measures.  
Sample size calculations were performed to detect different plausible treatment 
effects (with 80% power at 5% statistical significance) based on the observed 
differences between patients and controls.  
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5.5 Results 
5.5.1 Participant demographics and characteristics 
Nineteen patients with PPMS and 18 healthy controls were followed-up at one 
year (Table 5.1). Patients had a relatively short disease duration (mean disease 
duration= 4.65 years, range = 1 – 6.5), and a moderate level of disability (median 
EDSS 6.0). The PPMS cohort was significantly older than the healthy controls 
(p<0.026). Further details on patient characteristics, disability and conventional 
brain MRI are summarised in Table 5.1 and Table 5.2. Changes in conventional 
spinal cord and brain MRI measures between baseline and at 1 year in patients 
are also summarised in Table 5.1.  
Patients worsened in a number of clinical measures over the follow-up period, 
specifically: EDSS (p<0.0001); TWT (p<0.01); 9-HPT (p<0.008); ASIA-motor 
scores (p<0.003); and MSWS (p<00001) (Table 5.2).  
 Patients Controls P – value 
N 19 18  
Mean age at 
baseline 
50.8 (8.8) 42.4 (12.6) 0.03 
Gender (M:F) 9:10 5:13  
Mean Disease 
Duration at baseline 
(years) 
4.65 (1.64)  -  
Mean CSA (mm2) at 
baseline 
77.42 (9.84)* 
 
81.40(9.10) 
 
0.21 
 
Mean CSA (mm2) at 
1 year 
74.56 (9.11)* 81.14 (8.62) 0.03 
Change in CSA over 
12 months (mm2) 
2.86* 0.26 0.0001 
PBVC -1.59 (1.13)* -0.33 (1.07) 0.02 
Table 5.1: Mean (SD) demographics of patients and controls. * Linear regression 
model comparing patients with controls, correcting for age and gender. CSA – 
cross sectional cord area.  
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   Baseline 1 Year 
Mean T2 lesion 
volume  
10.73 (9.14) 
 
11.35 (10.14) 
EDSS (median) 
(range) 
5.0 (3.0 – 6.5) 
 
6.0 (4.5 – 7.5)* 
Mean TWT 
(z-score)  
0.28 (0.20) 
 
0.18 (0.33)* 
Mean 9-HPT 
 (z-score) 
-0.67 (1.04) 
 
-0.99 (1.16)* 
Mean grip strength 
(lbs force) 
54.93 (25.97) 
 
45.29 (25.36) 
Mean vibration 
perception 
threshold 
13.52 (9.56) 
 
16.95 (8.14) 
ASIA-motor 
baseline 
96.22 (4.57) 
 
90.00 (8.61)* 
ASIA-light touch 111.50 (1.20) 111.56 (1.34) 
ASIA-pin prick 111.61 (0.70) 107.89 (1.22) 
Mean summated 
MAS 
7.37 (8.87) 
 
6.47 (6.77) 
Mean MSWS-12 46.63 (10.41) 72.19 (24.01)* 
Mean sway, 32cm, 
EO 
0.80 (0.30) deg/sec 
 
0.91 (0.40) deg/sec 
Mean sway, 32cm, 
EC 
0.97 (0.44) deg/sec 
 
1.10 (0.56) deg/sec 
Mean sway, 4cm, 
EO 
0.94 (0.39) deg/sec 
 
1.09 (0.49) deg/sec 
Mean sway, 4cm, 
EC 
1.20 (0.43) deg/sec 
 
1.29 (0.43) deg/sec 
Mean Romberg 
32cm 
1.19 (0.23) 
 
1.22 (0.34) 
Mean Romberg 
4cm 
1.19 (0.14) 
 
1.33 (0.32) 
Table 5.2: Mean (SD) clinical characteristics of patients. P-values for paired t-
tests comparing baseline with 1-year follow-up, * p<0.05.  
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5.5.2 Cross-sectional difference in spinal cord measures between patients 
and controls at 1 year 
All QSI-derived indices of perpendicular diffusivity involving the anterior columns 
(Table 5.3), lateral columns (Table 5.4) and whole cord (Table 5.5) were 
significantly higher (reflected by increased ADCxy and FWHMxy and reduced 
P0xy) in patients than in controls at 1-year follow-up after adjusting for age and 
gender, which is similar to the baseline results by Abdel-Aziz et al., 2015. There 
was no significant difference in the Q-space metrics in the posterior columns 
(Table 5.6).  
Patients had significantly lower spinal tNAA concentration compared to controls 
at 1 year follow-up, after correcting for age and gender (regression coefficients 
(RC) -1.22, 95% confidence interval (CI) -2.37 to 0.08, p<0.04). There was no 
significant difference in Ins (p<0.58), Glx (p<0.82), tCr (p<0.72) and tCho (p<0.77) 
between patients and controls at 1-year follow-up after correcting for age and 
gender (Table 5.7).  
There was a significant difference in spinal cord area between patients and 
controls at 1-year follow-up (RC-7.39, 95% CI -14.12 to -0.66, p <0.03) after 
adjusting for age and gender (Table 5.1).   
An example of these findings are demonstrated in Figure 5.2. 
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Anterior column QSI indices at 0 and 12 months 
  PPMS Controls Adjusted difference 
QSI 
Index 
Time 
points 
(months) 
Estimate 
(RC) 
95%CI P-
value 
ADCxy 
(um2/ms) 
0 0.48 
(0.14) 
0.39 
(0.12) 
0.09 -0.01, 
0.19 
0.09 
 12 0.52 
(0.11) 
0.38 
(0.07) 
0.16 0.08, 0.24 0.0001 
FWHMxy 
(um x 
102) 
0 0.26 
(0.04) 
0.23 
(0.02) 
0.04 0.12, 0.06 0.004 
 12 0.26 
(0.04) 
0.24 
(0.01) 
0.03 0.01, 0.05 0.001 
POxy 
(a.u) 
0 0.19 
(0.03) 
0.22 
(0.03) 
-0.03 -0.05, -
0.005 
0.02 
 12 0.18 
(0.02) 
0.20 
(0.01) 
-0.03 -0.04, -
0.01 
0.0001 
ADCz 
(um2/ms) 
0 1.88 
(0.22) 
1.87 
(0.17) 
0.06 -0.07, 
0.20 
0.36 
 12 1.73 
(0.12) 
1.74 
(0.13) 
-0.01 -0.11, 
0.10 
0.92 
FWHMz 
(um x 
102) 
0 0.55 
(0.04) 
0.56 
(0.04) 
0.001 -0.02, 
0.03 
0.53 
 12 0.54 
(0.03) 
0.54 
(0.03) 
0.01 -0.02, 
0.03 
0.48 
POz 
(a.u) 
0 0.18(0.03) 0.21 
(0.03) 
-0.001 -0.006, 
0.003 
0.50 
 12 0.18 
(0.02) 
0.20 
(0.01) 
-0.002 -0.006, 
0.003 
0.52 
Table 5.3: Summary of mean (SD) diffusivity from the anterior column of the 
cervical cord in patients and controls at baseline and at 12 months follow–up. P-
values for adjusted group comparisons after correcting for age and gender. RC - 
regression coefficient. 
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Lateral column QSI indices at 0 and 12 months 
  PPMS Controls Adjusted difference 
 
QSI Index Time 
points 
(mont
hs) 
Estimate 
(RC) 
 95%CI P-
value 
ADCxy 
(um2/ms) 
0 0.40 
(0.11) 
0.32 
(0.10) 
0.09 0.02, 0.16 0.02 
 12 0.43 
(0.11) 
0.36 
(0.06) 
0.09 0.02, 0.17 0.02 
FWHMxy 
(um x 102) 
0 0.25 
(0.04) 
0.21 
(0.02) 
0.04 0.01, 0.06 0.004 
 12 0.25 
(0.04) 
0.22 
(0.02) 
0.03 0.01, 0.06 0.02 
POxy (a.u) 0 0.19 
(0.03) 
0.22 
(0.03) 
-0.03 -0.05, -
0.01 
0.002 
 12 0.19 
(0.03) 
0.21 
(0.02) 
-0.02 -0.04, -
0.00 
0.05 
ADCz 
(um2/ms) 
0 1.96 
(0.27) 
1.76 
(0.62) 
0.15 -0.12, 0.41 0.28 
 12 1.79 
(0.11) 
1.82 
(0.09) 
-0.03 -0.12, 0.06 0.51 
FWHMz 
(um x 102) 
0 0.57 
(0.04) 
0.58 
(0.03) 
-0.001 -0.03, 0.02 0.96 
 12 0.55 
(0.03) 
0.55 
(0.03) 
0.01 -0.01, 0.03 0.19 
POz (a.u) 0 0.11 
(0.01) 
0.11 
(0.004) 
0.002 -0.004, 
0.01 
0.60 
 12 0.11 
(0.004) 
0.11 
(0.003) 
0.000082 -0.003, 
0.003 
0.96 
Table 5.4: Summary of mean (SD) diffusivity from the lateral column of patients 
and controls at baseline and at 12 months follow–up. P–Values for adjusted group 
comparisons after correcting for age and gender.  
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Whole cord QSI indices at 0 and 12 months 
  PPMS Controls Adjusted difference 
 
QSI Index Time 
points 
(months) 
Estimate 
(RC) 
95%CI P-
value 
ADCxy 
(um2/ms) 
0 0.44 
(0.09) 
0.39 
(0.09) 
0.06 -0.002, 
0.12 
0.06 
 12 0.47 
(0.12) 
0.37 
(0.04) 
0.13 0.06, 
0.20 
0.001 
FWHMxy 
(um x 102) 
0 0.26 
(0.03) 
0.24 
(0.02) 
0.03 0.004, 
0.05 
0.02 
 12 0.25 
(0.03) 
0.23 
(0.02) 
0.03 0.006, 
0.05 
0.02 
POxy (a.u) 0 0.18 
(0.02) 
0.20 
(0.02) 
-0.02 -0.04, -
0.01 
0.01 
 12 0.19 
(0.02) 
0.21 
(0.02) 
-0.02 -0.04, -
0.01 
0.008 
ADCz 
(um2/ms) 
0 1.81 
(0.16) 
1.59 
(0.55) 
0.15 -0.06, 
0.35 
0.15 
 12 1.75 
(0.10) 
1.76 
(0.08) 
0.03 -0.04, 
0.10 
0.42 
FWHMz 
(um x 102) 
0 0.55 
(0.03) 
0.55 
(0.03) 
0.01 -0.01, 
0.03 
0.45 
 12 0.55 
(0.03) 
0.55 
(0.03) 
0.01 -0.01, 
0.03 
0.32 
POz (a.u) 0 0.12 
(0.01) 
0.11 
(0.004) 
0.001 -0.003, 
0.005 
0.71 
 12 0.11 
(0.004) 
0.12 
(0.01) 
-0.003 -0.01, 
0.001 
0.12 
Table 5.5: Summary of mean (SD) diffusivity from the whole cord of patients and 
controls at baseline and at 12 months follow–up. P–values for adjusted group 
comparisons after correcting for age and gender.  
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Posterior column QSI indices at 0 and 12 months 
  PPMS Controls Adjusted difference 
 
QSI 
Index 
Time 
points 
(months) 
Estimate 
(RC) 
95%CI P-
value 
ADCxy 
(um2/ms) 
0 0.42 
(0.11) 
0.37 
(0.107) 
0.05 -0.02, 0.11 0.18 
 12 0.42 
(0.08) 
0.35 
(0.09) 
0.07 0.00,  
0.13 
0.05 
FWHMxy 
(um x 
102) 
0 0.26 
(0.06) 
0.23 
(0.03) 
0.02 -0.01, 0.06 0.18 
 12 0.24 
(0.03) 
0.22 
(0.03) 
0.02 -0.01, 0.04 0.15 
POxy 
(a.u) 
0 0.19 
(0.03) 
0.21 
(0.03) 
-0.02 -0.04, 0.01 0.20 
 12 0.19 
(0.02) 
0.22 
(0.03) 
-0.02 -0.04, 0.004 0.11 
ADCz 
(um2/ms) 
0 2.03 
(0.46) 
2.01 
(0.40) 
-0.07 -0.43, 0.29 0.69 
 12 2.01 
(0.17) 
2.08 
(0.11) 
-0.01 -0.13, 0.10 0.81 
FWHMz 
(um x 
102) 
0 0.60 
(0.05) 
0.60 
(0.04) 
 
0.01 -0.02, 0.04 0.40 
 12 0.59 
(0.04) 
0.60 
(0.04) 
0.001 -0.03, 0.03 0.97 
POz 
(a.u) 
0 0.10 
(0.01) 
0.10 
(0.004) 
-0.002 -0.01, 0.001 0.18 
 12 0.11 
(0.01) 
0.10 
(0.01) 
-0.001 -0.01, 0.004 0.70 
Table 5.6: Summary of mean (SD) diffusivity from the posterior column of 
patients and controls at baseline and at 12 months follow–up. P–values for 
adjusted group comparisons after correcting for age and gender.  
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Metabolite Time 
Point 
(months) 
PPMS Controls Adjusted difference  
Estimate 
(RC) 
95% CI P-value 
tNAA 
(mmol/l) 
0 4.06 
(1.16) 
5.31 
(1.47) 
-1.28 -2.36, -
0.20 
0.02 
 12 3.70 
(1.57) 
5.07 
(1.03) 
-1.22 -2.37, -
0.08 
0.04 
Glx 
(mmol/l) 
0 4.65 
(1.11) 
5.93 
(1.66) 
-1.03 -2.34, 
0.29 
0.12 
 12 6.82 
(2.22) 
8.09 
(2.32) 
-4.28 -2.05, 
0.19 
0.07 
Ins 
(mmol/l) 
0 5.59 
(1.83) 
4.49 
(1.23) 
0.75 -0.53, 
2.03 
0.24 
 12 6.39 
(2.44) 
5.52 
(1.60) 
0.46 -1.24, 
2.17 
0.58 
tCho 
(mmol/l) 
0 1.30 
(0.38) 
1.32 
(0.41) 
-0.13 -0.47, 
0.22 
0.46 
 12 1.43 
(0.59) 
1.29 
(0.38) 
0.06 -0.37, 
0.50 
0.77 
tCr  
(mmol/l) 
0 3.84 
(1.46) 
3.76 
(1.13) 
-0.230 -1.39, 
0.79 
0.58 
 12 3.78 
(1.58) 
3.57 
(1.27) 
0.20 -0.94, 
1.34 
0.72 
Table 5.7: Cross-sectional summary of mean (SD) metabolite concentrations 
(mmol/l) from the cervical cord of patients and controls. P-values for adjusted 
group comparisons after correcting for age and gender.  
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Figure 5.2: Examples of a 3D-FFE axial image of the cervical cord outlined using 
the active surface model, P0xy map, FWHMxy map and a post processed spectra 
in a PPMS patient at baseline and then at 1-year follow-up. The graphs represent 
differences in height and width of the displacement distribution function from the 
posterior (left) and lateral column (right) from a patient at baseline and 1 year. 
The FFE image shows a reduction in cross-sectional cord area, increased 
FWHMxy in the posterior column, reduced P0xy in the lateral columns and 
reduced tNAA at 1 year. 
 
5.5.3 Longitudinal changes in MRI metrics over 1 year 
Spinal cord area was the only MRI metric in the spinal cord which significantly 
decreased over 1 year, such that the rate of reduction in cord area in the PPMS 
cohort over one year was 2.86 mm2 greater than in controls (RC-2.86, 95% CI -
4.36 to -1.37, p<0.0001), after correcting for age and gender.  
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The metabolites and Q-space measures did not change significantly over 1 year.  
Sample size calculations with 80% power using the spectroscopic protocol and 
Q-space imaging protocol used in this study, demonstrated slightly larger sample 
sizes would have enabled us to detect significant changes in perpendicular 
diffusivity in the posterior and lateral cord and in tCho as outlined in Table 5.8.  
PBVC was significantly greater in the PPMS cohort at -1.59% when compared to 
controls after adjusting for age and gender over 1 year (95% CI -0.21 to -2.08, p 
< 0.02) (Table 5.1).  
MRI Metric Sample size per 
arm 
MRI Metric Sample size 
per arm 
tNAA 625 Lateral ADCxy 4246 
Creatine 96 Lateral ADCz 261 
Choline 64 Lateral FWHMxy 61 
Ins 671 Lateral FWHMz 138 
Glx 445 Lateral POxy 58 
Posterior ADCxy 60 Lateral POz 363 
Posterior ADCz 82 Anterior ADCxy 88 
Posterior FWHMxy 35 Anterior ADCz 75 
Posterior FWHMz 100 Anterior FWHMxy 5618 
Posterior P0xy 990 Anterior FWHMz 694 
Posterior POz 129 Anterior POxy 2002 
  Anterior POz 142 
Table 5.8: Sample size calculations required to detect significant changes in MRI 
metrics in patients over time compared to changes observed in controls with 80% 
power. Those numbers highlighted in bold represent sample sizes, which are less 
than 100 per arm.  
 
The below is a summary table of the significant associations between change in 
MRI metrics and change in clinical disability scores in PPMS subjects. Each of 
these results will be discussed in more detail in Section 5.5.4, 5.5.6 and 5.5.7, 
as well as in Table 5.9, 5.10 and 5.11.  
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(A) Change in QSI 
metrics 
Change in clinical 
disability 
Cord FWHMxy 
Cord FWHMz 
Posterior FWHMz 
Posterior P0z 
Lateral FWHMz 
Vibration perception 
thresholds 
Cord ADCxy 
Anterior FWHMz 
ASIA-light touch 
Posterior P0z 
Lateral FWHMz 
Lateral ADCxy 
Postural stability (32EO, 
32EC, 4EO, 4EC) 
(B) Change in 
metabolites 
Change in clinical 
disability 
Ins EDSS 
tNAA 
tCr 
TWT  
tCr 
 
Postural stability (32EO,  
32 EC, 4EO, 4EC) 
(C) MRI measures 
baseline 
Predictors of clinical 
status at 1 year 
Cord FWHMz 
Anterior FWHMz 
Posterior FWHMxy 
Posterior P0xy 
Posterior ADCxy 
Lateral FWHMz 
EDSS 
Cord FWHMxy 
Cord P0xy 
Cord ADCxy 
Anterior FWHMxy 
Posterior P0xy 
Lateral FWHMxy 
Lateral P0xy 
Lateral ADCxy 
Postural stability 32EO 
Cord ADCxy 
Lateral FWHMxy 
Lateral ADCxy 
 
Postural stability 32EC 
Table 5.9: Summary of significant associations between: (A) change in QSI 
metrics and change in clinical disability scores, (B) change in metabolites and 
change in clinical disability scores and (C) predictors of clinical status at 1 year 
with baseline MRI measures. 32EO - 32cm eyes open, 32EC – 32cm eyes 
closed, 4EO – 4cm eyes open and 4EC – 4cm eyes closed. 
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5.5.4 Associations between change in Q-space imaging measures and 
change in clinical disability over 1 year 
Despite no significant change in Q-space metrics, over 1 year in patients 
compared to controls, increased whole cord perpendicular diffusivity (increased 
FWHMxy) was associated with impaired vibration sensation, such that, per unit 
increase in FWHMxy, there was a predicted 320.70 (95% CI 28.38 to 984.27) 
increase in vibration sensation (p=0.045). Changes in parallel diffusivity 
(increased FWHMz) in the posterior column was associated with a predicted 
117.11 (95% CI 20.77 to 198.11) increase in vibration sensation (p=0.02), in the 
lateral columns with a predicted 85.02 (95% CI 2.81 to 261.03) increase in 
vibration sensation (p=0.04) and in the whole cord with a predicted 120.59 (2.53 
to 389.60) increase in vibration sensation (p=0.05). A scatterplot representing 
these associations are shown in Figure 5.3. In the anterior column, per unit 
increase in FWMHz, there was a predicted -34.94 decrease (95% CI -94.25 to -
4.60) in ASIA-light touch scores (p=0.04). Changes in perpendicular diffusivity in 
the whole cord (increased ADCxy) were associated with impaired ASIA – light 
touch scores, such that per unit increase in ADCxy was associated with a 
predicted -8.15 decrease (95% CI -73.09 to -0.30) in ASIA-light touch scores 
(p=0.04).  
Increased parallel diffusivity (decreased P0z) in the posterior columns and lateral 
columns (increased FWHMz) and increased perpendicular diffusivity (increased 
ADCxy) in the lateral columns were associated with increased postural instability 
over 1 year.  These associations are presented in Table 5.10.  
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5.5.5 Associations between change in 1H-MRS measures and change in 
clinical disability over 1 year 
Despite no significant change in metabolites over 1 year, in patients increased 
tCr was associated with a decrease in TWT z-score (RC -0.07, 95% CI -0.14 to -
0.01, p=0.03) and with greater postural instability.  Decreased tNAA over 1 year 
was associated with a borderline significant decrease in TWT z-score in patients 
(RC 0.07, 95% CI -0.01 to 0.14, p=0.06).  There was borderline evidence of 
increased Ins being associated with an increase in EDSS (RC 0.50, 95% CI -0.04 
to 1.04, P=0.07). These associations are presented in Table 5.11. There was no 
significant association between change in cervical spinal cord area and clinical 
disability. 
 
 
 
 
 
 
Figure 5.3: Scatter plot 
demonstrating the 
association between change 
in vibration perception 
thresholds and change in 
parallel diffusivity in the 
posterior columns (FWHMz) 
in patients (unadjusted). 
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Predictors 
Dependent variables 
EDSS TWT VPTs ASIA-light 
touch 
 
Postural stability 32cm 
 
Postural stability 4cm 
 
EO EC EO EC 
Regression coefficients (95%CI) from linear 
regression, p-value  
Standardised regression coefficients (95% CI) from multivariate 
analysis Q-space metrics 
XY              Z 
Cord  
FWHM 
 
 
-9.84  
(-71.80, 
65.15) 
P=0.78**  
-2.77 
(-15.91, 
5.81) 
P=0.62** 
320.70  
(28.38, 
984.27) 
P=0.05** 
-49.86  
(-176.17, 
22.08) 
P=0.25**  
Sway: -0.42  
(-0.81, -0.03) 
Pitch: -0.39  
(-0.77, -0.14) 
Roll: -0.48  
(-0.89. -0.06) 
P=0.01* 
Sway: -0.43  
(-0.90, 0.04) 
Pitch: -0.48  
(-0.92, -0.05) 
Roll: -0.51  
(-0.97, -0.04) 
Romberg:  
-0.09  
(-0.66, 0.48) 
P=0.07* 
Sway: -0.55  
(-0.95, -0.15) 
Pitch: -0.52  
(-0.92. -0.11) 
Roll: -0.59  
(-0.99, -0.19) 
P=0.07* 
Sway: -0.58 
(-1.27, 0.12) 
Pitch: -0.69  
(-1.33, -0.06) 
Roll: -0.90  
(-1.20, -0.59) 
Romberg:  
-0.09  
(-0.67, 0.48) 
P=0.02* 
 Cord 
FWHM 
-15.19  
(-45.38, 8.24) 
p=0.24**  
-1.32  
(-5.37, 
3.13) 
p=0.49** 
120.59 
(2.53, 
389.69) 
p=0.05** 
-24.44  
(-74.85, 
15.56) 
p=0.26**  
Sway: 0.31  
(-0.19, 0.80) 
Pitch: 0.29  
(-0.20, 0.78) 
Roll: 0.24  
(-0.29, 0.77) 
P=0.35* 
Sway: -0.09  
(-0.68, 0.40) 
Pitch: -0.13 
(-0.71, 0.45) 
Roll: -0.11  
(-0.72, 0.51) 
Romberg:  
-0.40  
(-0.92, 0.12) 
P=0.21* 
Sway: 0.13  
(-0.50, -.76) 
Pitch: 0.21 
(-0.39, 0.81) 
Roll: -0.03 
(-0.71, 0.65) 
P=0.004* 
Sway: 0.02  
(-0.60, 0.64) 
Pitch: -0.30  
(-0.91, 0.32) 
Roll: -0.47  
(-0.97, 0.03) 
Romberg:  
-0.31  
(-0.82, 0.20) 
P=0.01* 
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Cord  
ADC 
 
 
-1.78  
(-11.24, 5,56) 
p=0.76**  
-0.45  
(-2.42, 
1.95) 
p=0.65** 
38.63  
(-64.74, 
187.95) 
p=0.57**  
-8.15  
(-73.09, -
0.30) 
p=0.04** 
Sway: -0.31  
(-1.44, 0.82) 
Pitch: -0.05  
(-1.51, 1.42) 
Roll: -0.62  
(-1.24, 0.01) 
P=0.43* 
Sway: -0.67 
 (-1.24, -0.09) 
Pitch: -0.62 
(-1.29, 0.05) 
Roll: -0.61  
(-1.47, 0.25) 
Romberg:  
-0.64  
(-1.43, 0.16) 
P=0.72* 
Sway: -0.45  
(-1.43, 0.53) 
Pitch: -0.27 
(-1.57, 1.03) 
Roll: -0.67  
(-1.20, -0.14) 
P=0.02* 
Sway: 0.67 
(0.009, 1.34) 
Pitch: 0.62  
(-0.25, 1.49) 
Roll: 0.33  
(-1.26, 1.92) 
Romberg:  
-0.64  
(-1.43, 0.16) 
P=0.12* 
 Anterior 
FWHM 
 
-20.08  
(-50.47, 3.99) 
p=0.15**  
-0.64  
(-4.66, 
3.95) 
p=0.74**  
48.02  
(-109.53, 
282.19) 
p=0.61**  
-34.94  
(-94.25, -
4.60) 
P=0.04** 
Sway: 0.05  
(-0.43, 0.52) 
Pitch: 0.07  
(-0.40, 0.53) 
Roll: -0.05  
(-0.56, 0.47) 
P=0.63* 
Sway: -0.18  
(-0.70, 0.35) 
Pitch: -0.22  
(-0.73, 0.29) 
Roll: -0.21  
(-0.75, 0.34) 
Romberg:  
-0.35  
(-0.85, 0.15) 
P=0.30* 
Sway: -0.12  
(-0.67, 0.42) 
Pitch: -0.04  
(-0.57, 0.49) 
Roll: -0.27 
(-0.80, 0.26) 
P=0.03* 
Sway: 0.01  
(-0.64, 0.66) 
Pitch: -0.24  
(-0.91, 0.43) 
Roll: -0.54  
(-0.99, -0.09) 
Romberg:  
-0.21  
(-0.75, 0.32) 
P=0.0001* 
 Posterior 
FWHM 
-8.76  
(-28.50, 5.15) 
p=0.32**  
-0.64  
(-4.73, 
0.86) 
p=0.60**  
117.11  
(20.77, 
198.11) 
P=0.02** 
-20.15  
(-47.22, 
10.26) 
p=0.22** 
Sway: 0.22  
(-0.27, 0.71) 
Pitch: 0.32  
(-0.14, 0.78) 
Roll: -0.009  
(-0.54, 0.52) 
P=0.13* 
Sway: -0.52  
(-0.93, -0.97) 
Pitch: -0.47  
(-0.90, -0.04) 
Roll: -0.49  
(-0.95, 0.009) 
Romberg:  
-0.72 
P=0.03* 
Sway: -0.09 
(-0.80, 0.62) 
Pitch: 0.02  
(-0.68, 0.73) 
Roll: -0.29  
(-0.98, 0.39) 
P=0.013* 
Sway: -0.10  
(-0.80, 0.59) 
Pitch: -0.33  
(-1.02, 0.36) 
Roll: -0.55  
(-1.03, -0.07) 
Romberg:  
-0.51  
(-0.96, -0.06) 
P=0.0001* 
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 Posterior 
P0 
-25.70  
(-173.70, 
116.79) 
p=0.72**  
7.38  
(-9.65, 
39.46) 
p=0.54** 
-1114.73  
(-1915.09, -
363.46) 
p=0.006**  
89.10  
(-184.76, 
282.93) 
p=0.47** 
Sway: -0.17 
(-0.27, 0.61) 
Pitch: -0.03  
(-0.43, 0.48) 
Roll: -0.44  
(-0.82. 0.05) 
P=0.005* 
Sway: -0.75  
(-0.97, -0.53) 
Pitch: -0.72  
(-0.96, -0.49) 
Roll: -0.72  
(-0.99, -0.46) 
Romberg: 0.76  
(0.49, 1.03) 
P=0.0001* 
Sway: -0.65 
(1.00, -0.30) 
Pitch: -0.59 
(-0.99, -0.22) 
Roll: -0.74  
(-1.01, -0.47) 
P=0.0001* 
 
 
Sway: -0.47  
(-1.07, -0.12) 
Pitch: -0.26  
(-1.03, -0.50) 
Roll: -0.55  
(-1.04, -0.06) 
Romberg: 0.65  
(0.25, 1.05) 
P=0.0001* 
 Lateral 
FWHM 
-12.85  
(-30.82, 4.61) 
P=0.15** 
-2.12  
(-5.35, 
0.39) 
P=0.14** 
 
85.02  
(2.81, 
261.03) 
P=0.04** 
-8.07 
(-50.56, 
23.24) 
p=0.62** 
 
Sway: 0.20  
(-0.28, 0.69) 
Pitch: 0.20  
(-0.27, 0,67) 
Roll: 0.07  
(-0.46, 0.61) 
P=0.0002* 
Sway: 0.02  
(-0.54, 0.57) 
Pitch: 0.01  
(-0.54, 0.56) 
Roll: 0.29  
(-0.82, 0.24) 
Romberg: 0.02  
(-0.51, 0.54) 
P=0.0005* 
Sway: 0.36  
(-0.22, 0.94) 
Pitch: 0.47  
(-0.03, 0.96) 
Roll: 0.15  
(-0.57, 0.86) 
P=0.0001* 
Sway: 0.57 
(0.04, 1.09) 
Pitch: 0.36  
(-0.34, 1.05) 
Roll: -0.06 
(-0.79, 0.67) 
Romberg:  
-0.02  
(-0.79, 0.67) 
P=0.0001* 
Lateral 
ADC 
 0.41  
(-4.98, 4.87)  
P=0.87** 
-0.23  
(-1.39, 
0.40) 
P=0.61** 
18.08  
(-19.99, 
73.18)  
P=0.47** 
-5.27  
(-12.96, 
2.42) 
P=0.18** 
Sway: -0.47  
(-0.81, -0.12) 
Pitch: -0.39 
(-0.74, 0.06) 
Roll: -0.64  
(-0.92, -0.35) 
P=0.003* 
Sway: -0.76 
(-0.98, -0.55) 
Pitch: -0.77  
(-0.98, -0.57) 
Roll: -0.70  
(-0.99, -0.40) 
Romberg: -0.68  
(-1.02, -0.35) 
P=0.0001* 
Sway: -0.71  
(-0.94, -0.48) 
Pitch: -0.69  
(-0.92, -0.45) 
Roll: -0.73  
(-0.97, -0.49) 
P=0.0001* 
Sway: -0.79  
(-0.99, -0.58) 
Pitch: -0.36 
(-1.29, 0.57) 
Roll: -0.29  
(-1.21, 0.64) 
Romberg: -0.68  
(-1.01, -0.35) 
P=0.0001* 
Table 5.10: Associations between change in Q-space metrics (predictors) and change in clinical scores (dependent variable) in 
patients. * Joint tests of association used for the postural stability measures. Significant differences are reported for each stance 
distance (32cm and 4cm) with eyes open (EO) and eyes closed (EC) if three or more of the stance conditions (32cm EO, 32cm 
EC, 4cm EO, 4cm EC) were significant. ** Linear regression performed with the change in MRI measure used as the predictor and 
the clinical measure as the dependent variable correcting for age and gender. Significant results highlighted in bold. 
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Predictors 
Dependent variables 
EDSS TWT VPTs ASIA-light 
touch 
 
Postural stability 32cm 
 
Postural stability 4cm 
 
EO EC EO EC 
Regression coefficients (95%CI) from linear regression, p-
value 
  
Standardised regression coefficients (95% CI) from 
multivariate analysis 
Myo-inositol 
 
0.50  
(-0.04, 1.04) 
P=0.07**  
0.02  
(-0.43, 0.09) 
p=0.44**  
-1.03  
(-6.39, 4.32) 
p=0.64**  
0.65 
(-0.23, 1.53) 
p=0.44**  
Sway: -0.91 
(-1.50, -0.32) 
Pitch: -0.90 
(-1.48, -0.33) 
Roll: -0.62  
(-1.34, 0.10) 
P=0.0001*  
Sway: -0.15  
(-1.02, 0.72) 
Pitch: -0.20  
(-1.06, 066) 
Roll: 0.32  
(-0.57, 1.21) 
Romberg: 
0.34 (-0.53, 
1.22) 
P=0.0001* 
Sway: -0.33 
(-1.12, 0.46) 
Pitch: -0.47  
(-1.21, 0.27) 
Roll: -0.07  
(-0.91, 0.77) 
P=0.06* 
- 
N-acetyl-aspartate 
 
-0.17  
(-0.75, 0.42) 
p=0.54**  
0.07  
(-0.01, 0.14) 
P=0.06*** 
-21.91  
(-79.88, 36.05) 
p=0.35**  
0.16  
(-0.76, 1.08), 
p=0.69**  
Sway: 0.60  
(-0.06, 1.27) 
Pitch: 0.21  
(-0.71, 1.13) 
Roll: 0.99 
(0.75, 1.22) 
P=0.0001* 
Sway: 0.47  
(-0.007, 0.94) 
Pitch: 0.34  
(-0.17, 0.85) 
Roll: 0.25  
(-0.31, 0.81) 
Romberg: 
0.40 
(-0.05, 0.84) 
P=0.07* 
 
 
 
- - 
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Creatine 
 
0.14 
(-0.49, 0.77) 
p=0.64**  
-0.07 
(-0.14, -0.01) 
P=0.03**  
 
 
-2.67  
(-7.18, 1.84) 
p=0.20** 
*  
0.17  
(-0.66, 0.10) 
p=0.65**  
Sway: 0.52 
(0.02, 1.01) 
Pitch: 0.35 
(-0.26, 0.95) 
Roll: 0.73 
(0.42, 1.04) 
P=0.003* 
 
Sway: 0.87 
(0.71, 1.03) 
Pitch: 0.85 
(0.66, 1.03) 
Roll: 0.78 
(0.54, 1.03) 
Romberg: 
0.59 (0.09, 
1.10) 
P=0.0001* 
 
Sway:0.49  
(-0.04, 1.02) 
Pitch: 0.50  
(0.00, 1.00) 
Roll: 0.41  
(-0.19, 1.01) 
P=0.01* 
 
Sway: 0.86  
(0.78, 0.93) 
Pitch: 0.35  
(0.21, 0.49) 
Roll: 0.21 
(0.12, 0.30) 
Romberg: 
0.77  
(0.67, 0.87) 
P=0.05* 
Table 5.11: Associations between change in 1H-MRS metabolites (predictors) and change in clinical scores (dependent variable) in 
patients. * Joint tests of association used for the postural stability measures. Significant differences are reported for each stance 
distance (32cm and 4cm) with eyes open (EO) and eyes closed (EC) if three or more of the stance conditions (32cm EO, 32cm EC, 
4cm EO, 4cm EC) were significant. ** Linear regression model performed with change in MRI measure used as the predictor and 
the clinical measure as the dependent variable correcting for age and gender. Significant results highlighted in bold. 
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5.5.6 Predicting clinical status at 1 year with baseline MRI measures 
Perpendicular diffusivity in the posterior columns (increased ADCxy, increased 
FWHMxy and decreased P0xy), and parallel diffusivity in the anterior columns 
(increased FWHMz), lateral columns (increased FWHMz) and whole cord 
(increased FWHMz) at baseline best predicted EDSS at 1 year after correcting 
for age, gender and EDSS at baseline, as outlined in Table 5.12. Figure 5.4 
represents the correlation between perpendicular diffusivity (FWHMxy) in the 
posterior column at baseline, predicting EDSS at 1 year. In particular, per unit 
increase in ADCxy and FWHMxy in the posterior columns was associated with 
a predicted 3.71 (95% CI 0.31 to 8.71) and 5.73 (95% CI 0.35 to 11.82) increase 
in EDSS respectively at 1 year (p=0.04 and p=0.05), while per unit decrease in 
P0xy was associated with a predicted 13.12 (25.07 to 0.09) increase in EDSS 
(p=0.04). Per unit increase in FWHMz in the anterior columns, lateral columns 
and whole cord was associated with a predicted 12.85 (0.21 to 0.96), 8.02 (0.02 
to 18.50) and 13.83 (2.44 to 33.00) increase in EDSS respectively at 1 year. 
QSI derived metrics of perpendicular diffusivity in the anterior, posterior, lateral 
columns and whole cord at baseline best predicted postural stability at 1 year, 
as outlined in Table 5.12. None of the other MRI metrics, including spinal cord 
area and the metabolites at baseline, predicted EDSS at 1-year. 
 
 
 
 
Figure 5.4: Scatter plot 
demonstrating the 
association between 
perpendicular diffusivity 
(FWHMxy) in the posterior 
column at baseline 
predicting EDSS at 1 year 
(unadjusted). 
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Clinical measure 
 
 
EDSS 
 
Postural stability 32cm 
Q-space imaging 
metrics baseline 
 EO EC 
XY Z Regression coefficients (95% CI), p-value from bootstrap analysis 
Cord 
FWHM 
 9.47 (-3.27, 22.59), p=0.17 Sway: 5.90 (0.51, 11.82), p=0.04 
Pitch: 4.62 (-3.38, 8.23), p=0.50 
Roll: 3.04 (-0.39, 8.08), p=0.18 
Sway: 9.56 (-11.20, 28.19), p=0.45 
Pitch: 6.80 (-11.48, 21.32), p=0.44 
Roll: 5.39 (-1.17, 15.87), p=0.96 
 
 
Cord  
FWHM 
 
13.83 (2.44, 33.00), p=0.03 Sway: 3.97 (-1.69, 16.50), p=0.33 
Pitch: 3.10 (-1.76, 13.50), p=0.35 
Roll: 2.09 (-1.20, 9.46), p=0.38 
Sway: 5.97 (-8.59, 38.68), p=0.55 
Pitch: 4.62 (-8.59, 29.83), p=0.60 
Roll: 3.59 (-2.39, 17.12), p= 0.45 
Cord 
P0 
 
 -14.66 (-31.10, 5.93), p=0.10 Sway: -9.23 (-28.26, -4.21), p=0.04 
Pitch: -7.31 (-11.35, -2.93), p=0.002 
Roll: -4.63 (-18.07, -0.29), p=0.04 
 
Sway: -13.48 (-421.20, 8.67), p=0.49 
Pitch: -9.00 (-25.79, 13.21), p=0.44 
Roll: -7.97 (-114,14, 0.55), p=0.23 
Cord 
ADC 
 
 4.26 (-0.21, 9.58), p=0.09 Sway: 2.72 (-3.13, 4.82), p=0.12 
Pitch: 1.94 (-2.32, 3.76), p=0.12 
Roll: 1.60 (0.44, 2.88), p=0.03 
Sway: 5.47 (-0.38, 10.65), p=0.07 
Pitch: 4.04 (0.80, 17.10), p=0.04 
Roll: 2.59 (1.23, 7.54), p=0.02 
Anterior 
FWHM 
 
 6.66 (-8.54, 15.97), p=0.25 
 
 
 
Sway: 4.13 (0.38, 38.69), P=0.04 
Pitch: 3.23 (0.65, 17.97), P=0.05 
Roll: 2.21 (-0.66, 15.31), p=0.26 
Sway: 7.67 (-3.99, 642.69), p=0.72 
Pitch: 5.75 (-5.38, 129.67), p=0.42 
Roll: 4.02 (-0.92, 13.60), p=0.20 
 
 Anterior 
FWHM 
12.85 (0.21, 0.96), p=0.02 
 
 
Sway: 3.17 (-1.79, 14.64), p=0.67 
Pitch: 2.59 (-2.20, 9.42), p=0.44 
Roll: 1.51 (-1.09, 9.91), p=0.87 
Sway: 2.81 (-8.55, 34.87), p=0.76 
Pitch: 2.11 (-7.27, 26.80), p=0.77 
Roll: 2.18 (-2.55, 17.48), p=0.61 
Posterior 
FWHM 
 5.73 (0.35, 11.82), p=0.05  Sway: 3.14 (-16.36, 6.36), p<0.31 
Pitch: 2.45 (-3.24, 6.12), p<0.24 
Roll: 1.60 (-0.27, 6.56), p<0.47 
Sway: 5.04 (-12.61, 91.21), p<0.63 
Pitch: 3.77 (-9.54, 74.95), p<0.56 
Roll: 2.73 (-5.07, 65.74), p<0.56 
Posterior 
PO 
 
 
 
-13.12 (-25.07, -0.09), p=0.04 
 
 
 
Sway: -7.04 (-13.18, -3.97), p=0.02 
Pitch: -5.58 (-8.77, 3.35), p=0.15 
Roll: -3.42 (-6.80, -0.07), p=0.05 
Sway: -10.06 (-93.95, 16.95), p=0.51 
Pitch: -6.92 (-26.59, 14.29), p=0.48 
Roll: -5.90 (-32.08, 4.72), p=0.39 
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Posterior 
ADC 
 
 3.71 (0.31, 8.71), p=0.04 
 
Sway: 1.50 (-5.83, 8.87), p=0.68 
Pitch: 1.07 (-3.20, 9.91), p=0.68 
Roll: 0.90 (-1.94, 5.58), p=0.52 
Sway: 4.73 (-7.67, 11.93), p=0.37 
Pitch: 3.86 (-18.36, 11.43), p=0.54 
Roll: 1.82 (-3.14, 5.57), p=0.46 
Lateral 
FWHM 
 
 7.82 (-2.73, 18.72), p=0.16 Sway: 6.02 (3.47, 15.63), p=0.01 
Pitch: 4.53 (-2.65, 9.60), p=0.12 
Roll: 3.27 (1.27, 9.96), p=0.004 
Sway:10.45 (0.80, 156.07), p=0.04 
Pitch: 7.68 (-2.80, 45.36), p=0.40 
Roll: 5.44 (1.24, 45.05), p=0.004 
 
 Lateral 
FWHM 
8.02 (0.02, 18.50), p=0.05 Sway: 2.91 (-1.91, 11.97), p=0.32 
Pitch: 2.19 (-1.52, 10.03), p=0.39 
Roll: 1.69 (-1.66, 5.60), p=0.31 
 
Sway: 4.63 (-6.92, 21.13), p=0.51 
Pitch: 3.77 (-5.44, 16.42), p=0.51 
Roll: 3.23 (-1.61, 9.87), p=0.25 
Lateral 
P0 
 -10.03 (-20.27, 7.42), p=0.14 Sway: -8.14 (-22.81, -3.36), p=0.01 
Pitch: -6.25 (-14.85, -3.10), p=0.02 
Roll: -4.26 (-10.38, -0.91), p=0.01 
Sway: -12.54 (-81.08, 1.54), p=0.51 
Pitch: -9.05 (-46.03, 3.59), p=0.66 
Roll: -6.63 (-24.44, -0.35), p=0.19 
Lateral 
ADC 
 2.68 (-1.60, 6.62), p=0.19 Sway: 1.96 (0.38, 3.86), p=0.013 
Pitch: 1.35 (-1.21, 2.86), p=0.12 
Roll: 1.17 (0.79, 2.29), p=0.0001 
Sway: 4.12 (1.01, 6.91), p=0.004 
Pitch: 3.19 (1.00, 7.38), p=0.008 
Roll: 1.90 (1.04, 4.18), p=0.001 
 
Table 5.12: Predictors of clinical status at 1 year with baseline MRI measures. Regression analysis using bootstrapping correcting 
for age, gender and baseline clinical measure. Significant results highlighted in bold. Multivariate analysis was not possible with this 
data, which is likely due to the small sample size. Significant results highlighted in bold.
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5.7 Discussion 
The findings from this study demonstrate that among all MRI metrics, (i) cervical 
spinal cord area had the greatest and most significant change over 1 year and (ii) 
there were significant associations between change in Q-space metrics and 
change in clinical scores. The findings from this follow-up study, demonstrate 
possible ongoing neurodegeneration in the cervical cord in early PPMS over a 
short follow-up period detected using spinal cord atrophy. Q-space metrics may 
detect clinically meaningful pathology within the cervical cord and may help in 
predicting disability.  
5.7.1 Differences in spinal cord area, metabolite concentrations and Q-
space imaging measures between patients and controls 
There was a significant decrease in cord area over a relatively short follow-up 
period in patients compared to controls, even though there was no significant 
difference in spinal cord area at baseline. Cord atrophy is thought to be a 
measure of the underlying destructive pathological process involved in MS. It has 
been demonstrated that spinal cord area is a useful imaging biomarker of axonal 
loss (Kearney et al., 2014a). The significant change in spinal cord area as 
demonstrated in this study suggests it may be a useful marker of 
neurodegeneration and further supports its role as an imaging biomarker in 
clinical trials. Several studies in MS subjects with a long disease duration found 
that cord atrophy is related to disability independently of brain lesion load and 
atrophy (Kearney et al., 2014b; Daams et al., 2014; Lin et al., 2004).  
tNAA and Glx reduced and Ins, tCho and tCr increased between baseline and 1 
year follow up in patients compared to controls.  This is in the direction you would 
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expect for each metabolite, but these changes did not reach statistical 
significance. The sample size and duration of this follow-up study was small and 
this may contribute to the lack of a significant change in metabolites. The sample 
size calculations for tCho (a marker of membrane turn over (Henning et al., 2008)) 
(N=64) and tCr (a marker of gliosis (Moore et al., 2012)) (N=96) gave acceptable 
numbers of patients per arm for these metabolites, suggesting tCho and tCr may 
have a role in explaining the pathological processes underlying disability 
progression but this needs to be further investigated. The sample size 
calculations, gave very high numbers for tNAA, which may suggest subtle 
changes in tNAA are difficult to detect, particularly over a short follow-up period. 
The three-year longitudinal extension of this study will further investigate the role 
of tNAA, tCho, tCr and Ins in disease progression.   
Glx, which represents the sum of glutamate and glutamine, is the main excitatory 
neurotransmitter in the central nervous system, with glutamate making up the 
majority of the Glx signal (Baker et al., 2008). The lower Glx seen in patients 
compared to controls, at both baseline and 1 year follow up, may arise due to 
neuro-axonal degeneration with the majority of glutamate located in the synaptic 
terminals (Kaiser et al., 2005; Muhlert et al., 2014; Abdel-Aziz et al., 2015). The 
concentration of Glx in both patients and controls was greater at 1 year, when 
compared to the baseline Glx concentration. It is difficult to say why this occurred 
as the same protocol was used at both time points. We do not know how Glx 
fluctuates over time and the variability in the measure may arise due to this in 
both patients and controls. It does not affect the overall message, of lower Glx in 
patients compared to controls at 1 year, similar to the baseline results.   
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Of note the majority of patients followed-up at 1 year had a lesion(s) in the 
spectroscopic voxel (18 out of 19 subjects), and therefore we were unable to 
determine if there was a significant difference between patients with and without 
cervical cord lesions 
Next, looking at the Q-space imaging metrics, higher diffusivity perpendicular to 
the long axis of the spinal cord in patients compared to controls cross-sectionally 
at 1 year, is in keeping with the results found in the baseline data (Abdel-Aziz et 
al., 2015) and is likely to reflect increased movement of water perpendicular to 
the long axis of the cord due to the breakdown of myelin and axonal membranes 
(Beaulieu et al., 2002; Abdel-Aziz et al., 2015).  The lack of a significant change 
in Q-space metrics in the spinal cord over 1 year may be due to the small sample 
size. A sample size calculation found that the minimum sample sizes required to 
detect a significant difference in perpendicular diffusivity metrics between the two 
groups with 80% power in the posterior and lateral columns gave acceptable 
numbers of patients per arm (Table 5.8). Q-space metrics in the anterior column 
gave extremely high numbers of subjects per arm. Axonal loss occurs most 
commonly in the lateral and posterior columns whilst the anterior columns are 
least affected by axonal loss (Bergers et al., 2002). This is consistent with the 
smaller sample sizes required to detect significant difference in Q-space metrics 
in the posterior and lateral columns, which is likely to reflect greater pathological 
changes occurring within these columns.  
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5.7.2 Associations between whole cord imaging measures and clinical 
disability 
In this study, I used a number of clinical measures e.g postural stability, vibration 
perception thresholds and dynamometry, which are thought to be more 
responsive to clinical damage in the spinal cord than EDSS and they are thought 
to have increased sensitivity for detecting correlations between MRI 
abnormalities in the spinal cord and disability (Oh et al., 2013; Zackowski et al., 
2009).  
The changes in metabolites over 1 year, specifically tNAA, Ins and tCr, were not 
significant in patients when compared to controls but have  correlated with clinical 
changes over that period. An increase in tCr was associated with deterioration in 
the TWT, which may suggest the role of gliosis in the spinal cord, contributing to 
disability progression. Increased tCr over 1 year was associated with increased 
postural instability, providing further evidence of the possible involvement of a 
gliotic process in disability progression. An increase in Ins was associated with 
borderline evidence of an increase in EDSS, which may further suggest the role 
of gliosis (similar to tCr) in the spinal cord as an important process driving 
disability progression in early PPMS. These associations require longer follow-up 
to evaluate the exact meaning of these clinical correlations.  
There was no significant change in Q-space metrics over time in patients. 
However, impaired vibration and light touch sensation were associated with an 
increase of whole cord QSI-derived perpendicular diffusivity, which may be due 
to reduced neuronal integrity and/or presence of demyelination (Abdel-Aziz et al., 
2015). An increase in whole cord QSI-derived parallel diffusivity over 1 year was 
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associated with impaired vibration sensation, which may arise due to gliosis and 
an increase in the extracellular space (Klawiter et al., 2011). Animal models have 
demonstrated a decrease in parallel diffusivity in the acute setting, which is likely 
to be due to acute axonal damage (Klawiter et al., 2011). However, after the acute 
stages, the diffusivity of the remaining axons is overshadowed by increased 
parallel diffusivity, which may result from gliosis and increased extracellular space 
(Klawiter et al., 2011). One study in acute versus chronic optic neuritis found a 
decrease in parallel diffusivity during the acute stage and increased parallel 
diffusivity at 1 year follow-up in patients compared to controls (Naismith et al., 
2009), suggesting an increase in parallel diffusivity in the chronic stage.  
The absence of a significant association between change in cord area and 
change in disability may arise due to the small sample size of this study and the 
short follow-up period. This is despite a significant difference in cord area 
between patients and controls.  
5.7.3 Associations between change in column-specific q-space imaging 
measures and change in clinical disability 
Increased QSI derived perpendicular and parallel diffusivity in the posterior cord 
over 1 year was associated with impaired vibration sensation and parallel 
diffusivity was associated with increased postural instability. This may arise due 
to a combination of axonal loss and/or demyelination, gliosis and an increase in 
the extracellular space. A previous study compared diffusion tensor imaging with 
QSI, and found that QSI-derived metrics had greater sensitivity at detecting 
abnormalities in lesional tissue and NAWM in MS patients (Assaf et al., 2002) 
and demonstrated that it was reproducible (Assaf et al., 2005). This latter study 
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also found that the QSI metrics correlated well with NAA/creatine ratio, in keeping 
with axonal loss (Assaf et al., 2005).  
5.7.4 Predicting clinical status at 1 year with baseline MRI measures 
Out of all the MRI metrics, Q-space imaging was the only MRI metric at baseline 
that significantly predicted EDSS at 1 year. The microstructural abnormalities 
detected using Q-space imaging at baseline is likely to reflect reduced neuronal 
integrity and it may be one of the main pathological processes driving disability 
progression in early PPMS. We will investigate if these predictors hold true at the 
3 year follow-up study planned for this cohort. Postural instability at 1 year was 
best predicted by Q-space imaging derived metrics at baseline from the whole 
cord and lateral columns again suggesting neuronal dysfunction driving 
impairment in postural stability. 
5.8 Limitations 
The sample size of this study was small, making significant results more difficult 
to detect. In addition, the short follow-up period (12 months) can make it difficult 
to detect significant changes longitudinally in MRI metrics. I plan to follow-up this 
cohort of patients at 3 years, where we hope more significant changes in MRI 
measurements will be detected, specifically for QSI metrics in the posterior and 
lateral columns. I will see if correlations with MRI metrics and clinical disability at 
1 year are still present at 3 years and if this further elucidates the role of neuronal 
dysfunction and gliosis in disease progression.  
The MRS protocol used in this clinical study reliably quantified Glx. In the brain, 
it is possible to separate Glutamate from Glutamine using echo time averaged 
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PRESS (Hurd et al., 2004; Hancu et al., 2009). However, this is technically very 
challenging in the spinal cord, using a 3T scanner as larger voxel sizes would be 
needed (Abdel-Aziz et al., 2015). Further developmental work is needed to be 
able to directly measure Glutamate in the spinal cord.  
5.9 Conclusion 
There was a significant change in spinal cord cross-sectional area over 1 year. 
Slightly larger sample sizes may have detected significant changes in 
perpendicular diffusivity in the posterior and lateral columns and in tCho between 
patients and controls over time. There was a significant association between 
change in Q-space metrics and change in clinical status over 1 year. The findings 
from this follow-up study demonstrates possible evidence of ongoing 
neurodegeneration in the spinal cord in early PPMS detected using spinal cord 
atrophy. In addition to this, Q-space metrics may detect clinically meaningful 
pathological processes occurring in the cervical cord, which contributes to 
disability progression in early PPMS. 
The results presented in this Chapter demonstrate the ability of spinal cord cross-
sectional area to detect cord atrophy over a relatively short follow-up period in 
PPMS. In the next Chapter, I will explore if similar results are seen in a larger 
cohort of patients with progressive MS and will determine sample sizes required 
to demonstrate a reduction in spinal cord cross-sectional area as an outcome 
measure in clinical trials in progressive MS.
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6.1 Introduction 
There are no effective treatments that modify the disease course in progressive 
MS, unlike the dramatic progress in the therapeutics of RRMS over the last 
decade. To date, clinical trials of anti-inflammatory therapies in progressive MS 
have generally been negative, and no treatment is available to slow progression 
(Fox et al., 2012).  A fundamental element to the successful development of 
treatments in progressive MS is the identification of biomarkers that reflect the 
pathological processes underlying progression (Thompson et al., 2015).  Phase 
II trials, which test efficacy and safety, rely on biomarkers that are more sensitive 
to therapeutic effects than clinical measures. These biomarkers provide a signal 
for phase III trials, where clinical disability is the primary outcome measure.  
Neurodegeneration and, in particular, neuronal and axonal loss, are the main 
mechanisms leading to irreversible disability in MS and this is perhaps most 
relevant in the spinal cord where cervical cord atrophy appears to be an 
independent determinant of EDSS scores (Kearney et al., 2014b).  A reduction in 
spinal cord cross sectional area, an indicator of spinal cord atrophy, can be used 
as an approximate marker of axonal loss (Losseff et al., 1996; Bot et al., 2004). 
Several studies in MS subjects with a long disease duration found that cord 
atrophy is related to disability independently of brain lesion load and atrophy 
(Kearney et al., 2014b; Daams et al., 2014; Kidd et al., 1993; Lin et al., 2004). 
Additionally, the rate of atrophy in the cervical cord is greater than that seen in 
the brain, which is currently used as an outcome measure in progressive MS trials 
(~1.5% vs. 0.5%-1.0% per year) (Lukas et al., 2015; Furby et al., 2010; De 
Stefano et al., 2010). In SPMS one study found median rates of cord atrophy of 
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1.6% per year (De Stefano et al., 2010), while even faster rates of cord atrophy 
were seen in PPMS (at ~3.75% per year) (Stevenson et al., 2000).   
To date, only a few clinical trials have used brain or spinal cord atrophy as an 
endpoint (Chataway et al., 2014; Kapoor et al., 2010; Yaldizli et al., 2015). This 
reflects the numerous challenges of detecting minimal changes in a small 
structure across a large group of patients in a multi-centre setting (Kearney et al., 
2015).  
In this study, I consider the potential of using spinal cord atrophy as an endpoint 
in phase II, single-centre, neuroprotective clinical trials in progressive MS. The 
specific aims of this study are to (i) measure the progression of spinal cord 
atrophy over time and evaluate its relationship with physical disability in 
progressive MS; and (ii) determine sample sizes required to demonstrate a 
reduction in spinal cord area as a primary outcome measure in a phase II clinical 
trial in progressive MS. For each aim, I first combined our two recent cohorts of 
PPMS and SPMS into a single progressive MS cohort, as they are thought to 
share more similarities than differences in their clinical, pathological and imaging 
characteristics (Fox et al., 2012). Secondly, I looked at each group independently, 
adjusting for brain atrophy development and changes in lesion loads.  
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6.2 Methods 
6.2.1 Subjects 
I retrospectively collected data of patients with SPMS and PPMS who participated 
in our previous spinal cord imaging studies (Kearney et al., 2015; Abdel-Aziz et 
al., 2015), and then analysed them separately. Inclusion criteria were a diagnosis 
of PPMS (Polman et al., 2005) or SPMS, and age between 18 and 65 years. I did 
not specifically check whether there was “recent” evidence of disability 
progression. Healthy controls were also recruited. All subjects were invited to 
come back for a follow-up after 1 year. Patients were clinically assessed on the 
day of the MRI at each time point.  
Of note, none of the PPMS or SPMS patients were on disease modifying therapy 
at the time of scanning at either baseline or at 1 year follow-up.  
All the MS patients recruited into this study were recruited from the MS clinics ran 
on a weekly basis at The National Hospital of Neurology and Neurosurgery, 
Queen Square London. All healthy controls recruited were work colleagues, 
friends and family as well as friends and family of the MS patients. All subjects 
recruited into the study provided written informed consent prior to taking part in 
the study, which was approved by the local research ethics committee (Study 
Reference: 10/H0713/74).  
The study in Chapter VI was a retrospective study, based on two previous studies 
carried out by three of my colleagues (Dr. Abdel-Aziz, Dr. Kearney and Dr. 
Plantone). Dr Abdel-Aziz and Dr Kearney carried out the baseline studies, 
including the clinical assessments. Dr Plantone carried out the 1 year follow-ups 
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for the SPMS patients and some of the PPMS patients and healthy controls 
(N=7). I carried out the clinical assessments for the remaining PPMS patients 
(N=19) and healthy controls (N=22) as these were the same PPMS patients 
involved in the study presented in Chapter V. The radiographers at the Institute 
of Neurology performed all the MRI scans at the two time points (Marios 
Yiannakas, Chichi Ugorji and Luke Hoy). I performed the analysis on the spinal 
cord data and the brain data using the Active Surface Model and SIENA 
respectively to compute the spinal cord atrophy and brain atrophy measurements 
at baseline and 1 year follow-up. Dr. Dan Altmann and Dr. Carmen Tur performed 
the statistical analysis for this study. I interpreted the results from the statistical 
analysis performed and the results and my interpretation of the results are 
outlined below. 
6.2.2 Clinical Assessments 
At the time of the MRI, all patients were clinically assessed with the EDSS 
(Kurtzke, 1983), 9-HPT (Goodkin et al., 1988) and TWT (Cutter et al., 1999). Z-
scores were calculated for the 9-HPT and TWT from normative values displayed 
in the National Multiple Sclerosis Society Task Force database (Fischer et al., 
1999). Mean grip strength from the upper and lower limbs were measured using 
the Jamar hydraulic dynamometer (Sammons Preston. Incorporated, 
Bolingbrook, IL, USA) (Svens & Lee, 2005). I also recorded the American Spinal 
Injury Association (ASIA) motor (m) and sensory (s) scores (Maynard et al., 1997) 
for all subjects with MS.  
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6.2.3 MRI acquisition 
All subjects were scanned at 3T using a Philips Achieva MRI system at baseline 
and at 1 year follow-up, using the manufacturer’s 16 – channel neurovascular coil 
(Philips Healthcare Systems, Best, Netherlands). The cervical cord was imaged 
in the axial plane, perpendicular to the longitudinal axis of the cord, to measure 
the cord mean cross sectional area. The imaging volume was centred on the C2/3 
intervertebral disc, using a fat – suppressed 3D slab-selective fast field echo 
(FFE) sequence [parameters; TR = 23ms; TE = 5ms; flip angle α = 7o; FOV = 240 
x 180mm2; voxel size = 0.5 x 0.5 x 5 mm3; NEX = 8; 11 axial contiguous slices].  
For calculation of brain volumes, a 3D T1-weighted magnetisation-prepared 
gradient-echo sequence was used [TR = 6.9 ms; TE = 3.1 ms; flip angle α = 8o; 
FOV= 256 x 256 mm2; voxel size = 1 x 1 x 1 mm3; NEX = 1; 180 sagittal 
contiguous slices].  
For calculation of brain T2 lesion volumes, PD/T2 weighted images were acquired 
using a dual-echo TSE sequence [parameters: TR = 3500 ms; TE = 15/85 ms; 
flip angle α = 90o; FOV= 240 x 180 mm2; voxel size = 1 x 1 x 3 mm3; NEX = 1; 50 
axial contiguous slices]. 
6.3 MRI analysis 
6.3.1 Spinal cord area measurement 
For the 3D-FFE images, three contiguous 5mm axial slices, centred on C2/3 disc 
were segmented using the active surface model (ASM) (Horsfield et al., 2010), 
as discussed in Section 2.9.3.2. Spinal cord cross sectional area measurements 
were performed using the 3D-FFE dataset in Jim 6.0 Software (Xinapse systems, 
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Northants, England). The mean cross sectional area of the three slices was then 
calculated. The ASM involves placing a predetermined size and shape region of 
interest in the centre of the cord on each slice. The program then uses intensity 
gradient information to calculate the radius and centre of each slice (Horsfield et 
al., 2010). The centre line is refined from the initial user estimate and 
segmentation then involves a multistage approach allowing greater complexity of 
the cord radius to be calculated (Horsfield et al., 2010). The cord outline is 
generated automatically for each slice, as shown in Figure 6.1. 
                                                                               
Figure 6.1: Spinal cord outline using the active surface model on the axial FFE 
images, FFE image in (A) and the cord outline in red using the active surface 
model (B).  
  
6.3.2 Brain atrophy measurement 
To avoid segmentation errors due to white matter lesions, an automated lesion-
filling technique was employed (Chard et al., 2010). Lesion masks were created 
based on 3D-T1 weighted sequences without reference to previously created 
masks on T2-weighted images. The lesion-filled images were segmented using 
STEPS (Cardoso et al., 2013). STEPS is a multi-atlas segmentation propagation 
technique, which uses an atlas library of 682 non-MS patients with associated 
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manual segmentations, of which the 30 most similar brain templates were used 
during a locally-weighted label fusion process. 
Using these brain masks, Structural Image Evaluation using Normalization of 
Atrophy (SIENA) were calculated. SIENA is a registration based method which 
computes atrophy between two aligned scans as the perpendicular edge 
displacement at each edge point, as discussed in Section 2.8.2. The mean edge 
displacement is converted into a global estimate of Percent Brain Volume Change 
(PBVC) between two time-points, using self-calibration based on registering both 
time points to the half-way space between them (Smith et al., 2001). Spinal cord 
and brain atrophy measures have been annualised. 
6.3.3 Brain T2 lesion volume 
Brain T2-lesion volume (T2LV) was calculated by outlining lesions on T2-
weighted MRI scans using a semi-automated edge finding tool (JIM v. 6.0). Total 
lesion volume was recorded in ml for each subject. 
6.4 Statistical analysis 
All analyses were performed in Stata 13.1 (Stata Corporation, College Station, 
Texas, USA).  
Changes in clinical measures over time were assessed through paired t-tests. To 
assess differences in the rate of change in cord area over time between patients 
and controls, I first calculated the individual changes in cord area between 
baseline and 1 year of follow-up. Then I fit a multiple linear regression model with 
‘change in cord area’ as the dependent variable and the binary variable ‘group’ 
(patients or controls) as the main predictor variable. This model was adjusted for 
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age and gender. Changes in lesion load and PBVC over the same period of time 
were also explored as covariates. To assess differences between the two patient 
subgroups and controls, similar models were fitted, but using a 3-category 
variable ‘group’ (SPMS, PPMS or controls) as the main predictor.  
To assess the association between clinical and cord area changes over 1 year, 
again individual changes in the clinical variable were calculated. Then, multiple 
linear regression models including the change in the clinical variable as the 
dependent variable were fitted, including the change in cord area over time as 
the main predictor variable. These models were fitted for each one of the clinical 
variables separately using the whole cohort of patients, and were adjusted for 
age and gender. Afterwards, in order to examine the relationship between clinical 
and cord area changes in the two patient groups, similar models were fitted but 
adding a binary variable ‘group’ (SPMS or PPMS) and an interaction term ‘group 
X cord area changes’ among the covariates.  
Sample size calculations were performed to detect different plausible treatment 
effects (with 80% power at 5% statistical significance) based on the observed 
differences between patients and controls.  
Statistical significance was considered when p values were below 0.05. 
6.5 Results 
6.5.1 Participant demographics and characteristics 
Forty-four patients with progressive MS, and 29 healthy controls were studied at 
baseline and after one year. Out of the 26 PPMS patients included in this 
retrospective study, 19 of the PPMS patients were from the study presented in 
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Chapter V.  Patient demographics, characteristics and disability of all progressive 
patients together and of the PPMS and SPMS subgroups are summarised in 
Table 6.1. There was a significant difference in age between the progressive MS 
cohort and the healthy controls (p<0.001). At baseline, PPMS patients had 
significantly shorter disease duration (p<0.0001), lower EDSS (p<0.004), lower 
brain T2 lesion volume (p<0.001) and larger spinal cord area (p<0.02) than SPMS 
patients. The duration of progressive disease was similar in both PPMS and 
SPMS (See Table 6.1).  
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Progressive 
MS 
N=44 
Healthy 
controls 
N=29 
PPMS 
N=26 
SPMS 
N=18 
Mean Age 
(years) 
52.02 
(9.33) 
42.36 
(11.16) 
50.27 
(9.68) 
54.88 
(8.23) 
Gender (F:M) 21:23 11:18 11:15 10:8 
Disease 
duration 
(years)  
14.13 
(12.41) 
- 
7.17 
(4.98) 
26.20 
(12.23)*** 
Progressive 
disease 
duration 
7.30 (4.42) - 
7.17 
(4.98) 
7.92 
(3.75) 
Median EDSS 
(range) 
baseline 
6.0 
(3.0 – 8.5) 
- 
5.0 
(3.0 – 7.5) 
6.0 
(4.0 – 8.5)*** 
Median EDSS 
(range) 1 year 
6.5 
(3.0 – 8.5)* 
- 
6.0 
(3.0 –8.0)* 
6.5 
(4.5 – 8.5)* 
Mean cord 
area baseline 
(mm2) 
73.82 
(10.33)** 
82.49  
(8.57) 
76.40 
(9.90)** 
69.78 
(10.84)** 
Mean cord 
area 1Y (mm2) 
71.52 
(10.16)** 
82.05 
(8.34) 
73.63 
(9.30)** 
68.29 
(10.83)** 
% decrease in 
CSA 
-3.11 -0.53 -3.63 -2.14 
PBVC 
-1.57 
(1.03)** 
-0.42 
(1.03) 
-1.65 
(1.16)** 
-1.40 
(0.73)** 
T2 lesion load 
(mls) - 
baseline 
15.71 
(13.53) 
- 
11.09 
(10.52) 
23.92 
(14.66) 
T2 lesion load 
(mls) – 1 year 
20.14 
(17.34)* 
- 
13.29 
(13.36)* 
30.42 
(17.87)* 
Table 6.1: Mean (SD) of main demographic and clinical findings in the 
progressive MS, healthy controls, PPMS and SPMS cohorts at 1 year. * Paired 
sample t-test comparing baseline with 1 year follow-up. ** Linear regression 
model comparing patients with controls, correcting for age and gender, p<0.05. 
*** Independent sample t-test comparing PPMS with SPMS. Those numbers 
highlighted in bold have a significant p-value <0.5. CSA - cross sectional cord 
area. 
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6.5.2 Spinal cord atrophy 
Patients had a smaller spinal cord area at both baseline and one year follow-up 
compared to controls (Table 6.1). The rate of change in cord atrophy in the 
progressive MS cohort over this 12-month period was 1.80 mm2 greater than in 
controls after adjusting for age and gender (95% confidence intervals (CI) -3.00 
to -0.61, p<0.004). This corresponded to a 3.11% decrease in spinal cord area 
over one year. 
Looking at the sub-group analyses, the rate of change in cord area in the PPMS 
subgroup was 2.23mm2 greater than controls (95% CI -3.55 to -0.91, p<0.001) 
(percentage decrease in cord area = 3.63%). An example of this is shown in 
Figure 6.2. The rate of change in cord area in the SPMS subgroup was 1.10 mm2 
greater than controls, but this was not statistically significant (95% CI -2.62 to 
0.42, p<0.15) (percentage decrease in cord area = 2.14%). Healthy controls had 
a reduction in cord area of 0.53%.  
 
Figure 6.2: FFE image at baseline (A) and 1 year follow-up (B) with visible 
evidence of cord atrophy in a subject with PPMS (47 year old male, baseline: 
EDSS 4.0, cord area = 85.95mm2; 1 year: EDSS 6.0, cord area = 82.37mm2). 
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6.5.3 Brain atrophy 
PBVC was significantly greater in the progressive MS cohort at -1.57% when 
compared to controls after adjusting for age and gender over the 12 months (95% 
CI -0.56 to -1.76, p<0.0001). Looking at the subgroup analysis, the PPMS 
subgroup had significantly greater PBVC at -1.65% when compared to controls 
(95% CI -0.56 to -1.97, p < 0.001) and the SPMS subgroup also had significantly 
greater PBVC at -1.40% when compared to controls (95% CI -0.04 to -1.64, p 
<0.04) after correcting for age and gender. The PBVC for controls over the 12 
months was -0.42%. There was also a significant increase in T2 lesion load in the 
progressive MS cohort over the 12 months (Table 6.1).  
In order to complete the analysis, all the above models were repeated correcting 
for T2 lesion load and PBVC. PBVC and T2 lesion load were never significant 
when included in the models and did not change the direction of the results for 
the spinal cord atrophy measures, therefore these covariates were not included 
in the final model.  
6.5.4 Associations between change in cord area and change in clinical 
scores 
Patients worsened in all clinical measures during the 12-month follow-up period. 
In particular, they progressed significantly in EDSS (p<0.001), ASIA-motor scores 
(p<0.013), 9-HPT (p<0.001) and grip strength (p<0.001), as outlined in Table 6.2.  
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 Progressive MS* PPMS* SPMS* 
Mean 9-HPT 
baseline (z score) 
-0.88 
(1.24) 
-0.62 
(0.95) 
-1.31 
(1.55) 
Mean 9-HPT 1 
year (z score) 
-1.26 
(1.29) 
-1.07 
(1.18) 
-1.58 
(1.44) 
Mean TWT 
baseline 
(z score)  
-2.13 
(5.22) 
-0.49 
(2.91) 
-4.84 
(6.94) 
Mean TWT 1 year 
(z score) 
-3.06 
(6.07) 
-1.05 
(3.98) 
-6.36 
(7.49) 
Mean Grip 
Strength baseline 
(kg force) 
32.46 
(26.45) 
45.30 
(27.29) 
15.33 
(11.81) 
Mean Grip 
Strength 1 year 
(kg force)  
17.53 
(11.45) 
20.13 
(12.31) 
14.07 
(9.50) 
ASIA – motor 
baseline 
85.37 
(14.78) 
88.92 
(11.92) 
80.44 
(17.17) 
ASIA – motor 1 
year 
80.19 
(19.99) 
85.52 
(12.83) 
72.78 
(25.58) 
ASIA – sensory 
(pin prick) baseline 
105.39 
(6.40) 
108.13 
(6.05) 
102.65 
(6.78) 
ASIA – sensory 
(pin prick) 1 year 
103.73 
(10.06) 
105.46 
(11.43) 
101.29 
(7.38) 
Table 6.2: Mean (SD) of clinical scores at baseline and 1 year follow-up. * Paired 
sample t-test comparing baseline with 1 year follow-up. Those numbers 
highlighted in bold have a significant p-value <0.5. 
 
No significant associations were demonstrated between change in cord area and 
change in clinical scores in the progressive MS cohort over the 12-month follow-
up period. When I investigated the two patient groups, PPMS patients 
demonstrated a significant decrease in 9-HPT of 0.11 (95% CIs 0.02, 0.20, p < 
0.02) for each mm2 decrease in cord area and borderline evidence of an increase 
in EDSS of 0.12 (95% CIs -0.25, 0.10, p = 0.06), over the 12-month follow-up, 
after correcting for age and gender. Figures 6.3 and 6.4 are scatter plots 
demonstrating the unadjusted correlations between change in cord area and 
change in EDSS (Figure 6.3) and change in 9-HPT (Figure 6.4) in the PPMS 
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subgroup. In SPMS, there was no significant association between change in cord 
area and change in clinical scores.  
                           
 
 
 
 
 
  
Figure 6.3: Scatterplot showing 
the association between changes 
in spinal cord area (mm2) with 
change in EDSS in the PPMS 
cohort (unadjusted analysis). 
Figure 6.4: Scatterplot showing 
the association between 
changes in spinal cord area 
(mm2) with change in 9-HPT z-
scores in the PPMS cohort 
(unadjusted analysis). 
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6.5.5 Sample size calculations for a neuroprotective clinical trial 
Sample size calculations for the whole group analysis, in a 12-month 
neuroprotective clinical trial, demonstrated the minimum sample sizes per arm 
required to detect a 50% treatment effect at 80% power were 157 per arm; when 
the two cohorts were analysed separately, the minimum sample size per arm 
reduced to 86 in the PPMS sub-group and increased to 709 in the SPMS sub-
group, as seen in Table 6.3.  
 
Treatment Effect 
Sample size per 
arm in 
progressive MS 
Sample size 
per 
arm in PPMS 
Sample size 
per arm in 
SPMS 
30% 436 238 1968 
50% 157 86 709 
100% 40 22 178 
Table 6.3: Sample size calculations for a neuroprotective clinical trial in 
progressive MS (80% power, 5% significance). 
 
6.6 Discussion 
Our single-centre study was consistent with previous results in showing 
significant cord atrophy in the progressive MS cohort when compared to healthy 
controls over 1 year.  The PPMS subgroup, who had shorter disease duration, 
lower EDSS, and larger cord area compared with SPMS, showed the fastest 
reduction in spinal cord cross sectional area. Sample size calculations gave 
realistically achievable numbers of patients per arm in the PPMS group, though 
this was not the case in those with SPMS. Thus spinal cord area shows potential 
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to be a feasible outcome measure for inclusion in single-centre, placebo-
controlled neuroprotective trials in PPMS. We will discuss each of these results 
in turn.  
Decrease in spinal cord area is a marker of cord atrophy, which in turn is an 
approximate marker of axonal loss. A post-mortem study found that cord atrophy 
occurred more rapidly in the early stages of progressive MS (Evangelou et al., 
2005), underlining the importance of early therapeutic intervention in this 
population (Evangelou et al., 2005), in order to minimise the amount of axonal 
loss, in neuroprotective clinical trials. This is reflected in the results from this 
study, where there was a significant difference in cross sectional cord area 
between PPMS patients and controls, but not between SPMS patients and 
controls. This is shown in the better performance of cord atrophy measures in the 
PPMS subgroup (who were early on in the disease course) compared to the 
SPMS subgroup. The SPMS subjects were older, had longer disease duration 
and were more disabled than those with PPMS, they had more marked spinal 
cord atrophy at the study baseline and had a lower rate in cord area reduction 
over time than the PPMS subjects (SPMS 2.14% vs. PPMS 3.63%). The PPMS 
subgroup had less cord atrophy at baseline and therefore had more to lose over 
time, while the critical loss of axons may have already occurred in the SPMS 
subgroup. This raises the possibility that cord atrophy may not be a useful 
biomarker in SPMS. The better performance of cord atrophy measures in the 
PPMS subgroup compared to the SPMS subgroup may be important in 
understanding progressive MS as well as in using cord atrophy as an outcome 
measure in clinical trials. A question arising is whether the rate of spinal cord 
atrophy has occurred in a non-linear fashion over time in the SPMS cohort and 
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would have been greater in earlier years. A long term study that follows people 
from RRMS through to SPMS would be required to clarify the temporal dynamics 
of spinal cord atrophy in relapse-onset MS.  
PBVC in the progressive MS cohort over the 12 months was significantly greater 
than that observed in the controls. There was a greater increase in PBVC in the 
PPMS subgroup compared to the SPMS subgroup.  
This is in keeping with the spinal cord atrophy measures, demonstrating the faster 
development of both cord and brain atrophy in the PPMS subgroup. Brain atrophy 
measures have been demonstrated to be robust outcome measures in phase 2 
and phase 3 clinical trials in primary and secondary progressive MS (Chataway 
et al., 2014; Kapoor et al., 2010).      
6.6.1 Clinical correlations 
The progressive MS cohort significantly progressed in a number of clinical 
measures over 1 year, including EDSS, ASIA-motor scores, 9-HPT and grip 
strength, as expected in a cohort of patients with progressive MS. However, there 
were no significant associations between change in cord area and change in 
clinical scores in the progressive MS cohort. This may be due to the very short 
follow-up period and the small sample size of the study, which makes it difficult 
to detect significant associations. Also, the patients recruited into this study were 
not recruited based on clinical progression in the year prior to recruitment, as this 
was a retrospective study and patients were not selected on the basis of this 
criterion.  
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In the PPMS subgroup, change in cord area was significantly associated with 
change (deterioration) in the 9-HPT and a borderline association with change 
(increase) in EDSS, which is in keeping with previous studies, reflecting the 
correlation which has been established between cord area and disability (Bot et 
al., 2004; Lin et al., 2004). The lack of a significant association between change 
in clinical measures and change in cord area in the SPMS subgroup, may be due 
to the smaller sample size of SPMS subjects (N=18) recruited into this study 
compared to the PPMS (N=26) cohort.  
Of note, none of the patients included in this study were on disease modifying 
therapy at the time of scanning, either at baseline or at 1 year follow-up. Therefore 
the effects of treatment on atrophy measures is not something which we need to 
consider with this progressive MS cohort. It has been demonstrated that patients 
participating in clinical trials often have active disease with clinical relapses and 
evidence of gadolinium enhancing lesions on MRI, particularly in RRMS cohorts. 
Resolution of this inflammation results in an initial accelerated decrease in brain 
volume during the first year of treatment, which is termed pseudoatrophy 
(Zivadinov et al., 2008). It is not known if the effects of pseudoatrophy continue 
to occur after one year. This needs to be further investigated to determine the full 
extent of pseudoatrophy after the initiation of certain therapies which may be 
related to resolution of inflammation as opposed to neurodegeneration (De 
Stefano and Arnold, 2015).  
A number of newer disease modifying agents available (natalizumab, dimethyl-
fumarate, fingolimod, alemtuzumab) for the treatment of RRMS, have 
incorporated brain volume as an outcome measure and have shown to improve 
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brain atrophy accrual when compared to placebo or another treatment (Vidal-
Jordana et al., 2015; Miller et al., 2007b; Miller et al., 2015; Radue et al., 2012; 
Coles et al., 2008; Cohen et al., 2012). To date only one phase II clinical trial in 
SPMS have had positive effects on brain atrophy (Chataway et al., 2014).  
To date, the effect of disease modifying therapy on spinal cord atrophy is 
unknown as spinal cord atrophy has only been used as an outcome measure in 
one clinical trial in PPMS. The INFORMS trials in PPMS, which investigated the 
effect of fingolimod on both brain and spinal cord atrophy was negative for both 
these measures.  
6.6.2 Sample size 
The overall sample size calculations gave achievable numbers of patients per 
arm in the progressive MS cohort. The PPMS group, who had shorter disease 
duration but had a similar progressive disease duration to SPMS, had smaller 
numbers per arm. The sample size calculations for the SPMS subgroup gave 
exorbitantly high numbers per arm (N=709), which is not a realistic number for a 
Phase II clinical trial, unlike the PPMS subgroup (N=86). This highlights the 
importance of recruiting subjects early in the primary progressive disease course 
into clinical trials and raises the question if cord atrophy behaves differently in 
SPMS as a result of the longer disease duration rather than the duration of 
progressive disease and the more marked spinal cord atrophy at baseline. It is 
likely that these numbers could be further reduced by recruiting only subjects with 
a history of disease progression in the previous 12 months.  
The active surface model has been used in one large cross-sectional multicentre 
study in MS, to detect cord atrophy, and confirmed the stability of this measure 
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among different centres and supports its use as an outcome measure to monitor 
disease progression in multicentre trials (Rocca et al., 2011). However, the 
challenges in assessing small absolute changes longitudinally in the size of a 
small structure should not be underestimated and in the real world setting of 
large, multicentre, long term, phase III clinical trials, methodological variability 
includes the use of multiple acquisition sequences and multiple scanner models, 
software and hardware upgrades and changes in scanners during follow up. Such 
methodological factors may require larger sample sizes than I have estimated 
from out single centre/scanner study (Yaldizli et al., 2015). Notwithstanding this, 
the importance of good image quality and analysis method are crucial for 
measuring spinal cord atrophy in order to obtain acceptable sample size 
estimates. Therefore, spinal cord atrophy has the potential to be used as an 
outcome measure in clinical trials with therapies that target neurodegeneration.  
Sample sizes for brain atrophy as an outcome measure in clinical trials in MS 
using registration based techniques like SIENA or BSI have demonstrated 
achievable numbers of patients in both RRMS (Anderson et al., 2007) and SPMS 
(Altmann et al., 2009). This has led to the use of brain atrophy as an outcome 
measure in multiple clinical trials in MS, both relapsing remitting and progressive 
forms of MS (Chataway et al., 2014; Kapoor et al., 2010). It has been 
demonstrated that whole brain atrophy is highly reproducible and sensitive to 
disease related changes, as well as correlating with disability. 
To date, the lack of a registration based method for detecting spinal cord atrophy 
has limited its ability to be used in a multicentre clinical trial in MS. One clinical 
trial in PPMS measured spinal cord atrophy in this cohort and results 
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demonstrated extremely high numbers of patients were required to detect a 50% 
treatment effect on spinal cord atrophy (Yaldizli et al., 2015). To date 
segmentation based methods are only available for measuring longitudinal 
change in spinal cord atrophy unlike brain atrophy where registration based 
methods are available. This is an ongoing limitation for measuring longitudinal 
change in spinal cord atrophy. Our research group is working on this and it is 
looking at developing a BSI technique for the spinal cord, like what is used in the 
brain (Prados et al., 2016). I await a fully validated registration based technique 
for measuring spinal cord atrophy and I hope this will give more achievable 
sample sizes, particularly in a multicentre setting.  
6.7 Conclusion 
Cord atrophy in progressive MS, especially in PPMS, can be observed over a 
period of time as short as 1 year. Based on this single centre, single scanner 
data, sample size calculations gave acceptable numbers of patients per arm, 
suggesting spinal cord atrophy shows potential to be a feasible outcome measure 
for placebo-controlled neuroprotective trials in early PPMS. The better 
performance of cord atrophy measures in the PPMS that the SPMS group, may 
be due to their earlier stage of disease and less cord atrophy at baseline. This 
may be important in improving our understanding of cord atrophy in progressive 
MS, and raises the possibility that cord atrophy may not be a useful outcome 
measure in SPMS with long disease duration. 
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7.1 Conclusions 
In this final chapter, the conclusions drawn from the studies presented in this 
thesis will be summarised in order to address the fundamental aim of this thesis, 
to investigate the development of new imaging biomarkers in MS.  
The United Kingdom Medical Research Council has defined a biomarker as “an 
objective measurement that acts as an indicator of normal pathological 
processes, pathogenic processes or pharmacologic responses to therapeutic 
intervention” (http://www.mrc.ac.uk). Imaging biomarkers can range from 
biomarkers associated with diagnosis, biomarkers associated with concurrent 
and future disability and biomarkers which are endpoints of clinical trials. The 
studies carried out as part of this thesis are predominantly focused on biomarkers 
that reflect the underlying pathology and may be responsible for clinical disability.  
A combination of innovative MRI techniques, applied to the brain of MS subjects, 
was explored in Chapter III and Chapter IV. These techniques were single voxel 
GABA spectroscopy and NODDI respectively. More established imaging 
measures of the spinal cord were then used in two further studies presented in 
Chapter V and Chapter VI. These included single voxel spectroscopy, Q-space 
imaging and spinal cord atrophy measurements. Each of these biomarkers is 
focused on neurodegeneration, which is a major cause of ongoing, irreversible 
disability, particularly in the progressive stages of MS.  
In the study presented in Chapter III, there was reduced GABA in the 
sensorimotor cortex and in the hippocampus of patients with SPMS when 
compared to controls and reduced GABA in the sensorimotor cortex was 
associated with motor disability. These findings suggest that reduced GABA 
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levels may reflect pathological abnormalities that may play a role in determining 
physical disability. These abnormalities may include decreases in the pre- and 
post-synaptic components of GABA neurotransmission and in the density of 
inhibitory neurons. Additionally, the reduced GABA concentration may contribute 
to the neurodegenerative process, resulting in increased firing of axons, with 
consequent increased energy demands, which may lead to neuroaxonal 
degeneration and loss of the compensatory mechanisms that maintain motor 
function. This study supports the idea that modulation of GABA 
neurotransmission, which can be quantified using MRS, may be an important 
biomarker of neurodegeneration and a potential target for neuroprotection in MS 
which needs to be further investigated.  
Chapter IV presented the results from a study in RRMS looking at a new 
advanced diffusion MRI technique, NODDI. The study found there was reduced 
NDI in NAWM in the brain of RRMS patients when compared to controls, in 
addition to a reduction in both NDI and ODI in T2 lesions. The results from studies 
carried out to date in MS using NODDI and in this study, are demonstrating the 
advantage of NODDI over standard DTI in estimating neurite density and 
dispersion, both of which are thought to influence FA independently. Therefore, 
NODDI has the ability to improve the characterisation of microstructural damage 
in the brain of MS patients. When NODDI was initially developed it was thought 
that NDI solely represented neurite density, raising the possibility that it may have 
the potential to be a useful axonal biomarker. However, recent histological work 
has proved that NDI is influenced by both axonal loss and/or demyelination, 
therefore disproving its ability to be a sole biomarker of axonal loss.  
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Chapter V presented a longitudinal follow-up spinal cord study in a cohort of 
patients with early PPMS, looking at a number of advanced quantitative MRI 
techniques, specifically Q-space imaging and 1H-MR spectroscopy in the cervical 
cord, in addition to spinal cord cross sectional area. Despite no significant 
difference in spinal cord area between the PPMS patients and the control group 
at baseline, spinal cord area was the only MRI metric which demonstrated a 
significant change (reduction) over the 12 month follow-up period. These findings 
demonstrate evidence of ongoing neurodegeneration in the spinal cord in early 
PPMS detected using spinal cord atrophy over a relatively short follow-up period. 
Q-space imaging metrics did not change significantly over the 12 months. 
However, Q-space imaging metrics at baseline significantly predicted EDSS and 
postural stability at 1 year, whilst the study also found significant associations 
between change in Q-space metrics and change in clinical status over 1 year, 
which may suggest Q-space imaging is a useful biomarker that is capable of 
detecting clinically meaningful pathology, which requires further investigation.  I 
were surprised that there were no significant changes over time in any of the 
advanced MRI techniques, as it was hoped, based on previous work, that these 
techniques may be more sensitive at detecting pathological changes in MS 
compared with more well established techniques. The short follow-up period may 
account for the lack of any significant changes in these metrics.  
Spinal cord atrophy is an approximate marker of neuroaxonal loss, which is one 
of the main mechanisms driving irreversible disability in MS. It has been 
demonstrated that the rate of cord atrophy is greater than the rate of brain atrophy 
in MS. However, to date brain atrophy has been included as an outcome measure 
in neuroprotective clinical trials in progressive MS, while spinal cord atrophy has 
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not. The study in Chapter VI found a significant reduction in cross sectional cord 
area in a cohort of patients with progressive MS when compared to controls over 
a 12 month follow-up period. There was a greater rate of cord atrophy in the 
PPMS subgroup compared to the SPMS subgroup despite both groups having a 
similar duration of progressive disease.  This may be related to the earlier stage 
of disease in the PPMS cohort and less marked cord atrophy at baseline, which 
may be important in helping us understand progressive MS. The sample size 
calculations gave achievable numbers of patients for the PPMS cohort, 
supporting cord atrophy as a biomarker of neuroaxonal loss in the cord and also 
an outcome measure in phase II neuroprotective trials, especially in early 
PPPMS. The very large sample size estimates for the SPMS cohort, raises the 
question if PPMS and SPMS should be kept separate in clinical trials (Lublin et 
al., 2014), as SPMS may behave differently to PPMS due to longer disease 
duration. To date, clinical trials have been carried out separately in each cohort.  
In relation to the statistical analysis used in the studies carried out as part of this 
thesis, I used a strict cut-off: any results which had a p<0.05, and therefore 
confidence intervals did not contain the null value, were determined significant 
and any results with a p>0.05 and the confidence intervals included the null value 
were deemed not significant. The main reason for doing this was because I 
carried out a lot of clinical tests with quite a lot of significant results in the studies. 
To try and reduce the reporting of a lot of borderline significant results, I focused 
on those results where there was strong evidence against the null hypothesis.  
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The use of strict P-values has weaknesses. When multiple independent 
hypotheses are tested, the risk that at least one of the tests used is falsely positive 
is high and this risk increases with the number of hypotheses tested.   
You may be incurring a type I error: you may consider as significant an 
association that does not exist. The risk of this type of error is greater if you carry 
out multiple tests. You may also incur a type II error: where you may consider as 
non-significant an association that truly exists. The risk of this type of error is 
greater if the sample size is small.  
Multiple comparisons refer to the simultaneous testing of a large number of 
statistical tests, which increases the likelihood of significant results (p<0.05) 
purely by chance alone. The commonest approach to the multiple comparison 
problem is not to set the critical level of significance to p<0.05, but to use a lower 
critical value of significance. The most common way of doing this is to perform a 
Bonferroni correction, where you divide the p-value by the number of tests 
performed. The Bonferroni correction is mainly used when there are a small 
number of multiple comparisons and one is looking for one or two which may be 
significant. If one has a large number of multiple comparisons and looking for 
quite a few significant results, then the Bonferroni correction is conservative and 
it may lead to a high rate of false negative results, therefore reducing statistical 
power. There is a lot of debate if a correction should be made or not when there 
are multiple comparisons. With the Bonferronni correction, as you reduce the risk 
of a Type I error, you increase the risk of a Type II error, so real differences may 
not be detected. The interpretation of a single test may depend on a number of 
other tests performed, therefore the evidence provided by the data is contained 
Chapter VII: Conclusions and future directions 
224 
within that specific data. As a result, the conclusions drawn from that dataset 
should not be altered based on the number of other tests performed. As part of 
the studies which I did as part of this thesis, I did not perform any Bonferroni 
corrections due to the limitations associated with it as discussed above.   
7.2 Future directions 
The studies presented in this thesis demonstrate that novel imaging biomarkers 
have the potential, to help us improve our understanding of the pathogenesis in 
progressive and relapsing forms of MS. The International Collaboration in 
Progressive MS have highlighted that the key to the successful development of 
therapies in progressive MS is in the development of biomarkers which are 
directly linked to the underlying pathology (Thompson, 2015). This is particularly 
important for phase II clinical trials.  
To build on the work carried out as part of this thesis, I propose the following 
research projects as a further stepping stone to help develop improved imaging 
biomarkers which are accurate, reproducible, sensitive to disease changes, 
correlates with and predicts relevant clinical measures, are user friendly and 
quantitative (Filippi & Agosta, 2010), to ultimately improve our understanding of 
the pathogenesis of MS and to help develop more successful treatments.  
For the GABA spectroscopy study in SPMS (Chapter III), in the future, it will be 
important to follow these patients up over time to see what happens to the GABA 
concentration in these regions - will GABA continue to decline in the sensorimotor 
cortex and in the hippocampus and will GABA in the sensorimotor cortex be 
associated with the progression of motor disability, which may provide further 
support for the role of GABA in the neurodegenerative process in SPMS. A GABA 
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spectroscopy study in RRMS is needed, to see how GABA levels differ to patients 
with progressive MS. Also, it would be very useful to combine PET imaging, in 
particular 11C-flumazenil, with 1H-MR spectroscopy, to investigate the co-
localisation of the PET signal changes (reflecting GABAA receptor density), with 
the 1H-MR spectroscopy derived GABA changes, to investigate if GABA is 
reflecting mechanisms in the grey matter that are crucial to disability and 
therefore may be a potential pharmacological target in SPMS.  
Potential future studies which may be useful for the application of NODDI, would 
be to investigate the longitudinal changes in NODDI metrics over time in MS 
subjects, to investigate its ability to detect microstructural changes over time 
using NDI and ODI and its association with clinical disability. Other MRI 
techniques e.g. magnetisation transfer imaging and myelin water imaging, may 
complement NODDI and provide a more complete picture of the effects of MS on 
brain and spinal cord tissue. Ultimately, when developing imaging biomarkers, 
one question which arises is how applicable is the imaging biomarker to 
multicentre clinical trials. Overall, to date the evidence suggests NODDI is slightly 
superior to DTI, but in my opinion, it does not have the ability to be used in a 
multicentre setting, as standardization and optimization of this technique across 
centres may be challenging, as well as it lacking a direct link to specific underlying 
pathology in MS.  
Results presented in Chapter V have shown that Q-space imaging metrics may 
be capable of detecting clinically relevant spinal cord pathology, as well as being 
a prognostic marker of disability progression. As well as this spinal cord atrophy 
was the only MRI metric which was significantly different between patients and 
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controls over time. A three year follow-up study, currently underway, will 
investigate if these findings are maintained over a longer time period.  It will be 
interesting to see if significant changes in Q-space metrics are detected, 
particularly in the posterior and lateral columns. Quantitative MRI techniques 
remain technically challenging in the spinal cord, but can provide very valuable 
information on the microstructural changes occurring within tissues. Multi-
parametric imaging models are very important for the future, to help improve our 
understanding of the interactions between the structural and metabolic 
abnormalities occurring in MS. 
The spinal cord is a very small structure, making detection of absolute changes 
in area very difficult to accurately measure particularly in a multicentre setting. 
The variability between sites including different scanners, different acquisition 
sequences, upgrade in software and scanners between time points makes spinal 
cord atrophy as an outcome measure in clinical trials very challenging.  There is 
an urgent need to develop a more standardised and fully automatic method for 
the detection of spinal cord atrophy over time, similar to what is available for the 
detection of longitudinal changes in brain atrophy e.g. SIENA. One such method, 
which is being investigated at UCL, is Boundary Shift Integral (BSI) using non-
binary segmentations of the baseline and repeated scans, in order to better 
localise and capture atrophy. BSI is a well-recognised technique for measuring 
brain volume change (Freeborough et al., 1997). The method assumes that a 
change in the volume of tissue must be associated with an exact shift in the 
boundary of the tissue. The change in volume is then estimated by computing the 
integral of all boundary shifts between the time points (Fox et al., 1997). However, 
to date it has not been successfully applied to the spinal cord. In a control group, 
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there was a smaller confidence interval and coefficient of variation using the BSI 
technique in the spinal cord when compared to cross-sectional cord area 
measurements using the active surface model (Prados et al., 2016). This new 
technique now needs to be applied to a cohort of patients with MS. A voxel-based 
analysis of spinal cord atrophy has also been carried out (Rocca et al., 2013), 
which has the potential to provide regional atrophy measurements in MS, which 
would be very useful.  One of the main limitations of BSI and voxel based 
measurements in the spinal cord, is the accurate registration of the images, which 
is very difficult to achieve in the spinal cord due to the high prevalence of motion 
artefacts in spinal cord imaging.  
In conclusion, the studies carried out as part of this thesis looked at a number of 
different imaging biomarkers, to investigate different pathological mechanisms 
potentially underlying MS and contributing to disability. A combination of different 
MRI modalities, such as PET imaging, 1H-MR spectroscopy specifically looking 
at Ins, Glx and GABA, spinal cord atrophy and newer contrast agents which are 
specific to different aspects of MS pathology, such as microglial and monocyte 
activation, gliosis, glutamate mediated excitoxicity, neurodegeneration and 
inflammation, may be the best way to proceed in the future, to ultimately improve 
our understanding of the mechanisms involved in the pathogenesis of MS.
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